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ABSTRACT 
 
Colon Cancer Chemoprotection through Epigenetic Effects of a Fish Oil/Pectin Diet.  
(August 2012) 
Young Mi Cho, B.S., Hanyang University, Seoul, Korea; 
M.S., Hanyang University, Seoul, Korea 
Chair of Advisory Committee: Dr. Joanne R. Lupton 
 
 Accumulated genetic and epigenetic abnormalities contribute to the development 
of colon cancer. We have shown that a combination of fish oil (containing 
decosahexaenoic acid, DHA, 22:6 n-3) and pectin (fermented to butyrate by colonic 
microflora) is protective against colon carcinogenesis in part by regulating the 
expression of genes involved in apoptosis, leading to apoptosis induction. 
 To determine how FO/P enhances apoptosis, we measured the expression of 
genes involved in apoptosis. We performed a pathway analysis on differentially 
expressed genes identified at three times during colon tumorigenesis: initiation, aberrant 
crypt foci (ACF) formation, and tumor stage, and compared these results with 
phenotypic observations at those times.  At initiation, FO/P down-regulated the 
expression of genes involved with cell adhesion and enhanced apoptosis compared with 
corn oil/cellulose (CO/C). At the ACF stage, expression of genes involved in cell cycle 
regulation was modulated by FO/P and proliferation was reduced in FO/P rats compared 
iv 
with CO/C rats. FO/P increased apoptosis and the expression of genes that promote 
apoptosis at the tumor endpoint compared with CO/C.  
 We next determined if changes in expression of genes involved in apoptosis by 
FO/P are associated with changes in promoter methylation of a key apoptosis regulator, 
Bcl-2. Genomic DNA was isolated from carcinogen-induced colon tumors and non-
involved tissues.  FO/P increased Bcl-2 promoter methylation in tumor tissues and 
colonocyte apoptosis relative to those observed with CO/C. A negative correlation 
between Bcl-2 DNA methylation and Bcl-2 mRNA levels was observed in the tumors.  
 Additionally, we examined gene specific promoter methylation of 24 apoptosis-
related genes using human colon cancer cells. Cells were treated with DHA or linoleic 
acid (18:2 n-6), and select cultures were also treated with butyrate. The combination of 
DHA and butyrate led to a significant reduction in the methylation of pro-apoptotic 
genes and an increase in apoptosis.  These data suggest that part of the mechanisms 
involved in the induction of apoptosis by FO/P may be through epigenetic regulation of 
genes involved in apoptosis throughout colon carcinogenesis.  
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CHAPTER I 
 INTRODUCTION AND LITERATURE REVIEW 
 
Colon cancer development 
 
Introduction 
 Colon cancer is the second leading cause of cancer mortality in the United States 
(1). In 2010, estimated deaths for colon cancer were 51,370, and 102,900 people were 
newly diagnosed with colon cancer in the United States.  Moreover, colon cancer 
incidence among Asians who migrated to the United States was higher than reported 
among those living in their homeland, suggesting that environmental factors such as diet 
and physical activity contribute to colon cancer incidence (2). It has been estimated that 
up to 80% of colon cancers may be preventable by dietary intervention (3). 
Colon physiology  
 The functions of the colon include absorption of sodium, chloride, and water as 
well as the secretion of potassium and bicarbonate.  The colon epithelia also functions as 
a barrier from fecal material (4). The colon epithelium is organized into crypts, which 
increases the colon surface area in order to enhance absorption. The colon contains 
microflora, which can digest and ferment materials, such as fiber, that are unable to be 
digested by humans.  Products of microbial fermentation include vitamins and short 
chain fatty acids (e.g., acetate, propionate, and butyrate), which can then be absorbed for 
____________ 
This dissertation follows the style and format of the Journal of Nutrition. 
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utilization by the body or the colon cells (5). 
 The colon epithelium is a dynamic system that is dependent upon a balance of 
cell birth, differentiation, and apoptosis (programmed cell death) to maintain tissue 
homeostasis. Colon epithelial cells are derived from stem cells in the bottom of the crypt 
and migrate along the crypt column toward the mucosal surface. Cells differentiate into 
their mature phenotypes in the middle and upper portion of the crypt, and typically only 
undergo apoptosis in the upper part of the crypt.  Apoptotic and necrotic, colonocytes are 
found in the fecal stream, along with live cells eliminated by sloughing.  
Colonocytes have a very rapid turnover, with all cells being replaced within 3-6 
days in humans (6) and 2-4 days in rodents (7). Due to the rapid turnover of colon 
epithelial cells, the colon is a common site for abnormal growths, such as adenomas and 
carcinomas (8).  
Apoptosis and colon cancer  
 In the colon crypts, epithelial cells are rapidly renewing but the cell population is 
maintained in a steady state by the balance of cell proliferation and cell loss. If this 
balance is disturbed and the rate of cell proliferation surpasses that of cell sloughing and 
apoptosis, cells can accumulate, and if they are transformed, they can develop into a 
tumor (9). Apoptosis plays a critical role in sustaining cell homeostasis by allowing the 
removal of damaged cells. Apoptosis is regulated by two major pathways; 1) the 
extrinsic death receptor pathway, and/or 2) the intrinsic mitochondrial pathway. In both 
pathways, cysteine aspartyl-specific proteases (caspases) are activated leading to 
cleavage of cellular substrates and morphological changes. The morphological changes 
3 
in apoptotic cells are nuclear DNA fragmentation, cell shrinkage and membrane 
blebbing (10). The extrinsic pathway is triggered by the binding of ligands to death 
receptors on the cell membrane; 1) the Fas ligand to the Fas (CD95/APO-1) receptor, 2) 
the tumor necrosis factor (TNF) ligand to the TNF receptor, or 3) the TNF-related 
apoptosis inducing ligand (TRAIL) to the DR4 and DR5 receptors. Each receptor has an 
intracellular domain that recruits adaptor molecules, resulting in activation of caspases 
(11).  
The intrinsic pathway occurs in the mitochondrial membrane with cytochrome C 
release. In the cytosol, released cytochrome C forms an apoptosome with apoptotic 
protease activating factor 1 (Apaf-1) and caspase 9, resulting in apoptosis (12).  Over-
expression of Bcl-2 inhibits apoptosis and is found in various cancers, including colon 
cancer (13).  Members of the Bcl-2 family are mainly located at the mitochondrial 
membrane, and include both anti- and pro-apoptotic proteins.  Anti-apoptotic members 
are Bcl-2, Bcl-XL, Bcl-w, and MCL1, and they contain the Bcl-2 homology (BH) 
domains 1, 2, and 4.  Pro-apoptotic members are subdivided into a Bax subfamily (Bax, 
Bak, and Bok) and BH3-only proteins (Bid, Bad, Bik, Hrk, and Bim). Pro-apoptotic 
effects of BH3-only proteins bind and inactivate anti-apoptotic proteins.  Bax and Bak 
are known to undergo conformational changes prior to their insertion into the outer 
mitochondrial membrane, thereby creating channels that allow cytochrome C release.  
Bcl-2 is able to inhibit the conformational changes and/or oligomerization of Bax and 
Bak within the mitrochondrial membrane, thereby inhibiting apoptosis (14).  p53 has a 
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vital role to induce apoptosis regarding the induction of pro-apoptotic genes, including 
Bax, Nova, and CD95 upon DNA damage (15). 
Genetic mutation in colon cancer  
 DNA can be damaged not only by environmental factors such as UV light and 
radiation but also by reactive oxygen species generated by metabolism. DNA 
surveillance mechanisms repair up to one million DNA damage sites per day.  Failure in 
DNA damage repair contributes to accumulation of damage enhancing the probability of 
gene mutations (16).  Mutations of the DNA sequence disrupt the expression and/or 
function of genes. The changes in sequence and their subsequent effects are not 
reversible. Genetic etiology of colon cancer is well established. In 1990, Fearon and 
Vogelstein proposed the multi-step development of colon tumorigenesis (17). 
 Mutation of oncogenes mainly causes gain-of-function through transcriptional or 
post-transcriptional modifications in the gene products.  For example, mutation of BRAF 
in human cancers activates BRAF kinase, resulting in phosphorylation of downstream 
targets such as Mitogen activated protein kinase (MAPK), which leads to aberrant 
growth of cells (18). In contrast, mutations that occur in tumor suppressor genes are 
often loss-of-function mutations that reduce the activity of the gene product. Mutational 
inactivation of tumor suppressor genes in colon carcinogenesis occurs in Apc and Tp53. 
At the initiation stage of carcinogenesis, Apc is mutated in 85% of sporadic colorectal 
cancers (19). This mutation causes activation of the Wnt signaling pathway by inhibiting 
degradation of β-catenin oncoprotein (20, 21). Mutations of Tp53 inactivates the 
transcriptional activity of p53, which normally mediates cell-cycle arrest and a cell-death 
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checkpoint (22). Accumulated mutations of oncogenes and tumor suppressor genes 
directly disturb cell homeostasis by activating genes involved in cell proliferation and by 
inhibiting pro-apoptotic genes.  
Non-invasive colon cancer detection  
 Ninety percent of patients survive if colon adenomas are detected at an early 
stage of malignant transformation (23). Therefore, early detection of initial changes in 
the colon is essential for the reduction of colon cancer death rate. The rapid turnover rate 
of colon epithelial cells (3-6 days in humans) makes it feasible to utilize exfoliated 
colonocytes in fecal material as a non-invasive technique to detect changes in gene 
expression.  
 Genetic and epigenetic alterations in fecal DNA have been tested as a non-
invasive screening tool.  Traverso et al. reported that mutations of the APC gene were 
able to be detected using fecal DNA from colorectal cancer patients. (24)  The type of 
microRNA from human stool was tested as a non-invasive screening tool, and it showed 
a unique and identifiable pattern in colorectal neoplasms (25).  The study by Chen et al. 
demonstrated that the promoter region of Vimentin was methylated in colon tumors and 
was detectable in fecal DNA from colon cancer patients but not in normal colon tissues 
(26). Another group found aberrantly methylated CDKN2A, MGMT, and MLH1 in colon 
polyps and in fecal DNA from patients with colorectal polyps (27).  Glockner et al. 
demonstrated that TFPI2 methylation may serve as a biomarker for the early detection of 
colon cancer using stool DNA in patients with colon cancer (28).  
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 Many trials have been conducted in order to develop a non-invasive technique to 
detect alterations in gene expression using mRNA isolated from exfoliated colonocytes.  
Isolated poly A+ RNA from fecal samples revealed that PKC βII expression was 2.5-
fold higher in carcinogen injected rats compared to saline injected rats (29).  In a 
separate study, human subjects with colon adenomas exhibited higher mRNA level of 
cyclin D1, and subjects with colon inflammation had elevated levels of COX-2 (30).  
Data from these experiments support the conclusion that mRNA isolated from exfoliated 
colonocytes could be used to monitor changes in gene expression during colon 
carcinogenesis.  Therefore, the non-invasive technique using exfoliated colonocytes 
makes it feasible to evaluate the effects of a chemopreventive diet on all stages of colon 
cancer within the same subject. 
 
Epigenetic modification in chromatin structure 
 
Introduction 
 Epigenetics refers to the study of changes in phenotype or gene expression 
derived from mechanisms other than DNA sequence changes (31). Epigenetic regulation 
of gene expression is critical to organism development and cellular differentiation, but it 
is also a key element in the development of cancer (32). During carcinogenesis, gene 
transcription is aberrantly regulated via epigenetic changes of chromatin structure. These 
changes include DNA methylation and histone modification (i.e. acetylation, 
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methylation, and phosphorylation), and these modifications occur primarily in the 
promoter region of genes (33, 34).  
DNA methylation  
 DNA methylation occurs primarily at cytosine-guanosine dinucleotides (CpG) by 
the addition of a methyl group at the 5’ position of cytosine. CpG islands are CpG-rich 
regions in or near the promoter region of genes (35). DNA methylation is mediated by 
DNA methyltransferases, which transfer methyl groups from S-adenosyl methionine to 
cytosines within CpG dinucleotides. DNA methyltransferase 1 (DNMT1) is known to 
maintain DNA methylation by catalyzing the addition of a methyl group to newly 
synthesized strands of hemi-methylated DNA, whereas DNMT3A and 3B are de novo 
methyltransferases required for initiating and establishing new methylation during 
development.  
 Mechanisms whereby DNA methylation hinders transcription have been 
proposed.  Perini et al. demonstrated that methylation within the promoter region of N-
Myc target genes prevents transcription factor binding to those sequences (36). 
Methylated DNA provides a binding site for methyl-binding proteins (MBPs), which 
form a repressive complex with histone deacetylases (HDAC) and histone 
methyltransferases (HMT) (37). MBPs act as important translators between DNA 
methylation and histone modifier genes that contribute a transcriptional silencing of 
genes by chromatin remodeling (Figure 1).  
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Figure 1. Epigenetic regulation by DNA methyltransferases, methyl-binding proteins, 
and histone modifying enzymes. DNA is methylated by DNA methyltransferases 
(DNMTs). Methylated cytosine residues (solid circles) are bound by methyl-binding 
proteins (MBPs) that subsequently recruit histone deacetylases (HDACs) and histone 
methyltransferases (HMTs). These enzymes mediate complex changes in the histone 
modification pattern of methylated genes that result in the establishment of repressive 
chromatin structures. acH4K12 = lysine 12 – acetylated histone H4; acH4K5 = lysine 5 
– acetylated histone H4; mH3K9 = lysine 9 – methylated histone H3; mono, di, tri = 
mono-, di-, tri-methylated; open circles = unmethylated cytosine residues. Image was 
reprinted with permission from “DNA Methyltransferase Inhibitors and the 
Development of Epigenetic Cancer Therapies (38)” Copyright 2005 by Oxford 
University Press. 
 
 
 
 Cancer cells exhibit aberrant DNA methylation patterns, global hypomethylation 
and gene-specific promoter hypermethylation of tumor suppressor genes. Global 
hypomethylation often occurs in cancers, particularly within regions of the genome 
containing extensive amounts of repetitive elements and retrotransposons (39). 
Chromosomal instability due to global hypomethylation might induce tumor initiation 
(40).  However, more attention has been focused on aberrant epigenetic silencing of 
tumor suppressor genes by promoter hypermethylation. According to a recent review 
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regarding DNA methylation and colon cancer, accumulated studies have revealed that 59 
genes were highly methylated in biopsy, stool, and serum samples of colon cancer 
patients (41). For instance, CDKN2A/p16 and MGMT, which are tumor suppressor genes 
involved in cell cycle control and DNA repair, were silenced by DNA methylation in 
colon carcinogenesis (27, 42).  Data indicate promoter hypermethylation of genes 
involved in apoptosis suppresses the transcription levels of those genes, resulting in the 
inhibition of apoptosis in cancerous cells (43). For instance, Dapk1 is a positive mediator 
of apoptosis, and thus a tumor suppressor candidate, and it is heavily methylated in 
colon and bladder cancer (44, 45). 
 In contrast to hypermethylation of tumor suppressor genes, hypomethylation of 
tumor promoters can facilitate tumorigenesis.  For example, a region in the first exon of 
the Bcl-2 oncogene is completely demethylated allowing high-levels of Bcl-2 expression 
in B-cell chronic lymphocytic leukemia and colon cancer (46, 47).  
 Because regulation of promoter methylation is apparently a contributing factor in 
colon carcinogenesis, it is important to study potential methods of reestablishing normal 
methylation patterns. Using animal models, it would be possible to study this process in 
vivo but using controlled conditions, such as diet.  For example, Borinstein et al. 
assessed DNA methylation in AOM-induced colon cancer and found cancer-specific 
aberrant DNA methylation of Zik1 and Gja9, whereas p16
 INK4a
, Igfbp3, Mgmt, Id4, and 
Cxcr4 were methylated in both the AOM-induced tumors and normal colon mucosa (48).  
However, there are few studies that have used this method to determine the effect of diet 
on DNA methylation. 
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Histone modification   
 Histone acetylation facilitates the binding of transcription factors to promoters 
and disrupts higher order chromosome structure, promoting transcription.  Jenuwein and 
Allis proposed the “histone code” which suggests that histone protein modification 
contributes to the alteration of chromatin structure, that leads to inherited differences in 
gene expression (49).  
 In addition to DNA methylation, histone modification is another epigenetic 
mechanism contributing to the regulation of gene transcription (50). Aberrant changes in 
histone modifications are found during cancer development (51).  The nucleosome, 
consisting of DNA and an octomer of two each of histones H3, H4, H2A and H2B is the 
unit of chromatin (52).  Chromatin structure is flexible, and the changes in chromatin 
structure caused by chemical modifications to the lysine on histone amino terminal tails 
contribute to the regulation of gene transcription.  
 Histone acetylation depends on the balance between the activities of histone 
acetyltransferase (HAT) and histone deacetylase (HDAC) (53). Mutations or 
translocations of HAT genes increase susceptibility of cancer.  Missense or truncating 
mutations of p300, which is one of the HAT genes, were found in human colon cancers 
(54). HDAC is a transcriptional repressor of tumor suppressor genes like p53 and RB 
and is highly expressed in cancers (55). Agents that inhibit HDACs, for instance butyrate, 
lead to maintenance of histone H4, H2B and H3 in the hyperacetylated state and promote 
the transcription of a variety of genes (56, 57). 
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 In addition to histone acetylation, histone H3 and H4 are methylated at the lysine 
residue, resulting in changes in chromatin structure. Histone methyltransferase (HMT) 
catalyzes the addition of up to three methyl groups to lysine residues. Methylation of 
H3K4, H3K36, and H3K79 induces a chromatin structure that promotes gene expression, 
whereas that of H3K9, H3K27, and H4K20 induces a chromatin structure that inhibits 
expression (58).   
 Another chromatin modifier, polycomb group (PcG) and trithorax group (TrxG) 
proteins function coordinately to modulate DNA accessibility throughout neonatal 
development (59). The PcG complex represses gene expression by regulation of H3K27 
methylation, whereas TrxG proteins promote transcription through regulation of H3K4 
(60, 61).  PcG complex has been proposed to be involved in cell cycle regulation and 
stem cell biology. Also PcG proteins bind to noncoding RNAs and components of RNA 
interference, mediating transcription gene silencing (62). 
Demethylating agents  
 In contrast to genetic mutations, epigenetic changes can be reversed. Restoration 
of tumor suppressor transcription by the reversal of these epigenetic processes is 
considered as a potential modality for cancer therapeutics. The DNA methyltransferase 
inhibitor 5-aza-2-deoxycytidine (5-Aza-dC, i.e., decitabine) has been approved by the 
Food and Drug Administration as an antitumor agent for the treatment of hematological 
malignancies, such as myelodysplastic syndromes (63) that exhibit aberrant DNA 
methylation patterns (64).  
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 5-Aza-dC is directly incorporated into DNA and acts as a substrate for DNMT. 
However, it adheres to DNMT and remains as a covalent protein-DNA adduct, thereby 
suppressing DNA methylation (65).  Kantarjian et al. demonstrated 69% of patients 
treated with decitabine experienced severe side effects including neutropenia, 
thrombocytopenia, febrile neutropenia, leucopenia, pyrexia, hyperbilirubinemia, and 
pneumonia (66). In order to avoid the side effects caused by this pharmacological 
approach, attempts are being made to find natural dietary compounds that exert 
demethylating effects.  
 Epigallocatechin-3-gallate (EGCG, green tea compound) interrupts DNMT 
activity by blocking the active site of the enzyme (67). Nandakumar et al. demonstrated 
that green tea polyphenols restore the expression of the tumor suppressor genes 
Cip1/p21 and p16
INK4a
 in human skin cancer cells by suppressing DNA methylation (68). 
Using the AOM-treated Apc
Min/+ 
mouse model, Volate et al. determined that 
consumption of low concentrations of green tea led to demethylation of the RXRα 
promoter region, which restored RXRα expression in colon mucosa (69). 
 Fang et al. reported that genistein, a soy isoflavone, reversed hypermethylation 
and reactivated RARβ, p16INK4a and Mgmt expression in human esophageal squamous 
cancer cells (70). Shu et al. found that curcumin resulted in a 29% reduction of promoter 
methylation of Neurog1 in prostate cancer cells, and this reduction led to the 2-fold 
increase of Neurog1 mRNA expression (71). Fini et al. revealed that Annurca apple 
polyphenols reduced DNA methylation of the promoters of hMLH1, p14
ARF
, and 
p16
INK4a
 and restored those genes’ expression by reduction of DNMT proteins (72). 
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The supply of methyl group in one-carbon metabolism  
 Dietary factors including folate, vitamin B12, B6, B2, methionine, and choline 
influence the supply of methyl groups in one-carbon metabolism (Figure 2).  These 
nutrients play an essential role as cofactors for biosynthesis of S-adenosyl methionine 
which is the methyl donor for methylation reactions (73). 
 Dietary folate is converted to 5 methyltetrahydrofolate (5-MTHF) by the enzyme 
methylene tetrahydrofolate reductase (MTHFR). A carbon unit from serine or glycine is 
transferred to tetrahydrofloate (THF) to form 5,10-MTHF. The transfer of the methyl 
group from 5-MTHF to homocysteine requires vitamin B12 and results in the synthesis 
of methionine, which is converted into S-adenosyl methionine.  
 There have been inconsistent data pertaining to the effect of folate deficiency on 
DNA methylation.  Cravo et al. proposed that a mechanism by which folate deficiency 
enhances colon carcinogenesis might be through an induction of genomic DNA 
hypomethylation (74). However, Balaghi and Wagner demonstrated that a prolonged 
folate deficiency failed to induce genomic DNA hypomethylation in liver even though it 
significantly reduced hepatic S-adenosyl methionine levels (75). The supplementation of 
folate to subjects with colon adenomas increased the extent of genomic DNA 
methylation at 6 months and 1 year but placebo administration increased it at 1 year, 
suggesting that the timing and duration of folate intervention is important in terms of 
DNA methylation (76).  
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Figure 2. One-carbon metabolic cycle. Nutrients related to one carbon metabolism 
contribute to the status of DNA methylation through the modulation of methyl group 
supply. B2, vitamin B2; B6, vitamin B6; B12, vitamin B12. 
 
  
 
 DHA may also affect DNA methylation because incorporation of DHA into 
membrane phospholipids requires S-adenosyl methionine-derived methyl group 
utilization to support phospholipid metabolism. Methyl groups are transferred by 
phosphatidyl ethanolamine-N-methyltransferase (PEMT) to ethanolamine in a series of 
steps that convert it to phosphatidylcholine.  A depletion of DHA in membrane 
phospholipids caused by low dietary DHA levels would reduce the demand for methyl 
groups to support phosphatidylcholine synthesis, and thus may increase availability of 
methyl groups for histone and DNA methylation (77). 
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Chemoprotection of dietary fish oil and pectin against colon cancer 
 
Fish oil rich in n-3 PUFA  
 Fish oil is rich in n-3 PUFA such as eicosapentaenoic acid (20:5
∆5,8,11,14,17
) and 
decosahexaenoic acid (22:6
∆4,7,10,13,16,19
).  In contrast, vegetable oils are known to contain 
high levels of n-6 PUFA, such as linoleic acid (18:2
∆9,12
) and arachidonic acid 
(20:4
∆5,8,11,14
).   n-3 PUFAs in fish oil are incorporated into the phospholipids of the 
mitochondrial membrane (78).  For instance, DHA is primarily incorporated into 
phosphatidylethanolamine (PE) which can be converted to phosphatidylcholine (PC) by 
adding a methyl group from S-adenosyl methionine (79).  Because n-3 PUFA is highly 
unsaturated, they enhance susceptibility to damage by reactive oxygen species generated 
via oxidative phosphorylation (80).  Peroxidation of phospholipids induces the release of 
cytochrome C from mitochondria into the cytosol, thereby facilitating induction of 
apoptosis (81).  
 We have demonstrated that n-3 PUFA promotes colonocyte apoptosis and 
reduces colon tumor formation in part by suppressing oncogenic Ras activation and NF-
κB signaling in colonocytes (82).  Another mechanism of chemoprotection by fish oil is 
to induce apoptosis for removal of DNA damaged cells during colon cancer initiation 
(83) and spontaneous apoptosis during colon cancer progression (84, 85).  Fish oil 
enhances apoptosis in part by suppression of Bcl-2 levels, an anti-apoptotic mediator 
(86).  
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Microarray analysis to compare global changes in gene expression profiles in 
AOM-injected rats as a function of dietary lipid (fish oil, corn oil, or olive oil) revealed 
that dietary fatty acid composition alters gene expression profiles in the colonic 
epithelium at both the initiation and promotional stages of tumor development (84).  
Therefore, fish oil or n-3 PUFA are capable of influencing gene expression throughout 
colon carcinogenesis. 
Butyrate from fermentable fiber, pectin  
 Butyrate is a product of microbial fermentation of fermentable fibers, such as 
pectin, and is a major energy source of colonocytes. Butyrate is also a HDAC inhibitor 
and hydrophobic pockets of HDAC facilitate its interaction with butyrate.  Two butyrate 
molecules are able to occupy the active site of HDAC, thereby inhibiting the enzyme 
(56). 
 Chemoprotective effects of butyrate include enhancement of apoptosis (87, 88) 
and suppression of proliferation (89, 90) in colon cancer cell lines.  The underlying 
mechanisms by which butyrate contributes to the changes in apoptosis, and cell cycle 
arrest include the effect of butyrate on HDAC inhibition, which elicits the transcriptional 
regulation of genes involved in those processes.  For instance, p21, the cyclin-dependent 
kinase inhibitor, was up-regulated by butyrate treatment in p53-null cells, and this 
increase was dependent on Sp1 response elements in the p21 promoter (91).  A 
subsequent study reported that Sp1/Sp3 recruit HDACs to the p21 promoter, resulting in 
histone deacetylation, whereas butyrate ameliorated the compressed chromatin structure, 
allowing the transcription of p21 and cell cycle arrest (56).  Crim et al. reported that 
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butyrate, which was released from capsules in the colon of carcinogen-injected rats, 
elevated the expression of p21 by histone hyperacetylation in vivo (92). 
 The inhibitory effect of butyrate on HDAC can lead to the induction of apoptosis.  
Nakata et al. demonstrated butyrate increased the expression of the death receptor 
5/TRAIL-R2 and the consequent activation of caspases in human malignant tumor cells 
(93).  Fan et al. also demonstrated that butyrate enhanced apoptosis through the Fas-
mediated, extrinsic pathway in colonocytes (94).   
The combination of fish oil and pectin  
 A study by Chang et al. demonstrated that the combination of FO/P is protective 
against colon carcinogenesis compared with CO/C, in part by enhancing colonocyte 
apoptosis (95). Studies from our lab continue to support that the induction of apoptosis 
contributes to chemoprotective effects of FO/P. Compelling evidence indicated that 
DHA and butyrate synergize to enhance mitochondrial Ca
2+
 accumulation, thereby 
inducing apoptosis (96, 97).  With respect to another mechanism of action for enhancing 
apoptosis, dietary FO/P suppressed the levels of PPARδ and prostaglandin 2, and 
elevated prostaglandin 3 in both AOM-alone and irradiated AOM rats (98). We have 
recently demonstrated that FO/P also modulates non-coding microRNA in AOM-
induced colon cancer, one of the epigenetic mechanisms whereby gene transcription is 
regulated (99).  Although many aspects of the chemoprotective properties of FO/P have 
been explored, no study has investigated their effects on promoter methylation.  
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Summary and purpose 
 
 Colon cancer is the second leading cause of cancer mortality in the United States. 
Data suggests that environmental factors, such as diet, play a critical role in determining 
the risk of colon cancer. In addition to accumulated genetic mutations of tumor 
suppressors and promoter genes, aberrant epigenetic alterations have been proposed as a 
factor involved in colon carcinogenesis.  
 Dietary fat and fiber are the most widely investigated components in the 
chemoprevention of colon carcinogenesis. Reliable evidence emerging from studies 
using animal models and cells have shown that diets rich in n-3 PUFA found in fish oil, 
(rich in DHA and EPA) and pectin (a producer of butyrate) protect against colon 
carcinogenesis by enhancing cellular apoptosis. Although the chemoprotective properties 
of DHA and butyrate have been extensively investigated, their effects on epigenetic 
mechanisms have not been determined.  
 Therefore, this study aimed to further elucidate the chemoprotective properties of 
fish oil (DHA) and fermentable fiber or butyrate by determining their influence on gene 
expression.  The goals included determining global changes in gene expression profiles 
at biologically important time points in carcinogen injected rats, and epigenetic 
regulation of genes involved in colonocyte apoptosis in vivo and in vitro.  In an attempt 
to elucidate the mechanisms of action the following hypotheses and specific aims were 
designed:  
 
19 
Hypotheses and specific aims 
 
1. The combination of FO/P compared to CO/C beneficially modulates gene expression 
during colon carcinogenesis. 
Aim. Determine gene expression using exfoliated colonocytes collected at three 
biologically important time points during colon tumorigenesis: initiation, 
ACF, and tumor stage.  
2. Changes in phenotypes caused by FO/P compared with CO/C are due to changes in 
gene expression occurring during colon carcinogenesis. 
Aim. Compare fecal microarray results with phenotypic data (aberrant crypt foci, 
apoptosis, cell proliferation, and colon tumor incidence) to establish the 
regulatory controls contributing to the chemoprotective effects of FO/P.  
3. Changes in expression of Bcl-2 in response to a FO/P diet are associated with changes 
in methylation of the promoter region of Bcl-2, which is known to be hypomethylated in 
colon cancer. 
Aim. Determine the methylation status of specific CpG dinucleotides of the Bcl-2 
promoter region and the transcription level of Bcl-2 in colon carcinomas. 
4. DHA and/or butyrate enhance colonocyte apoptosis by affecting epigenetic regulation 
of apoptosis-related genes in colon cancer cells.  
Aim. Determine if n-3 PUFA and/or butyrate modulates the level of gene 
expression of apoptosis related genes by suppressing aberrant gene 
promoter methylation or enhancing histone acetylation.  
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CHAPTER II 
A CHEMOPROTECTIVE FISH OIL- AND PECTIN-CONTAINING DIET 
TEMPORALLY ALTERS GENE EXPRESSION PROFILES IN EXFOLIATED 
RAT COLONOCYTES THROUGHOUT ONCOGENESIS
*
 
 
 We have demonstrated that fish oil- and pectin-containing (FO/P) diets protect 
against colon cancer compared with corn oil and cellulose (CO/C) by upregulating 
apoptosis and suppressing proliferation. To elucidate the mechanisms whereby FO/P 
diets induce apoptosis and suppress proliferation during the tumorigenic process, we 
analyzed the temporal gene expression profiles from exfoliated rat colonocytes. Rats 
consumed diets containing FO/P or CO/C and were injected with azoxymethane (AOM; 
2 times, 15 mg/kg body weight, subcutaneously). Feces collected at initiation (24 h after 
AOM injection) and at aberrant crypt foci (ACF) (7 wk postinjection) and tumor (28 wk 
postinjection) stages of colon cancer were used for poly (A)+ RNA extraction. Gene 
expression signatures were determined using Codelink arrays. Changes in phenotypes 
(ACF, apoptosis, proliferation, and tumor incidence) were measured to establish the 
regulatory controls contributing to the chemoprotective effects of FO/P. At initiation, 
FO/P downregulated the expression of 3 genes involved with cell adhesion and enhanced 
apoptosis compared with CO/C.  At the ACF stage, the expression of genes involved 
____________ 
*
Reprinted with permission from “A chemoprotective fish oil- and pectin-containing diet 
temporally alters gene expression profiles in exfoliated rat colonocytes throughout 
oncogenesis” by Cho Y, Kim H, Turner ND, Mann JC, Wei J, Taddeo SS, Davidson LA, 
Wang N, Vannucci M, Carroll RJ, Chapkin RS, Lupton JR, 2011. The Journal of 
Nutrition, 141, 1029–1035, 2011. Copyright 2011 by The Journal of Nutrition. 
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in cell cycle regulation was modulated by FO/P and the zone of proliferation was 
reduced in FO/P rats compared with CO/C rats.  FO/P also increased apoptosis and the 
expression of genes that promote apoptosis at the tumor endpoint compared with CO/C. 
We conclude that the effects of chemotherapeutic diets on epithelial cell gene expression 
can be monitored noninvasively throughout the tumorigenic process and that a FO/P diet 
is chemoprotective in part due to its ability to affect expression of genes involved in 
apoptosis and cell cycle regulation throughout all stages of tumorigenesis.  
 
Introduction 
 
Colon cancer continues to be the second highest contributor to cancer deaths in 
the United States (100). It has been estimated that up to 80% of colon cancers may be 
preventable by dietary intervention (3). We have demonstrated that diets containing the 
combination of fish oil  and pectin (FO/P), result in a lower tumor incidence than diets 
containing corn oil and cellulose (CO/ C) (101).  FO is high in (n-3) fatty acids whereas 
corn oil is high in (n-6) fatty acids.  Pectin is a highly fermentable fiber that yields more 
butyrate upon microbial fermentation whereas cellulose is poorly fermented.  One of the 
mechanisms by which FO/P is protective against colon cancer is the induction of 
apoptosis, a programmed cell death that allows the removal of damaged cells (83, 98, 
101). Tumor development depends not only on suppression of apoptosis, but also on an 
increase in cell proliferation. We have reported that a FO/P diet also suppresses cell 
proliferation relative to a CO/C diet (95, 101).  
22 
Cell cycle progression is mediated by cyclin dependent kinases (CDK) and 
cyclins which are under both transcriptional and post-transcriptional regulation (102). 
We have demonstrated that fish oil with butyrate increases the expression of p21
Waf1/Cip1
, 
a CDK inhibitor (92). Apoptosis is regulated by multiple routes including extrinsic and 
intrinsic pathways as well as the integrins, which control cellular adhesion (103, 104). 
We have examined the effect of diet on apoptosis at various time points during 
carcinogenesis (83, 84, 98) and have reported that the expression of bcl-2, one of the 
anti-apoptotic factors in the intrinsic pathway, is down-regulated in colon cells of rats 
fed a fish oil-rich diet (86).  Therefore, it is important to identify the regulatory 
relationships among genes during the tumorigenic process to further elucidate the 
synergistic chemoprotective effects of fermentable fiber and fish oil. 
We have developed a noninvasive technique in which intact eukaryotic mRNA 
can be successfully isolated from exfoliated colonocytes to monitor gene expression 
profiles (29, 105-107). This novel technique facilitates the determination of changes in 
gene expression contributing to the regulation of apoptosis and cell proliferation during 
disease development. In this study, we are using this non-invasive methodology to 
monitor gene expression at three biologically important time points during colon 
tumorigenesis: initiation, aberrant crypt foci formation (ACF), and tumor stage. The 
fecal gene expression results were compared with phenotypic data at the same time 
points to determine the mechanisms underlying the chemoprotective effects of a FO/P 
diet.  
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Materials and methods 
 
Animals and study  
Male Sprague-Dawley rats (Harlan Teklad, Madison, WI) were used to study the 
chemoprotective effect of FO/P at the initiation, ACF, and tumor stages of colon cancer. 
The animal use protocol was approved by the Institutional Animal Care and Use 
Committee of Texas A&M University and conformed to National Institutes of Health 
(NIH) guidelines. Rats were housed individually in a temperature and humidity 
controlled animal facility with a 12 h light/dark cycle. After 1 wk of acclimation and 31 
d receiving the experimental diets, rats were injected with azoxymethane (AOM; Sigma, 
St Louis, MO, 15 mg/kg body weight). For the initiation stage analyses, 22 rats were 
terminated 24 h after AOM injection. At termination, fecal material was collected and 
immediately homogenized in RNA isolation solution for microarray analysis and colon 
tissue samples were collected and processed as described below. Rats used for the ACF 
stage (n=40) were maintained using the same diet and treatment conditions with the 
exception that animals received a second AOM injection 1 wk after the first injection. 
Seven weeks after the second AOM injection, rats were terminated and colon tissue 
samples were collected. Rats for the tumor stage analyses (n=80) were raised using the 
same diet and treatment conditions as the ACF stage rats, except animals were 
terminated at 31 wk after the second AOM injection.  Feces from the tumor stage rats 
were collected at 7 and 28 wk after the second AOM injection, and colon tissue samples 
were collected at termination. 
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Diets 
Rats were assigned to receive a diet containing either FO/P or CO/C as 
previously described (101).  All diets contained oils at 15% by weight and 30% of 
energy. The two lipid sources differed in fatty acid composition; FO contained higher 
amounts of eicosapentaenoic acid (EPA, 20:5 (n-3)) and docosahexanoic acid (DHA, 
22:6 (n-3)) than CO, which had higher amounts of linoleic acid (LA, 18:2 (n-6)). The 
fish oil diet included 3.5 g corn oil/100 g diet to prevent essential fatty acid deficiency. 
The amount of fiber in the diet was 6% by weight, which is equivalent to 30 g/d for 
humans. Fiber sources had differences in fermentability; pectin is highly fermentable 
whereas cellulose is poorly fermented. Citrus pectin was obtained from Danisco Cultor 
(New Century, KS) and cellulose was provided from Harlan Teklad (Madison, WI). 
Corn oil and bulk vacuum-deodorized menhaden fish oil were obtained from Degussa 
(Waukesha, WI).  The antioxidant levels in the diets were balanced by including 15 mg 
d-α-tocopherol, 14 mg d-γ-tocopherol, and 5 mg tertiary butylhydroquinone/100 g diet in 
the FO/P diet and 19 mg tertiary butylhydroquinone/100 g diet in the CO/C diet. 
Animals were provided with fresh diet daily to prevent lipid oxidation, and given ad 
libitum access to food and water. 
Tissue collection  
Rats were killed by CO2 overdose and cervical dislocation. The colon was 
resected and 1 cm of the distal colon was fixed in 4% paraformaldehyde (PFA) and 
another 1 cm of distal colon was used for 70% ethanol fixation. At the ACF stage, the 
25 
remaining colon was used for ACF scoring. Tissues from the tumor stage were evaluated 
for tumor incidence.   
RNA isolation from fecal samples 
To enrich the level of eukaryotic mRNA in the fecal samples, poly (A)+ RNA 
was isolated from total RNA using oligo dT cellulose micro spin columns and the 
mTRAP Maxi kit (Active Motif, Carlsbad, CA) (105). Fecal poly (A)+ RNA isolation 
was followed by DNase treatment (Appendix B-2) and aliquots were analyzed on an 
Agilent Bioanalyzer 2100 (Agilent, Palo Alto, CA)  to assess mRNA quality and 
quantity (Appendix B-1). The remaining sample was used for microarray analyses. 
Microarray data acquisition 
Fecal poly (A)+ RNA was used to monitor gene expression using CodeLink
TM
 
Rat Whole Genome Arrays (Applied Microarray, Tempe, AZ) containing 35,129 gene 
probes. cRNA synthesis was performed using between 10-100 ng of fecal poly (A)+ 
RNA. Briefly, reverse transcriptase and a T7-oligo dT primer were used for first strand 
cDNA and DNA polymerase was used for second strand cDNA generation. After IVT 
incorporating biotinylated nucleotides, purified and fragmented cRNA was hybridized to 
a Rat Whole Genome Bioarray in an Innova 4080 shaking incubator (New Brunswick, 
Edison, NJ) at 300 rpm. After hybridization, the arrays were processed as described 
previously (84). Images of processed arrays were captured on an Axon GenePix Scanner 
(Arlington, TX).  
 
 
26 
High multiplicity aberrant crypt foci (HM ACF) assay 
To determine whether the FO/P diet was able to suppress formation of early 
preneoplastic lesions of colon cancer (aberrant crypts) compared with CO/C, we 
collected colon samples from rats 7 wk after the 2
nd
 AOM injection. Colons were opened 
and placed flat within folded Whatman #1 paper, followed by fixation in 70% ethanol 
for 24 h. To identify aberrant crypts, tissue was stained in a 0.5% solution of methylene 
blue for 45 s.  The total number of HM ACF (foci containing four or more aberrant 
crypts) were counted using a 40× objective (108).  
Colon cancer incidence 
Colons from rats terminated 31 wk after the second AOM injection were used to 
determine tumor incidence. Tumors were counted and tumor bearing tissues were fixed 
in 4% PFA for 4 h and embedded in paraffin blocks for histological examination. Tumor 
sections (4 µm) were stained with hematoxylin and eosin, and tumors were classified as 
adenomas or adenocarcinomas (101). 
In situ apoptosis 
Apoptosis was measured by TdT-mediated UTP-biotin nick end labeling 
(TUNEL assay) of fragmented pieces of DNA using 4 μm sections of PFA-fixed, 
paraffin-embedded tissue (Appendix B-4). Apoptotic cells with condensed chromatin, 
apoptotic bodies and intense brown staining were counted in 50 crypt columns for each 
animal. The apoptotic index was calculated as 100 times the mean number of apoptotic 
cells per crypt column divided by the total number of cells per crypt column (101).  
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Colonocyte proliferation 
Cell proliferation was measured using the proliferating cell nuclear antigen 
(PCNA) assay. Sections (4 μm) of 70% ethanol-fixed, paraffin-embedded tissue were 
incubated with PCNA monoclonal antibody (Signet Laboratories, Inc., Dedham, MA). 
Sections were incubated with biotinylated antimouse IgG (Vector Lab, Burlingame, CA) 
and then stained with diaminobenzidine tetrahydrochloride (DAB; Sigma) (Appendix B-
5) and counterstained with hematoxylin. Twenty-five crypt columns were counted per 
animal.  The number of cells per crypt column and the proportion of proliferating cells 
per crypt column were determined. 
qRT-PCR confirmation of fecal microarray data 
Four differentially expressed genes of known function and robust sample size 
from the microarray platform were selected for validation by qRT-PCR using an ABI 
7900HT. These genes were B4galt1 for the 24 h time point, Musdhl and Pdgfa (7 wk) 
and Id3 for the 28 wk time point. In addition, we selected three other non-differentially 
highly expressed genes with relevance to colon cancer (Ctsb, Tff3, and Txn1, (109-111). 
cDNA was synthesized from 2 ng fecal poly (A)+ RNA and amplified using Ovation 
PicoSL WTA RNA amplification System (NuGen Technologies, San Carlos, CA). PCR 
was performed using SYBR Green PCR master mix (Applied Biosystems, Foster City, 
CA). Primer sequences are shown in Table 1 (Integrated DNA Technologies, Coralville, 
IA). Data are presented as the ratio of the expression level in FO/P-fed rats to that of 
CO/C-fed rats.  
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Table 1. Primers for confirmatory qRT-PCR 
Gene symbol 
GenBank 
accession 
number 
Primer sequences Amplicon (bp) 
B4galt1 AI502557 
Fwd 5’AGCAGTGCACGCCTAATGG 
73 
Rev 5’ TTGTAGCAGGTTCATGACTGACTGT 
Ctsb NM_022597 
Fwd 5’ TCGTATGGATTAGAACAAGCTTCGT 
112 
Rev 5’ AGGGTTACGTGGCACCTACAA 
Id3 NM_013058 
Fwd 5' GCTGGTCTTCTGGTTTCCTTGGA 
116 
Rev 5' ACATGGTTACAGAAAGTCACCTTCCT 
Musdhl NM_138525 
Fwd 5' TGTGGTTCGGCAAGGACATCG 
142 
Rev 5' AGGCGGAGACTCTTCTTCTGGT 
Pdgfa NM_012801 
Fwd 5' GAGGAGGAGACGGATGTGAGGT 
119 
Rev 5' CACGCACATTGGCAATGAAGCA 
Tff3 NM_013042 
Fwd 5’ AGGGTAACACTCACCCCTGATCT 
66 
Rev 5’ TCTTCTGGACTCCCAGCTCCTA 
Txn1 NM_053800 
Fwd 5’ GTGTGGACCTTGCAAAATGATC 
80 
Rev 5’ CTACTTCAAGGAACACCACATTGG 
 
 
 
Statistical analyses 
 Gene expression data for the fecal samples were normalized using the two-stage 
semi-parametric normalization method of Liu et al (112), which is specifically designed 
for data generated from partially degraded mRNA. Data were analyzed in SAS using a 
linear mixed model ANOVA procedure to evaluate the diet effect (FO/P vs. CO/C) at 
each time point. To correct for multiple testing, a false discovery rate (113) was applied. 
All genes that were differentially expressed (False Discovery Rate P-value, P < 0.05) 
between diets from each time point were used for functional categorization and pathway 
analysis based on gene ontology (Database for Annotation, Visualization, and Integrated 
Discovery (DAVID) bioinformatics resources) (114). By importing the list of all 
differentially expressed genes, this program identified gene ontology (GO) categories 
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showing enrichment for genes in the list and the probability that the GO categories were 
being significantly affected by diet and time. We chose to study GO categories within 
the term “biological process” with a filter of enrichment P-value less than 0.05.  
Phenotypic data were analyzed using ANOVA to determine the effect of diet 
(FO/P vs. CO/C) on apoptosis, proliferation, and HM ACF. Colon tumor incidence was 
analyzed by Chi square analysis and reported as the percentage of rats bearing tumors. 
Values reported are LSmean ± SEM. 
 
Results  
 
The goal of this paper was to monitor the protection provided by the combined 
FO/P diet in terms of changes in global patterns of intestinal gene expression at the 
initiation, promotion and tumor stages. Gene expression was monitored using microarray 
procedures and the resulting data were compared with phenotypic data at each of the 
three time points to determine if the patterns of expression identified by gene ontology 
analysis were predictive of changes in disease phenotypes detected in these rats. 
Initiation stage 
At the initiation stage of colon tumorigenesis FO/P resulted in higher levels of 
apoptosis in the colonic crypt compared to CO/C (P=0.024, Table 2). Although there 
was no significant diet effect on the expression of genes involved in apoptosis 24 h after 
AOM injection, there was a lower expression of cell adhesion genes (B4galt1, Smoc1, 
and Scarb2) in FO/P rats compared to CO/C at this time point (Table 3).  
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Table 2. Effects of FO/P on phenotypes at each time point compared to CO/C in rat
1
 
Item CO/C FO/P 
24 h   
 Apoptotic index (%) 4.36 ± 0.17 (11) 5.59 ± 0.21* (11) 
    
7 wk   
 HM ACF 14.08 ± 1.81 (15) 5.78 ± 1.16* (15) 
 Proliferative zone (%)
2
 66.42 ± 0.66 (15) 62.79 ± 0.62* (15) 
 Apoptotic index (%) 0.09 ± 0.04 (15) 0.27 ± 0.07* (15) 
 Total cell # in a crypt 36.09 ± 0.24 (15) 33.03 ± 0.24* (15) 
    
31 wk   
 
Colon tumor incidence 
(%) 26.83 (41) 10.26* (39) 
  Apoptotic index (%) 0.33 ± 0.20 (19) 0.73 ± 0.31* (20) 
1
 Data are LSmean ± SEM.  The number in parentheses indicates the number of animals. 
2
 The proliferative zone was calculated as 100 times the position of the highest labeled 
cell divided by the number of cells per crypt column. 
*Different from CO/C, P < 0.05 
 
 
 
ACF stage 
Rats receiving the FO/P diet had fewer HM ACF than did rats receiving the CO/C diet 
(P=0.0002, Table 2). In addition, the extent of the proliferative zone was lower in rats 
receiving the FO/P diet compared to the CO/C diet (P =0.0001, Table 2). Relative to 
observations from rats consuming the CO/C diet, rats consuming the FO/P diet had an 
elevated apoptotic index (P=0.027, Table 2). The smaller number of cells in the crypt in 
FO/P group (P=0.0001, Table 2) is likely attributed to both a suppression of cell 
proliferation and induction of apoptosis.  In contrast to the initiation stage, at the HM 
ACF stage, there were 602 genes that were differentially (false discovery rate P-value 
<0.05) expressed as a function of diet. Upon completion of GO analyses, 80 biological 
process categories were found to be significantly enriched (Table 4).  
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Table 3.  Diet-induced differential gene expression at the initiation stage detected in 
fecal-derived exfoliated cells. 
 GenBank 
accession 
Gene 
symbol 
Gene name Relative 
expression
1
 
Function 
AI502557 B4galt1 Udp-gal:betaglcnac beta 1,4- 
galactosyltransferase, polypeptide 1 
0.37 cell adhesion 
NM_001002835 Smoc1 Sparc-related modular calcium binding 
protein 1  
0.60 promotes cell-
substrate 
adhesion 
CB726708 Scarb2 Scavenger receptor class B, member 2 0.05 cell adhesion 
BI281095 NULL 
UI-R-DD0-bzr-b-09-0-UIs1 UI-R-DD0 
cDNA clone UI-R-DD0-bzr-b-09-0-UI 3' 2.96 
 
BF404993 NULL 
UI-R-CA1-bio-b-08-0-UIs1 UI-R-CA1 
cDNA clone UI-R-CA1-bio-b-08-0-UI 3' 0.47 
 
BF398623 NULL 
UI-R-BS2-ber-a-01-0-UIs1 UI-R-BS2 
cDNA clone UI-R-BS2-ber-a-01-0-UI 3' 0.64 
 
BF523734 NULL 
UI-R-Y0-vb-g-07-0-UIr1 UI-R-Y0 cDNA 
clone UI-R-Y0-vb-g-07-0-UI 5' 0.41 
 
CB738608 NULL 
AMGNNUC:MRPE3-00069-A3-A 
placenta embryo D17 (10379) cDNA 
clone mrpe3-00069-a3 5' 0.57 
 
BF403189 NULL 
UI-R-CA0-bhs-g-02-0-UIs1 UI-R-CA0 
cDNA clone UI-R-CA0-bhs-g-02-0-UI 3' 0.12 
  
1
 Relative expression represents FO/P divided by CO/C expression level. 
 
 
 
Among the 80 clusters, five were directly involved with cell cycle regulation 
(GO:0007049 cell cycle, GO:0022402 cell cycle process, GO:0000074 regulation of 
progression through cell cycle, GO:0051726 regulation of cell cycle, and GO:0000079 
regulation of cyclin-dependent protein kinase activity). Because four of these categories 
are a subset of the parent category of cell cycle (GO:0007049), we focused on the parent 
category in order to include the maximum number of differentially expressed genes.  
The FO/P diet yielded almost uniformly lower levels of expression of both cell cycle 
promoters and suppressors in this cell cycle category (Table 5). 
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Table 4.  GO terms significantly overrepresented in genes altered by the FO/P diet 
compared to the CO/C diet at the ACF stage. 
GO number GO term (biological process) 
Enriched 
genes in 
list 
Total genes 
in list P value 
GO:0016043 Cellular component organization and biogenesis 81 2340 2.16E-06 
GO:0047496 Vesicle transport along microtubule 4 6 1.73E-04 
GO:0043283 Biopolymer metabolic process 105 3698 2.56E-04 
GO:0006996 Organelle organization and biogenesis 36 931 5.11E-04 
GO:0044238 Primary metabolic process 160 6310 5.12E-04 
GO:0022402 Cell cycle process 21 445 1.10E-03 
GO:0065007 Biological regulation 107 3929 1.10E-03 
GO:0006366 
Transcription from RNA polymerase II 
promoter 24 547 1.16E-03 
GO:0043170 Macromolecule metabolic process 139 5405 1.19E-03 
GO:0007049 Cell cycle 23 518 1.31E-03 
GO:0007018 Microtubule-based movement 9 103 1.42E-03 
GO:0009893 Positive regulation of metabolic process 19 398 1.81E-03 
GO:0006810 Transport 69 2333 1.97E-03 
GO:0051179 Localization 79 2761 2.02E-03 
GO:0051234 Establishment of localization 71 2420 2.03E-03 
GO:0031325 Positive regulation of cellular metabolic process 18 371 2.10E-03 
GO:0051649 Establishment of cellular localization 31 841 2.89E-03 
GO:0030705 Cytoskeleton-dependent intracellular transport 9 118 3.33E-03 
GO:0045941 Positive regulation of transcription 15 292 3.42E-03 
GO:0008088 Axon cargo transport 4 15 3.42E-03 
GO:0051641 Cellular localization 31 851 3.44E-03 
GO:0022607 Cellular component assembly 21 491 3.47E-03 
GO:0006139 
Nucleobase, nucleoside, nucleotide and nucleic 
acid metabolic process 75 2656 3.99E-03 
GO:0050789 Regulation of biological process 93 3447 4.09E-03 
GO:0065009 Regulation of a molecular function 20 464 4.11E-03 
GO:0043412 Biopolymer modification 46 1449 4.23E-03 
GO:0045935 
Positive regulation of nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic process 15 307 5.25E-03 
GO:0008090 Retrograde axon cargo transport 3 6 6.19E-03 
GO:0065003 Macromolecular complex assembly 19 448 6.24E-03 
GO:0006464 Protein modification process 44 1403 6.53E-03 
GO:0016568 Chromatin modification 8 106 6.81E-03 
GO:0006357 
Regulation of transcription from RNA 
polymerase II promoter 18 424 7.95E-03 
GO:0044237 Cellular metabolic process 152 6267 8.20E-03 
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Table 4 continued  
GO number GO term (biological process) 
Enriched 
genes in 
list 
Total genes 
in list P value 
GO:0006461 Protein complex assembly 13 262 9.19E-03 
GO:0051276 Chromosome organization and biogenesis 13 263 9.45E-03 
GO:0006950 Response to stress 34 1034 9.69E-03 
GO:0006325 
Establishment and/or maintenance of chromatin 
architecture 11 202 1.01E-02 
GO:0031323 Regulation of cellular metabolic process 52 1777 1.08E-02 
GO:0046907 Intracellular transport 24 658 1.10E-02 
GO:0000074 Regulation of progression through cell cycle 13 270 1.15E-02 
GO:0006323 DNA packaging 11 207 1.19E-02 
GO:0043687 Post-translational protein modification 37 1171 1.22E-02 
GO:0051726 Regulation of cell cycle 13 273 1.22E-02 
GO:0008152 Metabolic process 167 7051 1.23E-02 
GO:0045893 
Positive regulation of transcription, DNA-
dependent 12 240 1.23E-02 
GO:0045449 Regulation of transcription 46 1541 1.25E-02 
GO:0050790 Regulation of catalytic activity 17 412 1.31E-02 
GO:0043549 Regulation of kinase activity 11 212 1.38E-02 
GO:0006350 Transcription 48 1642 1.51E-02 
GO:0007010 Cytoskeleton organization and biogenesis 18 455 1.51E-02 
GO:0009100 Glycoprotein metabolic process 8 125 1.60E-02 
GO:0006259 DNA metabolic process 21 571 1.68E-02 
GO:0006351 Transcription, DNA-dependent 44 1486 1.69E-02 
GO:0007242 Intracellular signaling cascade 39 1280 1.69E-02 
GO:0051338 Regulation of transferase activity 11 219 1.70E-02 
GO:0032774 RNA biosynthetic process 44 1489 1.74E-02 
GO:0051704 Multi-organism process 11 224 1.96E-02 
GO:0019219 
Regulation of nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic process 46 1595 2.18E-02 
GO:0009101 Glycoprotein biosynthetic process 7 106 2.38E-02 
GO:0019222 Regulation of metabolic process 52 1863 2.47E-02 
GO:0050794 Regulation of cellular process 79 3052 2.57E-02 
GO:0018193 Peptidyl-amino acid modification 7 109 2.68E-02 
GO:0006355 Regulation of transcription, DNA-dependent 41 1407 2.71E-02 
GO:0010468 Regulation of gene expression 47 1663 2.78E-02 
GO:0006914 Autophagy 3 13 2.92E-02 
GO:0045859 Regulation of protein kinase activity 10 206 2.94E-02 
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Table 4 continued  
GO number GO term (biological process) 
Enriched 
genes in 
list 
Total genes 
in list P value 
GO:0000079 
Regulation of cyclin-dependent protein kinase 
activity 4 34 3.36E-02 
GO:0032502 Developmental process 72 2778 3.39E-02 
GO:0019538 Protein metabolic process 80 3138 3.44E-02 
GO:0045944 
Positive regulation of transcription from RNA 
polymerase II promoter 9 179 3.46E-02 
GO:0030518 Steroid hormone receptor signaling pathway 4 35 3.62E-02 
GO:0043406 Positive regulation of MAP kinase activity 5 60 3.67E-02 
GO:0018108 Peptidyl-tyrosine phosphorylation 5 61 3.86E-02 
GO:0016070 RNA metabolic process 50 1837 4.13E-02 
GO:0018212 Peptidyl-tyrosine modification 5 63 4.27E-02 
GO:0048522 Positive regulation of cellular process 29 954 4.30E-02 
GO:0030001 Metal ion transport 15 403 4.37E-02 
GO:0006512 Ubiquitin cycle 11 261 4.80E-02 
GO:0048518 Positive regulation of biological process 31 1050 4.97E-02 
GO:0048519 Negative regulation of biological process 30 1009 4.99E-02 
 
 
 
Tumor stage  
Similar to the reduction of early preneoplastic lesion numbers, colon tumor 
incidence evaluated 31 wk after the second AOM injection, was lower in FO/P fed rats 
than in CO/C rats (Table 2).  Part of the protection against tumor formation may be 
attributable to the enhanced apoptotic index in the FO/P rat colons, compared to those 
from rats consuming CO/C (Table 2), which was elevated at all three stages of the 
tumorigenic process.  
At the tumor stage, 81 genes were differentially expressed in response to diet, 
and 13 biological processes were identified by GO analysis as being enriched. Of the 13 
categories, six were associated with apoptosis (Table 6). Among the remaining 75 
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differentially expressed genes, we identified 16 genes known to be involved in signal 
transduction, and tumor development, progression and invasion (Table 7).  
 
 
 
Table 5. Diet-induced differential gene expression at the ACF stage detected in rat fecal-
derived exfoliated cells - relative expression of genes in the cell cycle category 
(GO:0007049) 
  GenBank Accession Gene symbol Description 
Relative 
expression1 
Cell cycle promoters    
 
BF388494 App Amyloid beta (a4) precursor protein 0.40 
 NM_012923 Ccng1 Cyclin G1 0.44 
 BI294914, BE113451 Ccnk Cyclin K 0.69 
 BQ206043 Ccnl1 Cyclin l1 0.31 
 AI411332 Ccnt2_predicted Cyclin T2 (predicted) 0.55 
 
AA819214 Cdc34_predicted Cell division cycle 34 homolog (S. 
cerevisiae) (predicted) 
0.51 
 
AW532478 Gfi1b_predicted Growth factor independent 1B (predicted) 0.64 
 
NM_053347 Nde1 Nuclear distribution gene E homolog 1 (A 
nidulans) 
0.54 
 
AA685941 Pafah1b1 Platelet-activating factor acetylhydrolase, 
isoform ib, alpha subunit 45kda 
0.56 
 NM_012801 Pdgfa Platelet derived growth factor, alpha 0.50 
 BI395817 Ruvbl1 Ruvb-like protein 1 0.56 
Cell cycle suppressors   
 
NM_001005902 Abtb1 Ankyrin repeat and BTB (POZ) domain 
containing 1 
0.40 
 
AY351678 Cdkn1c Cyclin-dependent kinase inhibitor 1C (P57) 0.48 
 BF406173 Ddit3 DNA-damage inducible transcript 3 0.46 
 BQ191258 Dst_predicted Dystonin (predicted) 0.39 
 NM_053484 Gas7 Growth arrest specific 7 0.49 
 NM_032080 Gsk3b Glycogen synthase kinase 3 beta 0.53 
 
AW916463.1 Pms2_predicted Postmeiotic segregation increased 2 (S. 
cerevisiae) (predicted) 
3.23 
 AW526814 Rbl2 Retinoblastoma-like 2 (p130) 0.61 
 
NM_031745.2 Clip1 CAP-GLY domain containing linker protein 
1 
0.32 
  
BI297192, 
NM_001024796.1 
Spin1 Spindlin 1 0.41 
1
 Relative expression represents FO/P divided by CO/C expression level. All genes have a 
p-value less than 0.05, indicating that genes were differentially expressed between diets. 
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Table 6. GO terms significantly overrepresented in genes altered by the FO/P diet 
compared to the CO/C diet at tumor stage 
GO number GO term (biological process) 
Enriched 
genes in list 
Total genes 
in list P value 
GO:0009628 Response to abiotic stimulus 5 212 3.18E-03 
GO:0006397 mRNA Processing 4 152 9.57E-03 
GO:0016071 mRNA Metabolic Process 4 181 1.53E-02 
GO:0042981 Regulation of apoptosis 6 525 1.70E-02 
GO:0043067 Regulation of programmed cell death 6 533 1.80E-02 
GO:0051704 Multi-organism process 4 224 2.67E-02 
GO:0008284 Positive regulation of cell proliferation 4 243 3.29E-02 
GO:0043065 Positive regulation of apoptosis 4 256 3.76E-02 
GO:0043068 Positive regulation of programmed cell death 4 259 3.87E-02 
GO:0051707 Response to other organism 3 113 4.23E-02 
GO:0006915 Apoptosis 6 681 4.52E-02 
GO:0012501 Programmed cell death 6 690 4.74E-02 
GO:0006396 RNA processing 4 285 4.90E-02 
 
 
 
 
Table 7.  Diet-induced differential gene expression at the tumor stage detected in rat 
fecal-derived exfoliated cells 
GenBank 
Accession 
Gene 
symbol 
Description 
Relative 
expression
1
 
Function 
Membrane 
related
2
 
      
Apoptosis from GO category    
NM_181386  Tmem23 Transmembrane protein 23 0.55 
Anti-
apoptosis 
Y 
BI302754, 
NM_013058   
Id3 Inhibitor of DNA binding 3 2.16 Pro-apoptosis  
NM_031054  Mmp2 Matrix metallopeptidase 2 0.69 
Pro-
apoptosis, 
tumor 
invasion 
Y 
AA999104  Fem1b 
Feminization 1 homolog b (C. 
elegans) (predicted) 
0.39 Pro-apoptosis   
BF542507 Hipk2 
Homeodomain interacting protein 
kinase 2 (predicted) 
0.10 Pro-apoptosis   
NM_017017  Hgf Hepatocyte growth factor 0.55 
Anti-
apoptosis 
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Table 7 continued 
GenBank 
Accession 
Gene 
symbol 
Description 
Relative 
expression
1
 
Function 
Membrane 
related
2
 
     
Signal transduction     
CF113820  Mtmr4 
Myotubularin related protein 4 
(predicted) 
3.88 
TGF beta 
signaling 
 
NM_019268  Slc8a1 
Solute carrier family 8 
(sodium/calcium exchanger), 
member 1 
0.41 
Calcium 
singaling, Pro-
apoptosis 
Y 
AW918423  Dupd1 
Dual specificity phosphatase and 
pro isomerase domain containing 
1 (predicted) 
0.46 
MAPK 
signaling 
 
CB749439  Ppp1r7 
Protein phosphatase 1, regulatory 
(inhibitor) subunit 7 
0.61 
MAPK 
signaling 
 
CB611690  Mfn1 Mitofusin 1 0.53 Anti-apoptosis Y 
NM_053788  Stx1a Syntaxin 1A (brain) 0.57 Pro-apoptosis Y 
NM_001002
835  
Smoc1 
SPARC-related modular calcium 
binding protein 1 
0.54 
Positive 
regulation of 
cell-substrate 
adhesion 
Y 
NM_019378  Snip SNAP25-interacting protein 0.70 
Negative 
regulation of 
cell adhesion 
 
NM_053346  Nrn1 Neuritin 0.65 
Hypoxia-
induced genes 
Y 
NM_130410  Il23a Interleukin 23, alpha subunit p19 0.56 
Immune 
response 
 
NM_017020  Il6ra Interleukin 6 receptor, alpha 0.52 
Immune 
response 
Y 
NM_031089  Pthr2 Parathyroid hormone receptor 2 0.41 
Cell 
proliferation 
Y 
      
Tumor      
CO562407  Cyp2s1 
Cytochrome P450, family 2, 
subfamily s, polypeptide 1 
0.62 Metabolism Y 
NM_001009
605  
Brms1 
Breast cancer metastasis-
suppressor 1 
2.60 
Cancer 
metastasis 
 
BI299377  Rbbp6 Retinoblastoma binding protein 6 2.03 
Tumor 
suppressor 
 
NM_020302  Adam3 
A disintegrin and metalloprotease 
domain 3 (cyritestin) 
0.58 
Tumor 
invasion 
Y 
1
 Relative expression represents FO/P divided by CO/C expression level.  All genes have 
a p-value less than 0.05, indicating that genes were differentially expressed by diet. 
2
 Y indicates genes included in the membrane category (GO:0016020). 
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qRT-PCR confirmation of fecal microarray 
To validate the the fecal microarray data, we performed qRT-PCR on select 
genes using the same fecal poly (A)+ RNA isolates. The regression between fecal 
microarray and qRT-PCR results demonstrate a reasonable degree of similarity in the 
pattern of expression for the seven genes selected for this comparison (R
2
=0.87, Figure 
3).  
 
 
 
 
Figure 3. Correlation of fecal microarray and qRT-PCR results within a subset of genes. 
Data are expressed as the level of gene expression from feces-derived exfoliated cells of 
FO/P rats relative to CO/C rats (R
2
= 0.87) 
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Discussion 
 
Most chemoprevention studies are targeted to a single time point in the 
carcinogenic process. We used a non-invasive technique that permits the isolation of 
eukaryotic mRNA from exfoliated colonocytes in fecal material (29, 105-107) in order 
to monitor temporal changes in gene expression. The purpose of the current study was to 
determine; 1) how diet influences the expression of genes at three discreet stages of 
tumorigenesis, and 2) if the differences were reflective of the changes in phenotypes 
measured at those time points. 
At the initiation stage of colon tumorigenesis there were only three annotated 
genes, which were differentially expressed as a function of diet.  The low number of 
diet-induced differential expression at the initiation stage was not unexpected as we have 
previously shown a relatively small number of differentially expressed genes between 
diets 12 h after AOM injection (84). The small number of differences between the diets 
could be explained by the extensive effect of AOM on the colonic epithelium, which 
prevented detection of diet effects on gene expression. These three genes are all involved 
in maintaining cell adhesion and it is known that cell adhesion to basement membranes 
prevents cell death (103), suggesting that the FO/P diet would facilitate apoptosis 
induction. The lower relative expression of cell adhesion related genes in cells after 
AOM injection likely contributes to the ability of FO/P rats to effectively eliminate cells 
with DNA damage (83, 115). Whether the elimination is through the induction of 
apoptosis or by cell sloughing (103, 116), these changes in gene expression would 
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explain some of the chemoprotection provided by a FO/P diet, relative to the effects 
observed with a CO/C diet.  
 At the HMACF stage, we found that 602 genes were differentially expressed as a 
function of diet. This suggests that as carcinogenesis progresses to this stage, the ability 
of diet to affect gene expression and thereby provide a chemoprotective effect is 
enhanced as reflected by the number of phenotypic changes that are detected (i.e. 
apoptosis, proliferative zone, and HM ACF). Gene ontology analysis of the 602 
differentially expressed genes revealed that cell cycle regulation was affected by a FO/P 
diet compared to CO/C. Changes in the expression of genes involved in cell cycle 
regulation are critical to the promotion of colon carcinogenesis (117). The cyclin-CDK 
complex initiates the phosphorylation of Rb, stimulating the regulation of cell cycle 
progression (102). Relative to the expression in the CO/C rats, expression of cyclin G1, 
K, L1, T2_predicted as well as cdc34_predicted were lower in rats consuming the FO/P 
diet. Rbl2 is known to control progression from G0 into the G1 phase of the cell cycle, 
and the level of its expression was lower in rats consuming a diet containing FO/P 
compared to CO/C. However, the phosphorylation of Rbl2 is needed to release E2F and 
activate the cell cycle. FO/P resulted in lower levels of expression of CDK and GSK3b, 
which is a reported kinase of Rbl2 (118) and is expected to reduce the degree of 
phosphorylation of Rbl2. Another promoter of cell cycle activity is Ruvbl1, which is up-
regulated in human colon cancers. Ruvbl1 enhances the transcription of Wnt target genes 
by interacting with -catenin (119).  In this experiment, the FO/P diet down-regulated 
the expression of Ruvbl1 compared to the CO/C diet, which suggests the FO/P diet may 
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inhibit Wnt signaling. These findings suggest that FO/P diet could suppress the 
uncontrolled cell proliferation that occurs in colon cancer cells at the ACF stage in part 
by modulating the expression of genes that are essential for cell cycle progression. 
In addition to the suppression of cell proliferation, we previously reported on the 
cell-specific expression of O
6
-methylguanine DNA methyltransferase (MGMT, DNA 
repair enzyme). The expression of MGMT in fish oil-fed rats was 4-fold higher than corn 
oil-fed rats in areas of colon crypts where apoptosis typically occurs (83). Pms2 is 
known to be involved in DNA mismatch repair systems, and mutation of Pms2 is 
documented to cause hereditary nonpolyposis colorectal cancer (120).  In the current 
study, we found that the expression of Pms2_predicted was 3-fold higher in FO/P rats 
compared to CO/C rats. We also observed that FO/P significantly enhanced apoptosis 
compared to CO/C (Table 2). Therefore, the FO/P diet may facilitate removal of DNA 
damaged cells by increasing DNA repair and apoptosis.  
At the tumor stage, the modulation of expression of several genes involved in 
apoptosis occurred in concert with the induction of apoptosis in the FO/P rats. Of the six 
differentially expressed genes involved in the apoptosis pathway, Mmp2 expression was 
increased in the colon of CO/C tumor-bearing rats. This is noteworthy because Mmp2 
has been implicated in colon cancer invasion (121). Expression of Id3, an apoptosis 
inducer (122), was higher in FO/P rats compared to CO/C, whereas Tmem23 and Hgf, 
both apoptosis inhibitors (123, 124), were lower in FO/P rats compared to CO/C. This 
pattern of gene expression is consistent with the apoptotic phenotype observed across all 
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time points, indicating at a molecular level why the FO/P diet is more effective in 
promoting apoptosis than the CO/C diet. 
The expression of 11 genes (e.g., Slc8a1, Dupd1, Ppp1r7, Mfn1, Stx1a, Smoc1, 
Snip, Nrn1, Il23a, Il6ra, and Pthr2) involved in several signal transduction pathways 
was down-regulated in FO/P fed rats compared to CO/C, suggesting that FO/P is capable 
of attenuating multiple signaling pathways at the tumor stage.  For example, Mfn1, 
which is a transmembrane GTPase, is one of the genes down-regulated by FO/P 
compared to CO/C.  Mfn1 mediates mitochondrial fusion, and elevated expression of 
Mfn1 has been demonstrated to increase the resistance of cells to death stimuli (125). 
With regard to this mechanism of action, 11 genes in the membrane category 
(GO:0016020) were differentially expressed at the tumor stage (indicated by “Y” in 
Table 2). This may be explained by the incorporation of DHA, a bioactive component of 
fish oil, into both plasma and mitochondrial membranes (80).  Indeed, we and others 
have demonstrated that (n-3) PUFA promote an oxidation-reduction imbalance in the 
intestine (126-129).  Recently, we have demonstrated that DHA promotes mitochondrial 
oxidative stress and increases mitochondrial Ca
2+
 levels, which directly induce apoptosis 
in colonocytes (96, 97). 
Tumor related genes involved in tumor formation, progression, and invasion 
were favorably modulated by FO/P consumption compared to CO/C. For example, the 
expression of Cyp2s1 was down-regulated by FO/P as compared to CO/C. This gene 
encodes for one of the cytochrome P450 superfamily members and plays a pivotal role 
in the oxidative metabolism of xenobiotics such as carcinogens. A study designed to 
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identify markers of colon cancer prognosis demonstrated that the expression of Cyp2s1 
was significantly higher in primary colon cancers than in normal colon tissue (130). 
Adam3, an indicator of tumor invasion, was also down-regulated in FO/P rats compared 
to CO/C (131, 132). In contrast, Brms1, a tumor suppressor gene, was up-regulated by 
FO/P compared to CO/C.  Similarly, FO/P rats had twice the level of Rbbp6 (also 
designated P2P-R) expression as CO/C rats, and overexpression of this gene results in 
mitotic arrest at prometaphase and mitotic apoptosis (133).  
Existing studies with the AOM model of colon carcinogenesis have reported 
gene expression at discreet points in the tumorigenic process (46, 11).  Those studies 
also found changes in expression of genes involved in cell adhesion (46), apoptosis or 
cell cycle (11).  The unique contribution of the current study is that we found that diet 
differentially affects apoptotic genes, depending upon the stage of tumorigenesis.  
Therefore, we have discovered time-specific effects of diet that contribute to 
chemoprotection against colon cancer.  Interestingly, although the FO/P diet promoted 
apoptosis at all three time points, it differentially impacted gene expression at each stage.  
These data are consistent with recent observations (47), indicating a clear time-
dependent, divergent regulation of gene expression signatures in response to the fatty 
acid content of the diet. 
We have demonstrated the feasibility of monitoring gene expression over time 
using an mRNA-based noninvasive technique.  This makes it possible to determine the 
mechanisms whereby a chemopreventive diet may inhibit colon carcinogenesis as well 
as to monitor human disease progression and identify critical time points for potential 
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diet intervention. In this study, we have identified differentially expressed genes 
involved in apoptosis and/or cell proliferation at three time points during colon 
carcinogenesis. At the initiation stage, there were few differential effects of diet on gene 
expression. At the promotion stage, the expression of many more genes was affected by 
diet, suggesting this stage is more susceptible to the FO/P dietary intervention. Gene 
ontology pathways enriched at this stage include cell proliferation.  However, at the 
tumor stage, the main gene expression pathway affected was principally associated with 
apoptosis. Consequently, the central mechanism by which FO/P produces a 
chemoprotective effect is through changes in gene expression that enhance cell cycle 
regulation and apoptosis throughout tumorigenesis. 
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CHAPTER III 
A CHEMOPROTECTIVE FISH OIL/PECTIN DIET ENHANCES  
APOPTOSIS VIA BCL-2 PROMOTER METHYLATION  
IN RAT AZOXYMETHANE-INDUCED CARCINOMAS 
 
 We have demonstrated that diets containing FO/P reduce colon tumor incidence 
relative to those containing CO/C in part by inducing apoptosis of DNA-damaged colon 
cells.  Relative to FO/P, CO/C promotes colonocyte expression of the anti-apoptotic 
modulator, Bcl-2, and Bcl-2 promoter methylation is altered in colon cancer.  To 
determine if FO/P, compared with CO/C, limits Bcl-2 expression by enhancing promoter 
methylation in colon tumors, we examined Bcl-2 promoter methylation, mRNA levels, 
colonocyte apoptosis, and colon tumor incidence in azoxymethane (AOM)-injected rats. 
Rats were provided diets containing FO/P or CO/C, and were terminated 16 and 34 wk 
after AOM injection.  DNA isolated from PFA-fixed colon tumors and uninvolved tissue 
was bisulfite modified and amplified by qRT-PCR to assess DNA methylation in Bcl-2 
CpG islands. FO/P increased Bcl-2 promoter methylation (p=0.009) in tumor tissues and 
colonocyte apoptosis (p=0.020) relative to CO/C.  An inverse correlation between Bcl-2 
DNA methylation and Bcl-2 mRNA levels was observed in the tumors. We conclude 
that dietary FO/P promotes apoptosis in part by enhancing Bcl-2 promoter methylation. 
These Bcl-2 promoter methylation responses, measured in vivo, contribute to our 
understanding of the mechanisms involved in chemoprevention of colon cancer by diets 
containing FO/P. 
46 
Introduction 
 
Epigenetic regulation of gene transcription occurs through mechanisms that 
include DNA methylation and histone modification (34, 35). DNA methylation occurs 
primarily at cytosine-guanosine dinucleotides (CpG) by the addition of a methyl group 
on the 5’ carbon position of cytosine. CpG islands are CpG-rich regions in or near the 
promoter region of genes, that when unmethylated allow the transcription of genes (35). 
Aberrant methylation of promoter CpG islands has been accepted as a crucial contributor 
to cancer development (134, 135) because the extent of promoter methylation in tumors 
is associated with disease progression, recurrence, and survival rates in colon cancer 
(136, 137).  A hallmark of tumorigenesis is an inhibition of apoptosis, and genes 
involved in apoptosis can be transcriptionally regulated through DNA methylation (43). 
Importantly, aberrant DNA methylation is potentially reversible by natural agents in the 
diet, such as soy isoflavones, apple polyphenols, green tea polyphenols, and biologically 
active compounds present in vegetables (68, 70, 72, 138), which may lead to induction 
of apoptosis in the colon. 
We have previously demonstrated that the combination of FO/P, compared with 
a control diet containing CO/C, promoted apoptosis during colon cancer development 
(85).  Fish oil is high in n-3 polyunsaturated fatty acids (PUFA), i.e., eicosapentaenoic 
acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3), whereas corn oil is high 
in the n-6 fatty acid, linoleic acid (LA, 18:2n-6). Pectin is a highly fermentable fiber that 
yields butyrate upon microbial fermentation, whereas cellulose is poorly fermented.  One 
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of the mechanisms by which FO/P enhances apoptosis is suppression of Bcl-2 levels, an 
anti-apoptotic mediator (86, 139).  Bcl-2 obstructs the intrinsic apoptotic pathway by 
preventing the release of cytochrome C from the mitochondria, thereby suppressing 
downstream caspase activation (140).  In leukemia cells, Bcl-2 is hypomethylated 
leading to high Bcl-2 expression (46).  These observations are relevant because high 
levels of Bcl-2 are observed in the metastatic state of various types of cancer including 
colon cancer (13).  Therefore, we hypothesized that the suppression of Bcl-2 expression 
in response to a FO/P diet may result from a previously unidentified modulation of the 
Bcl-2 promoter region.  To test this, we determined the methylation status of specific 
CpG dinucleotides of the Bcl-2 promoter region and the transcription level of Bcl-2. This 
study provides evidence that FO/P modulates apoptosis in part by epigenetic regulation 
of Bcl-2 expression in rat AOM-induced colon carcinomas.  
 
Materials and methods 
 
Animals and study design 
The animal use protocol was approved by the Institutional Animal Care and Use 
Committee of Texas A&M University and conformed to National Institutes of Health 
(NIH) guidelines. Ninety-six male Sprague-Dawley rats (Harlan Teklad, Madison, WI) 
were housed individually in a temperature and humidity controlled animal facility with a 
12 h light/dark cycle. After 1 wk of acclimation and 1 wk receiving the experimental 
diets, rats were injected with azoxymethane (AOM; Sigma, St Louis, MO, 15 mg/kg 
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body weight) twice, 1 wk apart. Twenty-two rats (CO/C n = 12, FO/P n = 10) were 
terminated at 16 wk and 74 rats (CO/C, n = 41; FO/P, n = 33) were used for final tumor 
analysis at 34 wk after the second AOM injection. Rats were killed by CO2 overdose and 
cervical dislocation.  Samples from 16 wk were used for apoptosis and DNA 
methylation analyses and those from 34 wk were used for apoptosis, DNA methylation 
and gene expression analyses (Figure 4).  
 
 
 
 
Figure 4. Experiment flow chart showing sample processing scheme at tumor stage. 
 
 
 
Diets 
Rats were provided a diet containing either FO/P or CO/C as previously 
described (101). The FO/P diet contained higher amounts of n-3 PUFA (EPA and DHA) 
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and pectin, a highly fermentable fiber. The CO/C diet had higher amounts of n-6 PUFA 
(LA) and cellulose, a poorly fermented fiber. The fish oil diet included 3.5 g corn oil/100 
g diet to meet essential fatty acid requirements. All diets contained oils at 15% by weight 
and 30% of calories, an amount that corresponds to current human dietary 
recommendations. The amount of fiber in the diet was 6% by weight, which is 
equivalent to 30 g/d for humans, also within the recommended range for humans. The 
antioxidant levels in the FO/P and CO/C diets were 1.5 g/kg α-tocopherol, 1 g/kg γ-
tocopherol, and 0.025 % tertiary butylhydroquinone. Fresh diets were provided daily to 
prevent lipid oxidation. 
Colon cancer incidence 
Colons from rats terminated 34 wk after the second AOM injection were used to 
determine tumor incidence. Tumors were counted and tumor tissues were fixed in 4% 
PFA for 4 h and embedded in paraffin blocks for histological examination. Tumor 
sections (4 µm) were stained with hematoxylin and eosin, and tumors were classified as 
adenomas or adenocarcinomas (101). 
In situ apoptosis 
Apoptosis was measured by TdT-mediated UTP-biotin nick end labeling 
(TUNEL assay) of fragmented pieces of DNA using 4 μm sections of PFA-fixed, 
paraffin-embedded tissue. Apoptotic cells with condensed chromatin, apoptotic bodies 
and intense brown staining were counted in 25 crypt columns for each animal. The 
apoptotic index was calculated as 100 times the mean number of apoptotic cells per 
crypt column divided by the mean number of cells per crypt column (101).  
50 
DNA extraction and preparation 
Genomic DNA was extracted from 10 µm PFA-fixed colon carcinomas and non-
involved tissue sections using a QIAamp DNA FFPE tissue kit (Qiagen, Valencia, CA).  
In addition, to prepare a universally methylated reference sample, rat liver genomic 
DNA was treated with CpG Methyltransferase (M.SssI, New England Biolabs, Ipswich, 
MA), which methylates cytosines in CpG dinucleotides with S-adenosyl methionine 
(SAM) as a methyl donor. Briefly, genomic DNA of rat liver was treated with M.SssI 
(0.05 units/µl final concentration) and SAM overnight, followed by another overnight 
incubation with an additional M.SssI (0.09 units/µl final concentration) and SAM (141).  
The M.SssI-treated DNA was purified using a DNA Clean and Concentrator kit (Zymo 
Research, Irvine, CA) (Appendix B-7).  
Sodium bisulfite modification and DNA recovery 
Two µg of genomic DNA or M.SssI treated DNA was sodium bisulfite modified 
using a Zymo EZ DNA Methylation Kit (Zymo Research, Irvine, CA) as per the 
manufacturer’s instructions. Sodium bisulfite converts unmethylated cytosines to uracils, 
but does not affect the methylated cytosines (Figure 5). 
qPCR detection of Bcl-2 promoter methylation status 
After sodium bisulfite conversion, genomic and M.SssI treated DNA were 
amplified by fluorescence-based qPCR using an ABI 7900 unit. Serial dilutions of 
M.SssI treated DNA were included on each plate to generate a standard curve. PCR 
amplification was performed with a final reaction mixture of 25 µl consisting of 600 nM 
of each primer, 200 nM probe, 200 µM dNTPs, 3.5 mM MgCl2, 10× TaqMan buffer 
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Figure 5. DNA sequence conversion by bisulfite modification 
 
 
 
without Uracil DNA glycosylase (AMPerase), 10× stabilizer, and water.  Bisulfite-
converted DNA was amplified at 95°C for 10 min, followed by 50 cycles at 95°C for 15 
s and 60°C for 1 min (Appendix B-8) (142). Primers and probes, designed specifically 
for bisulfite-converted DNA, were used for Bcl-2 and Col2a1, a reference gene to 
normalize for input DNA. Bcl-2 primers and probe were designed to contain 7 CpG 
dinucleotides in a CpG island located in the first exon of Bcl-2 (Figure 6).  
Primers and the probe were designed in a region of the Col2a1 gene that lacks any CpG 
dinucleotides to allow for equal amplification, regardless of methylation levels. The 
percentage of fully methylated molecules at a specific locus was calculated by dividing 
the Bcl-2:Col2a1 ratio of a sample by the Bcl-2:Col2a1 ratio of M.SssI-treated DNA and 
multiplying by 100. The primer and probe sequences are listed in Table 8. (Appendix B-
6) 
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Figure 6. Genomic structure of rat Bcl-2 and the location of primers and probe for DNA 
methylation. The | and ■ represent CpG dinucleotides.  
 
 
 
Table 8. Primer and probe sequence of promoter methylation 
Gene GenBank 
number 
Amplicon 
start, end 
Forward primer 
5' to 3' 
Reverse primer 
5' to 3' 
Probe sequence 
5' to 3' 
Bcl-2 NM_016993 496-573 
GGATATTTTTGT
AAAGTCGCGAC
G 
ACCTATAATCC
ACCTAACCCTC
CG 
6FAM-
CTAAAAATAAC 
TTCTCTCGTCGCT-
MGB
1
 
Col2a1 NM_012929 
13,169-
13,244 
GGTATTTTTGTT
GTTTTGAAGAG
TAGT TG 
CCTTCTCTCCT
CCTTAAACTCC
AA 
6FAM-
ACCTCTAATCCCT
CCCAAA-MGB 
1
MGB refers to a Minor Groove Binder non-fluorescent quencher in the 3' terminus of the probe 
(MGBNFQ). 
 
 
 
RNA extraction and transcription level measurement using qRT-PCR 
Total RNA was extracted from colon carcinomas using Totally RNA (Ambion, 
Grand Island, NY), followed by treatment with DNase. cDNA was synthesized from 2 
µg of total RNA using oligo dT primer and SuperScript II reverse transcriptase 
(Invitrogen, Grand Island, NY) (Appendix B-3). qRT-PCR was performed using an ABI 
7900 and TaqMan gene expression assays (Applied Biosystems, Foster City, CA) to 
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quantify mRNA expression levels of Bcl-2. The expression level of Bcl-2 
(Rn99999125_m1) was normalized to Eukaryotic 18S rRNA expression 
(Hs99999901_s1) (139).  Accuracy of the assay was validated by establishing linearity 
of response for each assay. Negative controls consisted of reverse transcription reaction 
components without RT enzyme. 
Statistical analyses 
Data were analyzed using independent samples t-test to determine the effect of 
diet (FO/P vs. CO/C) on apoptosis and Bcl-2 methylation. Colon tumor incidence was 
analyzed by Chi square analysis and reported as the percentage of rats bearing tumors. 
The relationship between DNA methylation and gene expression was determined by 
regression analysis. The values are reported as means ± SEM.  Differences between 
treatments were regarded as significant when P values were <0.05. 
 
Results 
 
FO/P diet promotes apoptosis and reduces colon tumor incidence 
 Rats receiving the FO/P diet had a significantly lower colon tumor incidence 
compared with those receiving the control CO/C diet (p=0.016, Figure 7A).  In addition, 
rats consuming the FO/P diet had a higher (p=0.028) number of apoptotic cells per crypt 
column (0.85 ± 0.17) compared to those consuming the CO/C diet (0.47±0.08).  This 
resulted in an elevated apoptotic index (percentage of apoptotic cells in crypt column) in 
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the non-tumor (uninvolved) regions of the colon in FO/P rats (means of data at 16 and 
34 wk after AOM injection), compared to CO/C (p=0.020, Figure 7B).   
 
 
 
 
Figure 7.  Colon tumor incidence (n = 74) (A), Average of apoptotic index values 
measured at 16 wk and 34 wk after AOM injections (n = 40) (B). The data are means ± 
SEM. *Different from CO/C, P<0.05.  FO/P = fish oil/pectin diet and CO/C = corn 
oil/cellulose diet. Data for this figure is found in Appendix Table A-1. 
 
 
 
FO/P enhances Bcl-2 promoter methylation in tumors at 34 wk after AOM injections 
 At the 16 wk time point, Bcl-2 promoter methylation tended to decline with the 
FO/P diet, but this effect was not significant (CO/C 0.94 ± 0.16, FO/P 0.65 ± 0.12, 
p=0.083, Figure 8A). In contrast, at the 34 wk time point, FO/P enhanced Bcl-2 
promoter methylation, which was significant (p=0.009) in carcinomas (CO/C 0.57 ± 0.06, 
FO/P 0.91 ± 0.19) but not in uninvolved colonic mucosa (CO/C 0.37 ± 0.04, FO/P 0.50 
± 0.11) (Figure 8B).  Bcl-2 promoter methylation was lower in uninvolved tissues at 34 
a 
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wk (0.42 ± 0.05) compared with those of 16 wk (0.79 ± 0.10) (p=0.001, Figure 8C), 
which likely reflects the continued progression of tumorigenesis.  
 
 
 
 
Figure 8.  Relative Bcl-2 promoter methylation 16 wk after AOM injections (6 
rats/group) (A), relative Bcl-2 promoter methylation 34 wk after AOM injections (14-25 
rats/group) (B), relative Bcl-2 promoter methylation of uninvolved tissues 16 wk and 34 
wk after AOM injections (n=12 at 16 wk, n=36 at 34 wk) (C), and relative Bcl-2 gene 
expression in carcinomas (3-4 rats/group) (D).  The data are means ± SEM.  *Different 
from CO/C, P<0.05.  FO/P = fish oil pectin diet and CO/C = corn oil/cellulose diet.  
Data for this figure is found in Appendix Table A-1 and A-2. 
 
a 
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Bcl-2 gene expression tends to be associated with reduced promoter methylation 
 Our hypothesis was that FO/P would increase Bcl-2 promoter methylation, 
leading to lower gene transcription.  In carcinomas collected at 34 weeks, Bcl-2 
promoter methylation was elevated in rats receiving the FO/P diet, which occurred in 
concert with numerically lower Bcl-2 transcription in carcinomas compared with CO/C 
(p=0.13, Figure 8D). When the extent of Bcl-2 promoter methylation was compared 
with Bcl-2 expression in carcinomas of rats consuming FO/P or CO/C, the anticipated 
negative correlation (slope= -0.005, R
2
=0.16) was observed even though the limited 
number of observations precluded obtaining a significant relationship (p=0.25,  Figure 
9). 
 
 
 
 
Figure 9. Correlation of Bcl-2 promoter methylation and gene expression in carcinomas 
(slope= -0.005, R
2
=0.16, p=0.25)  
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Discussion 
 
DNA methylation is a well-established epigenetic mechanism that leads to 
changes in gene expression without DNA sequence alterations. Aberrant 
hypermethylation of promoters is a recognized mechanism by which the expression of 
tumor suppressor genes is inhibited during colon cancer development (134, 135). In 
contrast to hypermethylation of tumor suppressor genes, a region in the first exon of Bcl-
2 oncogene is completely demethylated allowing high-levels of Bcl-2 expression in B-
cell chronic lymphocytic leukemia (46).  Aberrant promoter methylation has been 
proposed as a prognostic marker of cancers, and the extent of methylation in a tumor is 
associated with disease progression, recurrence, and survival rates in various types of 
cancer (143-145).  For instance, colon cancer patients with promoter hypermethylation 
exhibit shorter cancer-specific survival compared with those without promoter 
hypermethylation (137).  
The combination of FO/P has been extensively studied to identify its 
chemoprotective mechanisms in colon carcinogenesis, including its ability to 
synergistically induce apoptosis (96, 97, 146). Apoptosis can be induced by changes in 
the regulation of histone acetylation, another epigenetic means of regulating gene 
transcription (85, 92). In addition, we have recently demonstrated that FO/P modulates 
non-coding microRNA in AOM-induced colon cancer, another epigenetic mechanism 
whereby FO/P regulates gene transcription (99, 147).  
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In this study, we investigated the ability of FO/P to modulate methylation-based 
epigenetic regulation of the Bcl-2 gene in the AOM-induced colon cancer model. 
Methylation of the Bcl-2 promoter was targeted because we previously demonstrated 
that the combination of FO/P, compared with CO/C, suppressed the level of Bcl-2 
expression, which occurred in parallel with the induction of colonocyte apoptosis (139). 
Therefore, the goal of this paper was to determine if a diet enriched in FO/P modulates 
the level of Bcl-2 gene expression by enhancing promoter methylation in vivo.  
As we previously reported (95), the incidence of colon tumors in rats consuming 
a FO/P diet was lower than in those consuming a CO/C diet. Part of the protection 
against tumor formation may be attributable to the enhanced apoptotic index in the rats 
consuming FO/P compared with those from rats consuming CO/C (Figure 7).  
Our results indicated that AOM-induced colon carcinomas exhibited a higher 
relative methylation of the Bcl-2 promoter in rats consuming a chemoprotective FO/P 
diet, compared to CO/C.  Interestingly, this effect was not found in the uninvolved tissue 
sections.  Although no other studies have investigated the effect of diet on methylation 
of Bcl-2, several reports have demonstrated dietary effects on DNA methylation in other 
genes within cancer cells or animal models of cancer.  For example, Nandakumar et al. 
demonstrated that green tea polyphenols restored the expression of the tumor suppressor 
genes Cip1/p21 and p16
INK4a
 in human skin cancer cells by suppressing DNA 
methylation (68). Fang et al. reported that genistein, a soy isoflavone, reversed 
hypermethylation and reactivated RARβ, p16INK4a, and MGMT in human esophageal 
squamous cancer cells (70).  Using the AOM-treated Apc
Min/+ 
mouse model, Volate et al. 
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determined that consumption of low concentrations of green tea led to demethylation of 
the RXRα promoter region, which restored RXRα expression in colon mucosa (69). The 
current study is the first to demonstrate Bcl-2 promoter methylation regulation by diet in 
vivo.  
Babidge et al. demonstrated that specific CpG dinucleotides in the Bcl-2 gene 
were methylated in 20% of human colorectal tumors, but that four CpG dinucleotides in 
the promoter region were not methylated in any colorectal tumors (47). In the current 
study, Bcl-2 promoter methylation declined from the levels observed at the intermediate 
stage of tumorigenesis (16 wk) to those found in the non-involved tissues at 34 wk after 
AOM injections.  By modulating the transcriptional regulation of Bcl-2 at the tumor 
stage, levels of apoptosis were suppressed as is recognized to occur in colon cancer (86, 
139, 148). However, the FO/P diet was able to enhance Bcl-2 promoter methylation in 
carcinomas, which should enhance apoptosis.  Indeed, Koelink et al. demonstrated that 
decreased tumor apoptosis was associated with a significantly higher probability of 
disease recurrence in colon tumors (149).  Since cancer cells are resistant to the 
induction of apoptosis, reversing Bcl-2 promoter hypomethylation by a FO/P diet could 
offer a therapeutic approach. 
The levels of Bcl-2 transcripts were numerically lower in tumors from rats 
consuming a diet containing FO/P compared with CO/C.  Even though the difference 
between diet groups was not significant, the pattern of response was similar to a previous 
report (139), and reflects the elevated methylation state in carcinomas from the FO/P rats 
in this study. An extensive comparison could not be made due to the relatively small 
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number of samples for which both DNA and RNA was available.  However, other 
researchers have demonstrated that diets rich in fish oil prevented the expression of Bcl-
2 in the colon cancer cells (148, 150), as well as other cell types (151). Moreover, this 
result is comparable to those of Zhu et al., who reported that the Bcl-2 gene promoter is 
hypomethylated in colorectal cancer tissues, and that Bcl-2 methylation was inversely 
correlated with Bcl-2 protein expression in those tissues (152). Similar results were also 
demonstrated by Carvalho et al. who found that Bcl-2 mRNA expression was inversely 
correlated with promoter methylation in advanced stage prostate carcinomas (153).  
In summary, these data suggest that dietary FO/P promotes apoptosis in part by 
enhancing Bcl-2 promoter methylation in colon tumors relative to a CO/C diet. This 
finding contributes to our understanding of the mechanisms whereby diets containing 
FO/P are chemoprotective against colon cancer.  In order to fully appreciate how a diet 
containing FO/P modulates DNA methylation during colon carcinogenesis, the effects of 
FO/P on DNA methyltransferases (the enzymes responsible for DNA methylation) 
should be investigated.  
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CHAPTER IV 
NUTRIEPIGENETIC REGULATION OF APOPTOSIS-RELATED GENES  
BY DHA AND BUTYRATE 
 
 Aberrant epigenetic changes in chromatin, such as DNA hypermethylation and 
histone deacetylation, contribute to the transcriptional regulation of genes involved in 
apoptosis. We have demonstrated that decosahexaenoic acid (DHA, 22:6 n-3) and 
butyrate enhance colonocyte apoptosis. To determine if DHA and/or butyrate elevate 
apoptosis through epigenetic mechanisms thereby restoring the transcription of 
apoptosis-related genes, we examined global methylation, gene specific promoter 
methylation of 24 apoptosis-related genes, apoptosis, transcription levels of Cideb, 
Dapk1, and Tnfrsf25 and global histone acetylation in HCT-116 cell line. Cells were 
treated with combinations of (50 µM) DHA or linoleic acid (LA, 18:2 n-6), (5 mM) 
butyrate or an inhibitor of DNA methyltransferases, 5-aza-2’-deoxycytidine (5-Aza-dC, 
2 µM).  Among highly methylated genes, the combination of DHA and butyrate 
significantly reduced the methylation of the proapoptotic Bcl2l11, Cideb, Dapk1, Ltbr, 
and Tnfrsf25 genes, and increased apoptosis by 180% compared to untreated control.  
DHA treatment reduced the methylation of Cideb, Dapk1, and Tnfrsf25. These data 
suggest that the induction of apoptosis by DHA and butyrate are regulated, in part, 
through changes in the methylation state of apoptosis-related genes. 
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Introduction 
 
During carcinogenesis, gene transcription is aberrantly regulated via epigenetic 
changes. These changes include DNA methylation and histone modification and occur 
primarily in the promoter region of select genes (33, 34). Clinical studies have 
demonstrated a correlation between DNA methylation and the pathological and 
epidemiological features of colon cancer (134, 135, 154). Recent data indicate that 
promoter methylation of proapoptotic genes suppresses transcription, resulting in the 
cancer cell survival (43).  For instance, Dapk1 is a positive mediator of apoptosis, a 
tumor suppressor candidate, and is known to be heavily methylated in colon and bladder 
cancer (44, 45). Restoring transcription of tumor suppressor genes by the reversal of 
these epigenetic processes is considered a latent target of cancer prevention and 
treatment.  
We have previously shown that a combination of fish oil (high in DHA, an n-3 
polyunsaturated fatty acid (PUFA)) and the fiber pectin (fermented to short chain fatty 
acids including butyrate by the colonic microflora) is protective against colon 
carcinogenesis in part by up-regulating the apoptotic removal of DNA damaged cells 
(101).  In contrast, diets highly enriched in corn oil (high in LA, an n-6 PUFA) suppress 
apoptosis and promote colon cancer (84).  We have demonstrated that apoptosis 
induction by the combination of fish oil and pectin is in part contingent upon DHA 
incorporation into mitochondrial phospholipids (78), while  butyrate functions as an 
energy substrate and histone deacetylase inhibitor (56).  Another potential mechanism 
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involved in tumor suppression by fish oil/pectin is through the transcriptional regulation 
of key tumor suppressors or oncogenes.  In a previous study, we demonstrated the effect 
of fish oil/pectin on global changes in gene expression profiles in carcinogen injected 
Sprague-Dawley rats.  One result from the pathway analyses of those data was the 
observation that the expression of genes that promote apoptosis was up-regulated in rats 
consuming the fish oil/pectin diet at the tumor endpoint (85).  Moreover, we have 
reported that the promoter region of Bcl-2, an antiapoptotic mediator, in carcinogen-
induced colon tumors is highly methylated which was associated with induction of 
apoptosis in colonocytes from rats consuming a fish oil/pectin diet (155).  
However, it has not been determined if DHA and/or butyrate can directly affect 
the aberrant promoter methylation of cancer-promoting genes in cancer cells. Therefore, 
the aim of this study was to investigate the epigenetic regulation of apoptosis-related 
genes in colon cancer cells exposed to DHA and/or butyrate. For this purpose, we 
examined global DNA methylation and histone acetylation in combination with gene 
specific promoter methylation of 24 apoptosis-related genes in HCT-116 human colon 
cancer cells. 
 
Materials and Methods 
 
Cell culture 
 HCT-116 cells were cultured in McCoy’s 5A (Gibco, Grand Island, NY) 
supplemented with 10% fetal bovine serum (Hyclone, Logan, UT) and 2 mM GlutaMAX 
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(Gibco) at 37°C in 5% CO2. Cells (passages 11-13) were seeded onto 100 mm cell 
culture dishes or six-well plates at a density of 3.0×10
4 
cells and allowed to attach for 24 
h (Figure 10). (Appendix B-9) 
 Experiment I: Fifty µM bovine serum albumin (BSA)-complexed DHA or LA 
(Nu Chek Prep. Inc) was used to treat cells for 72 h (94). Cells were co-incubated with 5 
mM sodium butyrate (Sigma, St. Louis, MO) during the final 12 h of the fatty acid 
treatment period (96). 5-Aza-dC (2 µM), a potent inhibitor of DNA methylation (Santa 
Cruz Biotechnology, Santa Cruz, CA) served as a positive control, and cells were treated 
for 48 h (Appendix B-11).  Negative controls were cells incubated in media without 
BSA-complexed fatty acids or butyrate (Appendix B-10). 
 Experiment II: The goal of this experiment was to determine the time-course for 
gene expression relative to treatment with 5-Aza-dC, fatty acids and/or butyrate.  For 
this purpose, all cells received the assigned treatments at time 0, and gene expression 
was monitored in cells harvested at 48, 72 and 96 h post treatment initiation. The 
treatments included 50 µM BSA-DHA or BSA-LA, 5 mM butyrate, or 2 µM 5-Aza-dC.  
Global DNA methylation assay  
 Genomic DNA was isolated from HCT-116 cells using QIAamp DNA mini kit 
(Qiagen, Valencia CA, Appendix B-12). Global methylation was quantified using a 
MethylFlash methylated DNA quantification kit (Epigentek, Farmingdale, NY). Briefly, 
100 ng of genomic DNA was pipetted into multiwell plates coated with a 5-
methylcytosine antibody and incubated at 37°C for 90 min.  DNA was subsequently 
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Figure 10. Design of cell culture experiments. 
  
 
 
washed and a capture antibody added prior to incubation at room temperature for 30 
min.  At the end of the incubation period, the capture antibody solution was removed and 
replaced with an enhancer solution followed by another 30 min incubation at room 
temperature.  The extent of global methylation was measured by reading absorbance at 
450 nm. The relative methylation status of each sample was determined using positive 
and negative controls provided in the kit (Appendix B-13).  
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Apoptosis assay  
 Apoptosis was measured using Cell Death Detection ELISA plus kit (Roche, 
Indianapolis, IN). For this assay, the floating cells were collected, washed, lysed and 
centrifuged to remove intact DNA. The supernatant, which includes both mono- and 
oligonucleosomes from the cell lysates, was transferred to a streptavidin-coated 
microplate.  Anti-histone antibody and anti-DNA antibodies were added to the wells, in 
order to promote the binding of the antibody-nucleosome complex to the microplate.  
After a washing step to remove non-bound cellular debris, the samples were incubated 
with a peroxidase substrate and the absorbance was measured at 405 nm.  Data were 
normalized with the number of cells to calculate the apoptotic index as previously 
described (94) (Appendix B-14).  
Gene specific DNA methylation  
 DNA methylation of apoptosis-related genes was determined using a Methyl-
Profiler DNA methylation PCR array (SABiosciences, Valencia, CA, MeAH-121C-2). 
Genes included on the array are listed in Table 9. Briefly, 1 µM of genomic DNA from 
HCT-116 cells was separated into four equal aliquots and treated with: 1) a mock 
enzyme, 2) a DNA methylation sensitive enzyme, 3) a DNA methylation dependent 
enzyme, or 4) both the DNA methylation sensitive and dependent enzymes at 37°C 
overnight. The relative DNA methylation status was determined using Ct values from 
qRT-PCR as previously described (156). Data are presented as a percentage of cellular 
DNA containing methylated gene promoters, which included a combination of both the 
intermediate level of methylation and hypermethylated DNA (Appendix B-15).  
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Table 9. Gene specific DNA methylation targets using PCR array 
RefSeq 
accession 
number Symbol Description 
NM_009684 Apaf1 Apoptotic peptidase activating factor 1 
NM_007522 Bad BCL-2-associated agonist of cell death 
NM_009736 Bag1 Bcl-2-associated athanogene 1 
NM_007527 Bax Bcl-2-associated X protein 
NM_009741 Bcl2 B-cell leukemia/lymphoma 2 
NM_009754 Bcl2l11 BCL-2-like 11 (apoptosis facilitator) 
NM_153787 Bclaf1 BCL-2-associated transcription factor 1 
NM_007544 Bid BH3 interacting domain death agonist 
NM_007546 Bik Bcl-2-interacting killer 
NM_007465 Birc2 Baculoviral IAP repeat-containing 2 
NM_009761 Bnip3l BCL-2/adenovirus E1B interacting protein 3-like 
NM_009810 Casp3 Caspase 3 
NM_015733 Casp9 Caspase 9 
NM_009894 Cideb 
Cell death-inducing DNA fragmentation factor, alpha subunit-like 
effector B 
NM_009950 Cradd CASP2 and RIPK1 domain containing adaptor with death domain 
NM_029653 Dapk1 Death associated protein kinase 1 
NM_010044 Dffa DNA fragmentation factor, alpha subunit 
NM_010175 Fadd Fas (TNFRSF6)-associated via death domain 
NM_007836 Gadd45a Growth arrest and DNA-damage-inducible 45 alpha 
NM_007545 Hrk Harakiri, BCL-2 interacting protein (contains only BH3 domain) 
NM_010736 Ltbr Lymphotoxin B receptor 
NM_178589 Tnfrsf21 Tumor necrosis factor receptor superfamily, member 21 
NM_033042 Tnfrsf25 Tumor necrosis factor receptor superfamily, member 25 
NM_011640 Trp53 Transformation related protein 53 
 
 
 
Gene expression using qRT-PCR 
 Total RNA was extracted from HCT-116 cells using a RNAqueous Kit (Ambion, 
Grand Island, NY) and DNase treated. The cDNA was synthesized from 2 g total RNA 
using random hexamers and oligo dT primers with SuperScript II reverse transcriptase 
(Invitrogen). Transcript levels were determined using Taqman gene expression assays 
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(Applied Biosystems, Foster City, CA; Cideb Hs00205339_m1, Dapk1  
Hs00234489_m1, and Tnfrsf25 Hs00980365_g1) with an ABI Prism 7900HT PCR 
sequence detector. Expression levels were normalized to Eukaryotic 18S rRNA 
expression (Hs99999901_s1). Linearity of each assay was assessed prior to analysis of 
the samples. Negative controls that were prepared during the reverse transcription 
reactions by eliminating the RT enzyme were analyzed for each gene. 
Histone H3 and H4 acetylation 
 The acetylation levels of histone H3 and H4 were assessed using the EpiQuik 
total histone H3/H4 acetylation detection fast kit (Epigentek). Histone proteins were 
extracted as per Kit (Epigentek) instructions and the sample concentrations were 
measured using a BCA Protein Assay Kit (Pierce, Waltham, MA). Separate assays were 
performed to determine acetylation status for the H3 and H4 histones.  These assays used 
2 μg of nuclear proteins incubated with anti-acetylated histone H3-specific or H4-
specific antibodies.  In each assay a detection antibody was added along with a color 
development reagent, and the absorbance was measured at 450 nm (Appendix B-16 and 
B-17). 
Statistical analysis 
 Data were analyzed using one-way ANOVA and Duncan’s multiple range tests 
for global methylation, apoptosis, transcription level of Dapk1 and Tnfrsf2, and global 
H3 or H4 histone acetylation. To determine if gene-specific methylation was different 
between each treatment group and the negative control group, the statistical analysis was 
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carried out using a Wilcoxon rank test. Data are presented as means ± SEM, and means 
were considered different when the resulting p-value was less than 0.05. 
 
 Results 
 
Global methylation 
 We determined the effects of the PUFA and/or butyrate on the level of global 
DNA methylation in HCT-116 cells. Both DHA and butyrate independently decreased 
(p<0.05) global methylation whereas the combination of DHA and butyrate did not 
produce a significant demethylating effect compared to the negative control (media  
only). In comparison, the positive control, 5-Aza-dC (2 M), significantly suppressed 
global methylation, as expected (Figure 11).  
Gene-specific promoter methylation of apoptosis-related genes 
 We examined DNA methylation status at promoter CpG islands of 24 apoptosis-
related genes (Table 10). Of the 24 apoptosis-related genes on the assay card, over 60% 
of CpG dinucleotides in the promoter of 6 genes (Bcl-2, Bcl2l11, Cideb, Dapk1,  
Tnfrsf25, and Ltbr) were methylated in the negative control group. The positive control 
treatment, 5-Aza-dC, induced demethylation only when the CpG rich region of a gene 
promoter was heavily methylated (> 60%). 
 Treatment with 5-Aza-dC resulted in a 28% decrease in the level of promoter 
methylation in Dapk1, compared to the negative control (media only). The promoter 
methylation level of Bcl2l11 was 97% inhibited by 5-Aza-dC compared with the 
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Figure 11.  Global DNA methylation status (percent of the negative control) in HCT-116 
cells cultured with 5-Aza-dC, butyrate, DHA, LA, or co-treatment.  Values are means ± 
SEM.  Values not sharing common letters are significantly different, p < 0.05,  n = 6 per 
treatment from 2 independent experiments.  Negative controls represent cells incubated 
in media only.  DHA, decosahexaenoic acid; LA, linoleic acid. Data for this figure is 
found in Appendix Table A-3 and A-5. 
 
 
 
negative control.  Butyrate had demethylating effects on the Bcl2l11 promoter, and DHA 
treatment significantly decreased the levels of promoter methylation of Cideb, Dapk1, 
and Tnfrsf25 compared to the negative control group.  LA suppressed promoter 
methylation of Bcl-2, which is an anti-apoptotic mediator.  The combination of DHA and 
butyrate resulted in the demethylation of Bcl2l11, Cideb, Dapk1, Ltbr, and Tnfrsf25. 
Colonocyte apoptosis 
 We next determined if differences found in global methylation and gene-specific 
methylation affected apoptosis induction. DHA combined with butyrate induced 
significantly higher levels of apoptosis compared to all other treatment combinations 
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(Figure 12). The 5-Aza-dC treatment induced 68% more apoptosis compared to the 
untreated negative control treatment.  Butyrate either by itself or when combined with 
DHA or LA enhanced apoptosis. The combination of LA and butyrate exhibited a 
similar level of apoptosis compared to butyrate alone, suggesting that this combination 
did not augment apoptosis above that obtained with only butyrate. 
 
 
 
Figure 12. Colonocyte apoptosis in HCT-116 cells cultured with 5-Aza-dC, butyrate, 
DHA, LA, or co-treatment (percent of the negative control).  Values are means ± SEM.  
Values not sharing common letters are significantly different, P<0.05, n = 6 per 
treatment from 2 independent experiments.  The negative controls were cells incubated 
in media only.  Data for this figure is found in Appendix Table A-3 and A-5. 
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Table 10. Extent of apoptosis-related gene promoter methylation (%)
1
 in HCT-116 cells 
cultured with 5-Aza-dC, butyrate, DHA, LA, or co-treatment. 
  
Gene 
symbol 
Negative 
control 
Positive 
control  
5-Aza-dC 
Butyrate DHA LA 
DHA +      
butyrate 
LA +        
butyrate 
Highly methylated genes       
 Bcl-2 98.83 ± 0.27 80.62 ± 4.02* 98.26 ± 0.36 94.55 ± 3.31 97.78 ±0.25* 97.87 ± 0.48 98.35 ± 0.35 
 Bcl2l11 68.86 ± 1.74 2.10 ± 0.63* 52.58±10.24* 53.79 ±10.84 62.22 ± 2.66 52.11 ±9.82* 60.48 ±3.02* 
 Cideb 94.63 ± 1.52 77.01 ± 2.81* 88.83 ± 2.58 84.69 ±3.27* 85.02 ±0.94* 86.89 ±2.00* 89.62 ± 2.37 
 Dapk1 96.35 ± 0.28 69.84 ± 2.90* 94.86 ± 0.67 93.45 ±1.32* 94.88 ±0.16* 94.10 ±0.31* 94.88 ± 0.55 
 Ltbr 64.55 ± 1.29 29.39 ± 4.87* 61.64 ± 1.21 59.68 ± 2.70 59.99 ±1.15* 57.94 ±1.54* 61.11 ± 1.10 
Tnfrsf25 97.20 ± 0.53 76.79 ± 2.30* 95.43 ± 0.90 92.80 ±1.85* 93.26 ±0.53* 94.07 ±0.99* 95.41 ± 0.93 
Not highly methylated genes 
      
 Apaf1 0.76 ± 0.10 0.45 ± 0.13 0.40 ± 0.13 0.67 ± 0.23 0.53 ± 0.12 0.54 ± 0.22 0.32 ± 0.07* 
 Bad 1.08 ± 0.09 2.16 ± 0.89 2.25 ± 0.58 2.32 ± 0.61 2.13 ± 0.52* 1.90 ± 0.38* 1.55 ± 0.56 
 Bag1 6.81 ± 0.58 14.84 ± 5.43* 15.88 ± 3.66 15.89 ± 3.80 15.67 ±1.93* 14.13 ±2.93* 12.85 ± 4.22 
 Bax 0.69 ± 0.07 0.65 ± 0.11 0.58 ± 0.20 0.81 ± 0.18 0.65 ± 0.14 0.75 ± 0.26 0.41 ± 0.08* 
 Bclaf1 0.96 ± 0.11 1.15 ± 0.39 1.40 ± 0.34 1.68 ± 0.38 1.49 ± 0.31 1.49 ± 0.19* 1.30 ± 0.40 
 Bid 6.56 ± 0.24 7.52 ± 2.74 12.78 ± 2.89 11.23 ± 2.53 13.03 ±1.20* 11.60 ±1.39* 12.04 ± 2.4* 
 Bik 2.84 ± 0.20 10.67 ± 5.25* 9.84 ± 2.91 24.80 ±9.70* 30.42 ±9.85*  8.92 ± 2.35* 7.48 ± 3.30 
 Birc2 2.00 ± 0.17 3.67 ± 1.47 4.62 ± 1.06 4.92 ± 1.36 5.16 ± 1.05* 4.16 ± 0.93* 3.17 ± 1.15 
 Bnip3l 0.81 ± 0.10 0.69 ± 0.15 1.03 ± 0.39 1.12 ± 0.21 1.07 ± 0.11 1.03 ± 0.24 0.61 ± 0.19 
 Casp3 1.21 ± 0.05 2.06 ± 0.67 10.74 ± 8.13* 2.38 ± 0.61 2.31 ± 0.40* 2.00 ± 0.35* 1.71 ± 0.54 
 Casp9 3.58 ± 0.34 5.11 ± 0.31* 3.22 ± 0.19 3.44 ± 0.24 3.15 ± 0.26 3.74 ± 0.62 2.80 ± 0.10 
 Cradd 1.54 ± 0.56 1.33 ± 0.23 1.48 ± 0.32 1.59 ± 0.37 1.35 ± 0.18 1.69 ± 0.34 1.00 ± 0.20 
 Dffa 0.80 ± 0.05 0.65 ± 0.14 0.68 ± 0.25 0.77 ± 0.16 0.74 ± 0.19 0.79 ± 0.19 0.45 ± 0.09* 
 Fadd 0.50 ± 0.09 0.50  ± 0.10 0.49  ± 0.19 0.71  ± 0.18 0.67  ± 0.17 0.59  ± 0.12 0.28  ± 0.08 
Gadd45a 10.85 ± 1.26 17.73 ± 6.69 27.02 ± 7.71 32.17 ±10.33 31.76 ±5.09* 26.42 ± 6.85 22.36 ± 7.30 
 Hrk 16.14 ± 1.23 32.76 ± 4.88* 32.95 ± 6.15 37.31 ±6.85* 46.33 ±4.10* 33.85 ±  7.14 30.83 ±6.23* 
 Tnfrsf21 0.67 ± 0.08 0.58 ± 0.19 0.67 ± 0.24 0.79 ± 0.23 0.48 ± 0.10 0.62 ± 0.22 0.37 ± 0.08* 
  Trp53 1.20 ± 0.50 1.75 ± 0.67 1.92 ± 0.47 2.11 ± 0.47 2.01 ± 0.39* 1.88 ± 0.33 1.49 ± 0.54 
1
 Data are presented as a percentage of cellular DNA containing methylated gene 
promoters, which included a combination of both the intermediate level of methylation 
and hypermethylated DNA. 
* Different from the negative control group (p < 0.05). Data are expressed as means ± 
SEM from 5-6 samples per treatment from 2 independent experiments.  The negative 
controls represent cells incubated in media only.  
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The transcription levels of Tnfrsf25 and Dapk1 
 To determine the time-course of gene expression, HCT-116 cells were incubated 
with experimental agents for 48, 72, and 96 h and the transcription levels of Cideb, 
Dapk1, and Tnfrsf25 were quantified by qRT-PCR. These genes were chosen because of 
their hypermethylated status and response to 5-Aza-dC, DHA, and the combination of 
DHA and butyrate. The 5-Aza-dC treatment induced the expression of Dapk1, and 
Tnfrsf25 after 72 and 96 h incubation (Figure 13).  Dapk1 expression was elevated by 
more than 100 and 200% at 72 h and 96 h of 5-Aza-dC treatment, respectively, as 
compared with the negative control cells.  The transcript level of Cideb was only 
detectable following 5-Aza-dC treatment, suggesting that 5-Aza-dC restored the 
expression of this gene (data not shown).  Butyrate dramatically up-regulated Tnfrsf25 
and Dapk1 transcript levels at 48h, but declined thereafter. Similar to the data obtained 
with butyrate alone, the combination of butyrate with DHA or LA resulted in a rapid 
elevation in transcript levels, followed by a subsequent decline in expression. 
Global histone H3/H4 acetylation 
 The increase in transcript levels of Tnfrsf25 and Dapk1 by butyrate treatment led 
us to examine whether gene expression was influenced by a treatment effect on histone 
acetylation status. Therefore, we assessed the global histone acetylation levels of H3 and 
H4 in HCT-116 cells. Cells treated with 5-Aza-dC demonstrated no significant changes 
in histone acetylation state.  Interestingly, global H3 histone acetylation levels were 
elevated in butyrate treated cells compared to the negative controls, but there was no 
significant difference between butyrate and the other treatment groups. The global H4  
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Figure 13. Time-course analysis of Tnfrsf25 (A) and Dapk1 (B) transcript levels in HCT-
116 cells cultured with 5-Aza-dC, butyrate, DHA, LA, or co-treatment (expressed as 
percentage of the negative control). Values are means ± SEM. *Different from the 
negative control sample measured at the same time point, P < 0.05, n = 3 per treatment.  
The negative controls were cells incubated in media only.  Data for this figure is found 
in Appendix Table A-4 and A-6.  
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histone acetylation level increased in cells treated with LA or LA combined with 
butyrate (Figure 14). 
 
 
 
 
Figure 14. H3 and H4 histone acetylation in HCT-116 cells incubated with 5-Aza-dC, 
butyrate, DHA, LA, or co-treatment (expressed as percentage of the negative control). 
Values are means ± SEM. *Different from the negative control, P < 0.05, n = 3 per 
treatment.  The negative controls were cells incubated in media only.  Data for this 
figure is found in Appendix Table A-3 and A-5. 
 
 
 
Discussion 
 
The transcriptional regulation of apoptosis-associated genes by DNA methylation 
is one of the mechanisms by which cancerous cells avoid apoptosis. The aberrant 
alteration of DNA methylation is either by hypermethylation to suppress expression of 
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proapoptotic genes or by hypomethylation to promote expression of antiapoptotic genes 
(43).  
Studies have been conducted on DNA methylation status of apoptosis-related 
genes in prostate cancer (157), glioblastoma multiforme (158), and bladder cancer (44). 
Specifically, promoter regions of apoptosis-related genes are hypermethylated and 
correlate with tumor phenotype, so that aberrant DNA methylation of apoptosis-related 
genes can be considered a biomarker for cancer diagnosis. 
In this study, we investigated the promoter methylation status of 24 apoptosis-
related genes in response to DHA or LA and/or butyrate co-treatment in human colon 
cancer cells. Methylation of apoptosis-related genes was targeted because we previously 
demonstrated that the combination of fish oil/n-3 PUFA and pectin/butyrate affected the 
expression level of genes involved in apoptosis and enhanced colonocyte apoptosis (85, 
139). The goal of this paper was to determine if DHA and/or butyrate modulates the 
expression level of apoptosis-related genes by suppressing promoter methylation in  
vitro. Hypermethylation was detected for six apoptosis-related genes, including Bcl-2, 
Bcl2l11, Cideb, Dapk1, Ltbr, and Tnfrsf25, which are also methylated in colon cancer or 
other types of cancers (45, 47, 159-161). Friedrich et al. had similar results in bladder 
tumor samples, wherein Dapk1, and Tnfrsf25 were hypermethylated compared with 
nonmalignant adjacent tissue (44).  
DHA and LA treatments decreased promoter methylation of Cideb, Dapk1, and 
Tnfrsf25, which are all linked to a proapoptotic phenotype. However, LA combined with 
butyrate did not exhibit a demethylating effect on these three genes.  DHA combined 
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with butyrate also reduced DNA methylation of these three genes as well as Bcl2l11 and 
Ltbr (Table 10). We have previously demonstrated that combination chemotherapy 
using DHA and butyrate most effectively enhanced colonocyte apoptosis (96).  We 
demonstrate for the first time that part of the enhanced apoptosis by the combination of 
DHA and butyrate may be attributable to the demethylating effect of proapoptotic genes 
in colon cancer cells.  
Butyrate decreased promoter methylation of Bcl2l11 as well as global 
methylation. In addition, it caused a 4-fold increase in the transcription levels of Tnfrsf25 
and Dapk1 at 48 h, and also increased their expression when combined with LA and 
DHA. These increases in gene expression might be due to an effect of butyrate on 
histone deacetylation because it is a well-known inhibitor of histone deacetylase. It is 
known that histone acetylation mainly occurs at the promoter region of genes in the 
process of transcription whereas histone deacetylation occurs in the promoter region 
leading to gene expression silencing (162). The promoter region of Dapk1 and Tnfrsf25 
are proximate to sites where histone modifications occur (163). Therefore, the increased 
histone acetylation by butyrate might contribute to the induction of gene expression of 
these genes. We found that butyrate enhanced global histone H3 methylation and this 
result is comparable to that of Kobori et al., who noted that 10 mM butyrate enhanced  
25% more histone H3 acetylation than a control group in human colon cancer cells  
(164). However, it will be necessary to study site-specific histone acetylation to fully 
appreciate the influence of histone modifications on increases of Dapk1 and Tnfrsf25 
expression.  
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With respect to the time-dependent increases in gene expression due to the 5-
Aza-dC treatment, our results are comparable to those of others showing that 5-aza-
cytidine, the analog of 5-Aza-dC, increased the expression level of p16 as incubation 
time progressed (165). Indeed, 72 h exposure to 2 µM 5-Aza-dC suppressed Dapk1 
promoter methylation by 28% and induced a 1.5-fold increase in Dapk1 transcription 
(Figure 13).  Recently, Shu et al. reported that curcumin resulted in a similar reduction 
in promoter methylation of Neurog1 in prostate cancer cells and that this reduction led to 
the 2-fold increase of Neurog1 mRNA expression (71). However, the decreases in 
promoter methylation caused by DHA, compared to the negative control in this study 
were less than 50% of the decrease obtained with the positive control (5-Aza-dC, 18-
27%).  
The 5-Aza-dC treatment, a DNMT inhibitor, has been intensively studied as a 
compound that inhibits DNA methylation and restores the expression level of tumor 
suppressor genes (38). This compound is incorporated into DNA and acts as a substrate 
for DNMT. However it adheres to DNMT and remains as a covalent protein-DNA 
adduct, thereby suppressing DNA methylation.  Dietary compounds, such as 
epigallocatechin-3-gallate (EGCG, green tea compound) interrupt DNMT activity by 
blocking the active site of the enzyme (65). Therefore, it is possible that the 
demethylating effect of DHA might be exerted through mechanisms other than that 
employed by 5-Aza-dC. DHA is primarily incorporated into phosphatidylethanolamine 
(PE), which is converted to phosphatidylcholine (PC) through the addition of methyl 
groups from S-adenosyl methionine (79). Recently, Kale et al. found that when DHA 
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was lacking, there was less PE-containing DHA, and the resulting excess in available 
methyl groups could be used for DNA methylation by DNMT (77).  This finding 
suggests that DHA could suppress DNA methylation by consuming methyl groups.  
Therefore, DHA may indirectly suppress DNMT activity whereas 5-Aza-dC directly 
inactivates DNMT.  In our current study, DHA inhibited global methylation and 
promoter methylation of proapoptotic genes, yet the demethylating effect of DHA was 
not sufficient to induce gene expression. There was a similar report that reduced 
promoter methylation by butyrate was not sufficient to allow re-expression of genes 
(166).  
In summary, we have shown that the combination of DHA and butyrate promotes 
apoptosis in part by enhancing promoter methylation of the proapoptotic genes Bcl2l11, 
Cideb, Dapk1, Ltbr, and Tnfrsf25 in colon cancer cells. We observed that DHA has 
global and modest gene-specific demethylating activity, which may have implications 
for a synergistic effect with the inhibitor of DNA methylation, such as 5-Aza-dC.  
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CHAPTER V 
SUMMARY AND CONCLUSION 
  
Summary 
 
 Colon cancer is the second leading cause of cancer mortality in the United States. 
The incidence of colon cancer is known to be affected by environmental factors, such as 
diet. Studies using AOM injected rats revealed that the combination of FO/P, compared 
to CO/C, is protective against colon cancer (95). Fish oil contains high concentrations of 
n-3 PUFA, such as DHA and EPA which are bioactive compounds in fish oil. In contrast, 
corn oil contains high levels of n-6 PUFA like linoleic acid that is prevalent in Western 
diets. It is documented that diets containing high levels of n-6 PUFA promote colon 
cancer (84). Fermentable fibers, such as pectin, can be utilized by microorganisms in the 
colon and fermented to short chain fatty acids like butyrate.  One mechanism whereby 
the combination of FO/P is chemoprotective is the induction of apoptosis, a programmed 
form of cell death (95, 98).   
 Accumulated genetic mutations of tumor suppressor genes and oncogenes are 
found during colon cancer development.  If DNA mutations occur within sequences 
encoding proteins, it could disrupt the expression and function of those genes, resulting 
in the growth of neoplastic cells.  In addition, epigenetic alterations, such as DNA 
methylation and histone modification, contribute to colon carcinogenesis through 
changes in gene transcription.  The epigenetic regulation of transcription is 
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accomplished by preventing transcription factor binding or providing a binding site for 
methyl-binding proteins, which form a repressive complexs with histone deacetylases 
and histone methyltransferases. 
 To monitor the changes in the expression of genes involved in apoptosis and cell 
proliferation during the tumorigenic process, we analyzed temporal gene expression 
profiles from exfoliated rat colonocytes.  The combination of FO/P modulated global 
gene expression profiles at biologically important time points in carcinogen injected rats 
and these changes in gene expression were consistent with phenotypic observations at 
each time point. At initiation, FO/P down-regulated the expression of genes involved 
with cell adhesion and enhanced apoptosis compared with CO/C.  At the ACF stage, the 
expression of genes involved in cell cycle regulation was modulated by FO/P and the 
zone of proliferation was reduced in FO/P rats compared with CO/C rats.  The diet 
containing FO/P also increased apoptosis and the expression of genes that promote 
apoptosis at the tumor endpoint compared with CO/C.  
 We then proceeded to determine if changes in expression of genes involved in 
apoptosis in response to a FO/P diet are associated with changes in methylation of the 
promoter regions of these genes. Methylation of the Bcl-2 promoter was targeted 
because we previously demonstrated that the combination of FO/P, compared with  
CO/C, suppressed the level of Bcl-2 expression and the induction of colonocyte 
apoptosis (139).  To test the hypothesis that changes in expression of Bcl-2 in response 
to a FO/P diet are associated with changes in methylation of the promoter region of Bcl-
2, the methylation status of the Bcl-2 promoter region and the transcription level of Bcl-2 
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were measured in colon tumors and non-involved colon tissues of rats exposed to a 
carcinogen. The FO/P diet increased Bcl-2 promoter methylation in tumor tissues and 
colonocyte apoptosis relative to those observed with the CO/C diet. A tendency for a 
negative relationship between Bcl-2 DNA methylation and Bcl-2 mRNA levels was 
observed in the tumors.  
 The final study examined the ability of DHA and butyrate to affect DNA 
methylation of genes involved in apoptosis using human colon cancer cells. The 
combination of DHA and butyrate led to a significant reduction in the methylation of 
Bcl2l11, Cideb, Dapk1, Ltbr, and Tnfrsf25, which are all pro-apoptotic genes that exhibit 
highly methylated promoter regions in these cancer cells.  The combination of DHA and 
butyrate also led to an increase in apoptosis in this colon cancer cell line.  DHA 
treatment provoked global demethylation and the decreases in the methylation of Cideb, 
Dapk1, and Tnfrsf25, whereas LA suppressed promoter methylation of Bcl-2.  
 
Conclusion 
 
 The effects of chemotherapeutic diets on epithelial cell gene expression can be 
monitored noninvasively throughout the tumorigenic process. This noninvasive 
technique makes it feasible to monitor human disease progression and identify critical 
time points for potential diet intervention. The diet containing FO/P is chemoprotective 
in part due to its ability to affect expression of genes involved in apoptosis and cell cycle 
regulation throughout all stages of tumorigenesis.  The changes in the transcription 
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levels of apoptosis-related genes and the induction of apoptosis by this dietary 
intervention were regulated through changes in the methylation state of these genes. 
Taken together, this study enhances an understanding of how the chemoprotective FO/P 
diet modulates the transcription of apoptosis-related genes during colon carcinogenesis, 
so that we could have an underlying principle for the benefits of this dietary intervention 
on colon cancer.  
 
Future research 
 
 This was the first study to show that a chemoprotective FO/P diet modulates 
epigenetic mechanisms including promoter methylation. We saw significant effects of 
FO/P on promoter methylation of apoptosis-related genes in human colon cancer cells 
and a carcinogen injected colon cancer model, but further research is needed. 
 Future research should study the mechanism by which FO/P modulates promoter 
methylation of cancer-related genes. This work should determine if the combination of 
n-3 PUFA and butyrate are affecting DNA methylation through their ability to influence 
either expression or activity of DNA methyltransferases (DNMTs), which are the 
enzymes that regulate methyl group transfer.  It has been reported that DNMT1 is over-
expressed in several types of cancers. Experiments could be planned to investigate the 
dose and time dependent effects of n-3 PUFA and/or butyrate on the activity of DNMT1, 
DNMT3A and DNMT3B in normal and colon cancer cell lines. 
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 It would be also beneficial to study the effect of DHA on the supply of S-
adenosyl methionine.  Dietary DHA could increase DHA-containing phospholipids 
which competitively use methyl groups. Future experiments should determine if DHA 
affects the availability of the methyl group which can be used for DNA methylation. 
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 APPENDIX A 
TABLES OF RESULTS 
 
 
Chapter III 
Table A-1. The effect of FO/P on colon cancer incidence, apoptosis index, Bcl-2 
promoter methylation, and Bcl-2 expression 
Item CO/C FO/P 
P-value 
(one-sided) 
Colon tumor incidence (%) 75.60 51.50 0.016 
Apoptosis index 1.40 ± 0.23 2.62 ± 0.52 0.020 
Relative Bcl-2 promoter methylation at 16 wk 
(non-involved tissues) (%) 
100.00 ± 16.54 68.64 ± 12.87 0.083 
Relative Bcl-2 promoter methylation at 34 wk 
(non-involved tissues) (%) 
100.00 ± 10.72 134.48 ± 29.47 0.204 
Relative Bcl-2 promoter methylation at 34 wk 
(carcinomas) (%) 
153.27 ± 17.54 245.11 ± 50.31 0.009 
Relative Bcl-2 gene expression in carcinomas (%) 100.00 ± 31.74 53.32 ± 21.52 0.13 
Values are means ± SEM. 
 
 
 
 
Chapter III 
Table A-2. The effect of time on Bcl-2 promoter methylation  
Item 16 wk 34 wk 
P-value 
(one-sided) 
Relative Bcl-2 promoter methylation  
(non-involved tissues) (%) 
100.00 ± 13.11 52.87 ± 6.18 0.001 
Values are means ± SEM. 
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Chapter IV 
Table A-3. Global methylation, apoptosis, and histone acetylation in HCT-116 cells 
cultured with 5-Aza-dC, butyrate, DHA, LA, or co-treatment (% of negative control) 
    
Negative 
control 
Positive 
control  
5-Aza-dC Butyrate DHA LA 
DHA +      
butyrate 
LA +        
butyrate 
Global 
methylation 
100.00 ± 
5.86 
60.63 ± 
5.52 
68.39 ± 
11.38 
65.85 ± 
11.50 
89.32 ± 
12.17 
88.35 ± 
9.48 
89.78 ± 
4.62 
Colonocyte 
apoptosis 
100.00 ± 
7.42 
167.87 ± 
11.73 
177.05 ± 
27.44 
68.59 ± 
11.38 
95.41 ± 
15.65 
284.31 ± 
64.94 
169.67 ± 
36.28 
Histone 
acetylation 
H3 100.00 
93.58 ± 
5.91 
119.95 ± 
5.36 
120.74 ± 
0.62 
123.01 ± 
0.77 
122.18 ± 
3.95 
116.98 ± 
3.11 
H4 100.00 
83.76 ± 
14.72 
115.51 ± 
6.36 
103.47 ± 
13.11 
137.59 ± 
13.94 
116.06 ± 
22.92 
177.92 ± 
12.00 
Values are means ± SEM. 
 
 
 
 
Chapter IV 
Table A-4. Tnfrsf25 and Dapk1 expression in HCT-116 cells cultured with 5-Aza-dC, 
butyrate, DHA, LA, or co-treatment (% of negative control) 
Gene 
symbol 
Time 
Negative 
control 
Positive 
control 
5-Aza-dC 
Butyrate DHA LA 
DHA +      
butyrate 
LA +        
butyrate 
Tnfrsf25 
48h 
100.00 ± 
11.15 
103.60 ± 
26.54 
519.94 ± 
84.70 
79.95 ± 
16.31 
57.54 ± 
20.02 
386.18 ± 
115.62 
234.98 ± 
43.78 
72h 
100.00 ± 
17.70 
153.18 ± 
7.76 
88.63 ± 
14.39 
67.11 ± 
25.36 
75.92 ± 
6.72 
65.20 ± 
15.15 
85.48 ± 
18.18 
96h 
100.00 ± 
6.10 
141.20 ± 
11.06 
45.74 ± 
7.87 
109.70 ± 
7.07 
97.11 ± 
3.86 
35.62 ± 
3.26 
37.48 ± 
5.52 
Dapk1 
48h 
100.00 ± 
9.08 
137.31 ± 
33.81 
500.57 ± 
103.09 
57.07  ± 
2.03 
68.78 ± 
6.58 
281.22 ± 
55.93 
216.67 ± 
16.79 
72h 
100.00 ± 
9.57 
244.54 ± 
10.93 
168.91 ± 
31.67 
73.05 ± 
12.71 
71.32 ± 
4.86 
106.80 ± 
31.61 
149.99 ± 
21.43 
96h 
100.00 ± 
3.32 
319.42 ± 
7.89 
35.29 ± 
6.75 
78.58 ± 
6.64 
77.33 ± 
1.62 
25.40 ± 
5.65 
26.22 ± 
2.24 
Values are means ± SEM. 
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Table A-5. P-values for global methylation, apoptosis, and histone acetylation in HCT-
116 cells cultured with 5-Aza-dC, butyrate, DHA, LA, or co-treatment 
Group Group Apoptosis 
index 
Global 
methylation 
Histone  
H3 acetylation 
Histone 
H4 acetylation 
Negative control 
Positive control 
5-Aza-dC  
1.34E-01 2.82E-03 2.26E-01 4.12E-01 
 
Butyrate 9.04E-02 1.81E-02 1.49E-03 4.33E-01 
 
DHA 4.83E-01 1.10E-02 1.09E-03 8.59E-01 
 
LA 9.18E-01 3.99E-01 4.62E-04 7.08E-02 
 
DHA +Butyrate 1.93E-04 3.58E-01 6.31E-04 4.17E-01 
 LA + Butyrate 1.24E-01 4.34E-01 4.76E-03 1.18E-03 
Positive control  
5-Aza-dC  
Negative control 1.34E-01 2.82E-03 2.26E-01 4.12E-01 
 
Butyrate 8.37E-01 5.51E-01 1.33E-04 1.21E-01 
 
DHA 3.13E-02 6.88E-01 1.00E-04 3.23E-01 
 
LA 1.11E-01 2.65E-02 4.54E-05 1.42E-02 
 
DHA + Butyrate 1.26E-02 3.17E-02 6.04E-05 1.15E-01 
 LA + Butyrate 9.68E-01 2.86E-02 3.99E-04 2.35E-04 
Butyrate Negative control 9.04E-02 1.81E-02 1.49E-03 4.33E-01 
 
Positive control 
5-Aza-dC  
8.37E-01 5.51E-01 1.33E-04 1.21E-01 
 
DHA 1.94E-02 8.50E-01 8.78E-01 5.41E-01 
 
LA 7.35E-02 1.12E-01 5.57E-01 2.70E-01 
 
DHA + Butyrate 2.07E-02 1.29E-01 6.67E-01 9.78E-01 
 LA + Butyrate 8.68E-01 1.15E-01 5.66E-01 5.85E-03 
DHA Negative control 4.83E-01 1.10E-02 1.09E-03 8.59E-01 
 
Positive control 
5-Aza-dC  
3.13E-02 6.88E-01 1.00E-04 3.23E-01 
 
Butyrate 1.94E-02 8.50E-01 8.78E-01 5.41E-01 
 
LA 5.48E-01 7.57E-02 6.62E-01 9.76E-02 
 
DHA + Butyrate 2.34E-05 8.82E-02 7.81E-01 5.23E-01 
 LB 2.85E-02 7.83E-02 4.69E-01 1.69E-03 
LA Negative control 9.18E-01 3.99E-01 4.62E-04 7.08E-02 
 
Positive control 
5-Aza-dC  
1.11E-01 2.65E-02 4.54E-05 1.42E-02 
 
Butyrate 7.35E-02 1.12E-01 5.57E-01 2.70E-01 
 
DHA 5.48E-01 7.57E-02 6.62E-01 9.76E-02 
 
DHA + Butyrate 1.42E-04 9.39E-01 8.73E-01 2.81E-01 
 LA + Butyrate 1.02E-01 9.72E-01 2.54E-01 5.45E-02 
DHA + Butyrate Negative control 1.93E-04 3.58E-01 6.31E-04 4.17E-01 
 
Positive control 
5-Aza-dC  
1.26E-02 3.17E-02 6.04E-05 1.15E-01 
 
Butyrate 2.07E-02 1.29E-01 6.67E-01 9.78E-01 
 
DHA 2.34E-05 8.82E-02 7.81E-01 5.23E-01 
 
LA 1.42E-04 9.39E-01 8.73E-01 2.81E-01 
 LA + Butyrate 1.39E-02 9.13E-01 3.22E-01 6.19E-03 
LA + Butyrate Negative control 1.24E-01 4.34E-01 4.76E-03 1.18E-03 
 
Positive control 
5-Aza-dC  
9.68E-01 2.86E-02 3.99E-04 2.35E-04 
 
Butyrate 8.68E-01 1.15E-01 5.66E-01 5.85E-03 
 
DHA 2.85E-02 7.83E-02 4.69E-01 1.69E-03 
 
LA 1.02E-01 9.72E-01 2.54E-01 5.45E-02 
 DHA + Butyrate 1.39E-02 9.13E-01 3.22E-01 6.19E-03 
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Table A-6. P-values for Tnfrsf25 and Dapk1 expression in HCT-116 cells cultured with 
5-Aza-dC, butyrate, DHA, LA, or co-treatment  
Group Group 
Tnfrsf25 Dapk1 
48 h 72 h 96 h 48 h 72 h 96 h 
Negative control 
Positive control 
5-Aza-dC  
9.66E-01 3.55E-02 7.94E-04 5.82E-01 1.75E-04 7.15E-14 
 
Butyrate 1.69E-04 6.27E-01 6.44E-05 2.95E-05 3.02E-02 6.64E-07 
 
DHA 8.12E-01 1.72E-01 3.33E-01 5.27E-01 3.62E-01 1.37E-02 
 
LA 6.16E-01 3.10E-01 7.70E-01 6.44E-01 3.33E-01 9.91E-03 
 
DHA + Butyrate 3.83E-03 1.50E-01 1.09E-05 1.60E-02 8.15E-01 1.19E-07 
 LA + Butyrate 1.25E-01 5.35E-01 1.49E-05 9.95E-02 1.02E-01 1.36E-07 
Positive control  5-
Aza-dC  
Negative control 9.66E-01 3.55E-02 7.94E-04 5.82E-01 1.75E-04 7.15E-14 
 
Butyrate 1.83E-04 1.35E-02 1.10E-07 7.93E-05 1.92E-02 2.00E-15 
 
DHA 7.79E-01 2.09E-03 5.74E-03 2.45E-01 3.25E-05 1.98E-14 
 
LA 5.87E-01 4.49E-03 4.47E-04 3.18E-01 2.93E-05 1.84E-14 
 
DHA + Butyrate 4.18E-03 1.77E-03 3.12E-08 4.72E-02 2.72E-04 1.25E-15 
 LA + Butyrate 1.35E-01 1.03E-02 3.91E-08 2.50E-01 5.17E-03 1.30E-15 
Butyrate Negative control 1.69E-04 6.27E-01 6.44E-05 2.95E-05 3.02E-02 6.64E-07 
 
Positive control 
5-Aza-dC  
1.83E-04 1.35E-02 1.10E-07 7.93E-05 1.92E-02 2.00E-15 
 
DHA 1.09E-04 3.62E-01 1.17E-05 1.00E-05 4.72E-03 5.56E-05 
 
LA 6.67E-05 5.87E-01 1.10E-04 1.34E-05 4.19E-03 7.45E-05 
 
DHA + Butyrate 1.28E-01 3.23E-01 3.13E-01 5.09E-03 4.74E-02 2.14E-01 
 LA + Butyrate 3.95E-03 8.92E-01 4.08E-01 7.44E-04 5.19E-01 2.53E-01 
DHA Negative control 8.12E-01 1.72E-01 3.33E-01 5.27E-01 3.62E-01 1.37E-02 
 
Positive control 
5-Aza-dC  
7.79E-01 2.09E-03 5.74E-03 2.45E-01 3.25E-05 1.98E-14 
 
Butyrate 1.09E-04 3.62E-01 1.17E-05 1.00E-05 4.72E-03 5.56E-05 
 
LA 7.90E-01 7.06E-01 2.14E-01 8.62E-01 9.53E-01 8.71E-01 
 
DHA + Butyrate 2.37E-03 9.35E-01 2.27E-06 4.41E-03 2.57E-01 6.32E-06 
 LB 8.20E-02 4.35E-01 3.03E-06 3.01E-02 1.75E-02 7.50E-06 
LA Negative control 6.16E-01 3.10E-01 7.70E-01 6.44E-01 3.33E-01 9.91E-03 
 
Positive control 
5-Aza-dC  
5.87E-01 4.49E-03 4.47E-04 3.18E-01 2.93E-05 1.84E-14 
 
Butyrate 6.67E-05 5.87E-01 1.10E-04 1.34E-05 4.19E-03 7.45E-05 
 
DHA 7.90E-01 7.06E-01 2.14E-01 8.62E-01 9.53E-01 8.71E-01 
 
DHA + Butyrate 1.39E-03 6.46E-01 1.78E-05 6.27E-03 2.35E-01 8.22E-06 
 LA + Butyrate 5.00E-02 6.82E-01 2.46E-05 4.21E-02 1.56E-02 9.79E-06 
DHA + Butyrate Negative control 3.83E-03 1.50E-01 1.09E-05 1.60E-02 8.15E-01 1.19E-07 
 
Positive control 
5-Aza-dC  
4.18E-03 1.77E-03 3.12E-08 4.72E-02 2.72E-04 1.25E-15 
 
Butyrate 1.28E-01 3.23E-01 3.13E-01 5.09E-03 4.74E-02 2.14E-01 
 
DHA 2.37E-03 9.35E-01 2.27E-06 4.41E-03 2.57E-01 6.32E-06 
 
LA 1.39E-03 6.46E-01 1.78E-05 6.27E-03 2.35E-01 8.22E-06 
 LA + Butyrate 8.90E-02 3.90E-01 8.50E-01 3.46E-01 1.53E-01 9.16E-01 
LA + Butyrate Negative control 1.25E-01 5.35E-01 1.49E-05 9.95E-02 1.02E-01 1.36E-07 
 
Positive control 
5-Aza-dC  
1.35E-01 1.03E-02 3.91E-08 2.50E-01 5.17E-03 1.30E-15 
 
Butyrate 3.95E-03 8.92E-01 4.08E-01 7.44E-04 5.19E-01 2.53E-01 
 
DHA 8.20E-02 4.35E-01 3.03E-06 3.01E-02 1.75E-02 7.50E-06 
 
LA 5.00E-02 6.82E-01 2.46E-05 4.21E-02 1.56E-02 9.79E-06 
 DHA + Butyrate 8.90E-02 3.90E-01 8.50E-01 3.46E-01 1.53E-01 9.16E-01 
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APPENDIX B 
EXPERIMENTAL PROTOCOLS 
 
 
 
 
B-1. Sample Preparation for qRT-PCR 
 
Purpose: To prepare RNA samples for gene expression measurement 
 
Procedure 
 
1. RNA isolation using RNAqueous kit (Ambion, AM1912); small scale phenol-
free total RNA isolation kit without modification. 
 
2. DNase treatment using DNA-free kit (Ambion, AM1906) 
See Appendix B-2. 
 
3. Quantification using Nanodrop 
 
4. Agilent analyzer to check the quality of RNA 
Select a kit depending on concentration of RNA samples. 
- Total RNA and mRNA samples of 25 to 500 ng/µl  
 Agilent RNA 6000 Nano Kit (Cat. # 5067-1511 from Agilent Technologies) 
- For samples down to 50 pg/µl of total RNA or 250 pg/µl of mRNA.  
 Agilent RNA 6000 Pico Kit (Cat. # 5067-1513 from Agilent Technologies) 
 
5. Reverse transcription to make cDNA 
See Appendix B-3. 
 
6. Run qRT-PCR 
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B-2. DNase treatment using DNA-free kit (Ambion, AM1906) 
Purpose: To remove contaminating DNA from RNA preparations 
Procedure 
1. Add 10X DNase I Buffer (0.1 volume of RNA sample) and 1 μl rDNase I to the 
RNA, and mix gently by flicking the tube and spin down using countertop 
centrifuge. (If the RNA contains more than 20 ng/µl, dilute the sample to 20 
ng/µl before adding the DNase I Buffer and rDNase I) 
 
2. Incubate at 37°C for 30 min.  
 
3. Add resuspended DNase Inactivation Reagent (typically 0.1 volume of sample 
from step #1) and mix well.  
 
4. Incubate 2 min at room temperature, mixing occasionally.  
 
5. Centrifuge at 10,000 x g for 1.5 min. 
  
6. Transfer the RNA (in supernatant) to a new tube. 
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B-3.  Reverse Transcription 
Purpose: To prepare cDNA from RNA for PCR 
 
Gibco SuperScript II RT Protocol  
Cat # 18064-014 
Use ART Tips and Nuclease free water. 
 
25 µl reaction 
Random hexamers   0.24 µl Roche 11034731001 (1 mM stock) 
Oligo dT (500 ng/µl)   1.25 µl Promega Oligo(dT)15 primer 
RNA     0.2-200 ng 
Nuclease free water   up to 14.75 µl 
 
Heat above components at 65 °C, 5 min using Thermocycler (file name; YMC65RT). 
Cool slowly to room temperature. (5°C decrease every two minutes) 
 
Make a cocktail: 
5X 1
st
 strand buffer  5 µl  Invitrogen (18064-014) 
0.1M DTT   2.5 µl  Invitrogen (18064-014) 
*Primer RNase inhibitor  0.5 µl  Eppendorf  
10 mM dNTP mix  1.25 µl  Promega -10 mM each dNTP 
SuperScript
TM
 II RT   1 µl  Invitrogen (18064-014) 
  
Add 10.25 µl of cocktail Mix. 
Mix each tube and spin down using countertop microfuge. 
Incubate at 37 °C, 1 hr. 
Terminate by heating at 90 °C, 5 min. 
Place on ice and freeze at -80 °C. 
 
 
* 7500 unit, 30 Unit/µl, recombinant, not human placental 
 
The negative RT is done by replacing the SuperScript with Nuclease free water. 
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B-4. Apoptosis – ApopTag 
Purpose: To determine apoptosis in 4% PFA fixed colon tissue. 
reagent  company          catalog # 
Apotag Kit:  Chemicon    S7101 
Proteinase K  Ambion   2546 
PBS   Life Technologies  21600-069  
 
Note:  To be performed on 4%PFA fixed tissue. 
 
***Put 200 ml PBS for Prot. K in 37 C oven and begin bleach rinse. 
 
1.  Deparaffinize and rehydrate tissue: 
 ___Xylene, 3X, 5 min 
        let xylene just dry, circle sections w/ PAP pen, dry 1 min 
 ___100% EtOH, 2X, 5 min 
 ___95% EtOH, 1X, 3 min 
 ___70% EtOH, 1X, 3 min 
 ___PBS, 1X, 5 min 
(Get Equilibration Buffer and Reaction Buffer out of freezer-put on ice) 
 
2.  Pretreat tissue – 3 min, in 37 
Proteinase K (10 g/ml PBS)  = 0.1 ml Proteinase K (Ambion # 2546) in 200 ml PBS. 
 
3.  Wash in dH2O, 2x, 2 min 
 
4.  Quench Endogenous Peroxidase: 0.3% H2O2 in 100% Methanol: 
3.0 ml 30% H2O2 in 297 ml 100% Methanol or 2.0 ml in 198 ml (add fresh H2O2 
immediately before quenching).  30 min, RT 
 
5.  Wash in dH2O, 2x, 5 min 
  
6.  Wash all slides in PBS 5 min. 
 
7.  Gently tap off PBS and carefully blot around sections.  (Do this step and following 
step one slide at a time to avoid drying out sections.) 
 
8.  Apply EQUILIBRATION BUFFER to all sections:  incubate in humidified chamber 
for 15 sec to 1 hr @ RT. 
 (# of slides X 150 l) (e.g., 9 slides X 150l = 1.35 ml) 
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9.  Tap off equilibration buffer and immediately apply REACTION BUFFER (for 
negative controls) or working strength TdT Enzyme with dilution ratio 1/40 (enzyme 
/reaction buffer for sample sections).  (Get TdT directly from freezer & keep on ice) 
 
Apply only reaction buffer to negative control sections: 
___(# sections) X 40l 
 
For normal sample sections (# sections X 50l): 
___ l reaction buffer (for __ slides) 
___ l TdT enzyme (for __ slides) 
 
Incubate in a humidified chamber at 37C, 1 hr 
(Prepare Stop/Wash so it can warm to RT.) 
 
12. Put slides in coplin jar with Working Strength Stop/Wash Buffer (1ml + 34 ml 
dH2O).  Agitate for 15 sec; incubate 10 min, RT. 
Take aliquot of ANTI-DIGOXIGENIN PEROXIDASE (# slides X 150 l) and 
allow to warm to room temperature (__ slides x 150l = ______) 
 
13.  Wash slides in PBS, 3X, 1min 
 
14.  Blot dry the slides quickly (do one slide at a time) and apply ANTI-DIGOXIGENIN 
PEROXIDASE to all sections; incubate 30 min. in humidified chamber @ RT. 
 
15.  Wash in PBS 4X, 2min 
 
16.  While washing prepare 0.5% DAB solution (0.5 mg/ml):  
Filter 2 ml stock DAB (50 mg/ml) through slightly damp (w/PBS) Whatman #1 
filter and follow through filter w/198 ml PBS. Also, prepare dH2O for after staining 
(step 19). 
 
17.  IMMEDIATELY before staining add 100 l fresh 30% H2O2 to DAB solution. 
 
18.  Stain slides until light brown color shows up  (< 20 sec) 
 
19.  Wash in dH2O, 3X, 1 min  
 Leave in 4
th
 wash for 5 min 
 During this wash deactivate DAB solution and equipment w/ bleach – leave these 
materials in bleach overnight. 
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20. Counterstain w/ Methyl Green (reusable): 
 Dip quickly into Methyl green 
 Rinse in dH2O 5X;  
1) Dip and briefly agitate and move to second dH2O. 
2) Dip and briefly agitate and move to third dH2O. 
3) Dip 10 times and leave ~ 30 sec. 
4) Leave for 1 min without agitation. 
5) Leave for 1 min without agitation. 
 
21. Dehydrate: USE ALL FRESH REAGENTS 
__70% EtOH, 1X, 1 min 
__95% EtOH, 1X, 1 min 
__100% EtOH, 1X, 1 min 
__Xylene: 3X, 2 min (dip 10 times/ea) 
 
22.  Apply Permount and cover glass.  (80:20, Permount:Xylene) 
Use the wet mounting method (Do one slide at a time. Don’t allow a slide to dry after 
last xylene.) Dry 24 hours before viewing on microscope. 
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B-5.  Cell proliferative zone using PCNA methodology 
Purpose: To determine cell proliferative zone in 70% ethanol fixed colon tissue. 
Staining protocol using the sequenza slide rack (Shandon, Pittsburgh, PA) 
 
Reagents: 
 
1.  Phosphate buffered saline (PBS) 
2.  Vectastain ABC Elite Kit -- mouse IgG 
 Source: Vector Lab. 
 Cat #: PK-6102, 1 ml/ea. 
 Contains: blocking serum 
 biotinylated antimouse IgG 
 avidin-biotin complex 
3.  PCNA monoclinal antibody (anti-PC10, murine) 
 Source: Signet lab 
 Cat #: 523-01, 1ml/ea 
Note: Each new lot # of anti-PC10 antibody must be tested with a 1:50, 1:100, 
1:150, 1:200 dilution in PBS.  Prepare antibody dilution with PBS, under sterile 
conditions.  Use 4 micron thick single serial sections of colonic tissue to test the 
antibody dilutions.  Record the optimal dilution for the lot # tested. 
4.  Diaminobenzidine or DAB-tetrahydrochloride 
 Source: Sigma 
 Cat #: D-5637 
 Prepare DAB stock solution, 50 mg/ml in ddH2O. Store as 2 ml aliquots at -20C. 
5.  Harris hematoxylin solution 
 Source: Sigma 
 Cat #: HHS16-500ML 
 
Critical steps prior to staining: 
1.  Tissue fixation in 70% ethanol. 
2.  Processing and baking of tissue at temperatures not exceeding 50 C. 
3.  Keep slides moist at all times during the staining procedure. 
4.  Include one negative control slide (slide not treated with antibody, PBS only) in each 
batch of slides stained. 
 
Procedures: 
1.  Deparaffinize slides 
 Xylene, 3X, 5 min 
 100% EtOH, 2X, 5 min 
 95% EtOH, 2X, 3 min 
 70% EtOH, 1X, 3 min 
 ddH2O, 1X, 3 min 
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2.  Leave slides in 3% H2O2 for 30 min to remove endogenous peroxidase activity. 
 3% H2O2: 20 ml of 30% H2O2 made up to a final volume of 200 ml with 
methanol. 
 
3.  Wash in PBS 5 min, 3 times. 
 Mount slides onto coverplates using PBS and insert into sequenza. 
 
4.  Prepare Vectastain Blocking Serum by adding 3 drops of stock Normal Serum 
(yellow label) to 10 ml of PBS in yellow mixing bottle. 
 
5.  Add 3 drops* to each coverplate in sequenza and replace top to maintain humidity.  
Let stand for 20 min. 
 
6.  Wash with PBS by filling each coverplate in the sequenza with one ml of PBS. 
 
7.  Add 150 l of anti-PC10 (use the optimal dilution obtained by dilution series: 1:200) 
to each coverplate in sequenza and replace top.  For the negative control slide use PBS 
instead of anti-PC10.  Let stand for 1 hour. 
 
8.  Wash with PBS by filling each coverplate in the sequenza to the top with PBS.  Let 
stand for 5 min. 
 
9.  Prepare Vectastain biotinylated anti-mouse IgG by mixing 3 drops of stock normal 
serum with 10 ml PBS in Blue mixing bottle, then add 1 drop of stock biotinylated 
antibody (blue label), Mix Gently.  (or use 5 ml of serum solution from step 4, mix with 
25 l of stock biotinylated antibody) 
 
10.  Add 3 drops to each coverplate in sequenza and replace top.  Let stand for 45 min.   
 
11.  Prepare ABC reagent in advance to be used in step 13.  The ABC reagent is 
prepared by adding 2 drops of reagent A (gray label) to 5 ml PBS in the ABC Reagent 
large mixing bottle.  Then add exactly 2 drops of Reagent B (gray label) to the same 
mixing bottle, mix immediately, and allow ABC Reagent to stand for about 30 minutes 
before use.  This should be done in a darkened area. 
 
* Note: 1 drop = 50 l 
12.  Wash with PBS by filling each coverplate in the sequenza to the top with PBS.  Let 
stand for 5 min. 
 
13.  Apply Vectastain ABC reagent that had been prepared in step 11.  Add 3 drops to 
each coverplate in sequenza, replace top, and let stand for 30 min. 
 
14.  Wash with PBS by filling each coverplate in the sequenza to the top with PBS.  
Remove slides from sequenza and place in PBS for 5 min. 
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15.  Prepare DAB solution 
 For 200 ml: 2 ml stock DAB (50 mg/ml) 
  bring volume up to 200 ml with PBS 
 Immediately before staining, add 100 l 30% H2O2. 
 
16.  Leave slides in DAB solution for 1 min, agitate twice. 
 
17.  Wash with ddH2O 5 min, 3 times. 
 
18.  Deactivate all DAB materials (glassware, pipet tips, used stock vials, stir bars) and 
used DAB solutions with bleach overnight, and flush with excess water in drain next  
day. 
 
19.  Counterstain with Hematoxylin  < 1 sec. 
 
20.  Wash with ddH2O 2 min, 2 times. 
 
21.  Dehydrate slides: 
 1 x 1 min 70% ETOH. 
 1 x 1 min 95% ETOH. 
 1 x 1 min 100% ETOH. 
 1 x 2 min Xylene. 
 
22.  Apply Permount and cover glass.  (80:20, Permount:Xylene) 
Use the wet mounting method (Do one slide at a time. Don’t allow a slide to dry after 
last xylene.) Dry 24 hours before viewing on microscope. 
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B-6. Design of PCR primers & probe to determine promoter methylation 
Reference: Campan M, Weisenberger DJ, Trinh B, Laird PW. MethyLight. Methods 
Mol Biol. 2009;507:325-37  
 
Purpose: Design PCR primers and probes to measure promoter methylation using qPCR 
 
Procedure 
 
1. http://uswest.ensembl.org/index.html 
Select species. (Rat or Human) 
Input gene name (For example, Bcl-2) 
Results summary shows Domain, Family, Gene, Marker, etc. 
Select “Gene” 
Among the list of genes, select Bcl-2. 
2. In the left column, select “sequence”. 
In the bottom of left column, there is “Configure this page” 
Change 600 to 1000 of 5’ flanking sequence (upstream) 
Now we know the sequence of Bcl-2 and the location of the first exon 
(transcription start site) that is highlighted with pink background.  
Copy sequence of gene from the first to the end of the first exon. 
3. http://genome.ucsc.edu/ 
Select “Blat” in the bar of the main menu. 
Select species. 
Paste the sequence from # 2 step and hit “submit”. 
Select the first “Browser” 
Scroll down to “Expression and regulation” 
CpG islands “pack” activate CpG island  Refresh 
Zoom out X3 
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4. Select CpG island which is close to the transcription start site.  
Click the selected CpG island in the figure. 
“CpG island info” gives us the position, the sequence of the CpG island. 
Click the “View DNA for this feature. 
 
5. In Microsoft word, paste DNA sequence of CpG island 
1) Replace “CG”  “XG” (All CG have to change to XG) 
2) Replace all “C”  “T” 
3) Replace all “X”  “C” 
These steps give us bisulfite modified DNA sequence with the assumption that all 
CpG were methylated. 
 
6. Bring bisulfite modified DNA sequence of CpG island to the primer design 
software, Primer express 3.0 
Check the type as TaqMan MGB quantification. 
Check “Double stranded” Box 
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Click “Find Primers/Probes” 
 
Criteria for primers & probe design 
1. Try to choose primers that have CpGs at the 3’end of the sequence and many 
non-CpG cytosines throughout the primer. 
2. For the probe, make sure that the 5’ base is not a G, 
try to use probe with many non-CpG cytosines throughout the probe and that 
the CpGs are in the middle of the sequence. 
3. Probe should not be more than 31-32 bp in length. 
4. Avoid primers and probes with long stretches of single nucleotide repeats. 
(AAAAAAAA) 
5. Design all reactions with a primer Tm from 58-60 °C, and the probe Tm of 
68-70 °C.  
Let’s start from primers and probe set from primer express 3.0. 
Bring “Primer probe test tool” and modify the sequence to get the best primer and probe 
within criteria.  These primers and probe will amplify only the fully methylated DNA. 
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B-7. Preparation of fully methylated DNA using CpG methyltransferase 
Reference:  
Weisenberger et al. Determination of the CpG Island Methylator Phenotype (CIMP) in 
colorectal cancer using MethyLight. Protocol Exchange (2006) 
doi:10.1038/nprot.2006.152  
Campan M, Weisenberger DJ, Trinh B, Laird PW. MethyLight. Methods Mol Biol. 
2009;507:325-37  
 
Purpose:  To generate artificially fully methylated genomic DNA, which will serve 
as a positive control. 
 
Materials: 
 CpG Methyltransferase (M.SssI) Cat #. M0226L from New England Biolabs 
10X buffer and S-adenosyl methionine (SAM) were provided with M.SssI. 
 DNA clean & concentrator-5. Cat #. D4003S from Zymo research 
 Genomic DNA of rat liver extracted using DNeasy Blood & Tissue Kit Cat #. 
69504 from Qiagen 
 Turn on the incubator 37°C 
Procedure 
 
CpG Methyltransferase treatment 
 
1. Dilute SAM to 1.6 mM using the supplied 32 mM SAM stock. 
 SAM stock 1 µl + RNase/DNase free water 19 µl 
2. Dilute M.SssI to make 0.05 unit M.SssI. 
 M.SssI 1 µl (4 units) + RNase/DNase free water 79 µl 
3. Add DNA, diluted SAM, 10X buffer, and diluted M.SssI in 1.5 ml 
microcentrifuge tubes. 
  final conc. Unit Sample 
DNA 0.05 µg/µl 1 µg 
SAM 0.16 mM 2 µl (diluted) 
10X buffer 1 X 2 µl 
Enzyme 0.0025 unit/µl 1 µl  (diluted) 
RNase/DNase free water     11 µl 
 
4. Mix thoroughly - Pipette up and down at least six times. 
5. Spin down using countertop centrifuge. 
6. Incubate overnight at 37°C.  In the morning proceed to step #7. 
7. Dilute M.SssI to make 1 unit M.SssI. 
 M.SssI 1 µl (4 units) + RNase/DNase free water 3 µl 
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8. Add diluted SAM and M.SssI (Step 6) and incubate overnight at 37°C. 
  final conc. Unit sample B 
SAM 0.2 mM 1 µ l  (diluted) 
Enzyme 0.09 unit/µl 2 µ l  (1 unit) 
 
9. Stop the reaction by heating at 65°C for 20 minutes.  
 
 
 
 
Clean M.SssI-treated DNA with DNA clean & concentrator-5 
 
1. In a 1.5 ml microcentrifuge tube, add 2 volumes of DNA Binding Buffer to each 
volume of DNA sample. Mix briefly by vortexing. 
2. Spin down using countertop centrifuge. 
3. Transfer mixture to a provided Zymo-Spin™ Column in a Collection Tube.  
4. Centrifuge at 10,000 x g for 30 seconds. Discard the flow-through.  
5. Add 200 μl Wash Buffer to the column. Centrifuge at 10,000 x g for 30 seconds.  
6. Repeat wash step (Step 5).  
7. Transfer the column to a 1.5 ml microcentrifuge tube.  
8. Add 10 μl RNase/DNase free water directly to the column matrix.  
9. Centrifuge at 10,000 x g for 30 seconds to elute the DNA. 
10.  Measure DNA concentration using Nanodrop. 
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B-8. PCR Reaction for methylation measurement 
 
Reference: Weisenberger et al. Determination of the CpG Island Methylator Phenotype 
(CIMP) in colorectal cancer using MethyLight. Protocol Exchange (2006) 
doi:10.1038/nprot.2006.152 
 
Materials: 
 Sigma JumpStart Taq DNA polymerase Cat #. D4184 
– JumpStart Taq DNA Polymerase 
– 10x PCR Buffer without MgCl2 
 1M MgCl2 Cat #. AM9530G from Invitrogen 
 Nuclease free water 
 10 mM dNTP mix from Promega 
 Tween-20 (polyoxyethylenesorbitan Monolaurate): Fisher #BP-337-100 
 Gelatin: Sigma #G-9391 
PROCEDURE 
 
1. Taqman 10X stabilizer preparation: 0.1% Tween-20, 0.5% gelatin 
 Measure 8ml of Nuclease free water in a 15ml sterile screw capped tube.  
 Add 2ml of Tween-20 to Nuclease free water and pipet the solution repeatedly 
until all the Tween is mixed with Nuclease free water and to remove traces of 
Tween from the pipet.  
 It can be stored at room temperature until needed.  
 Weigh out 0.2g gelatin and add it to 50ml conical screw capped tube.  
 Add 20ml of Nuclease free water.  
 Heat at 37°C in an incubator to dissolve the gelatin and after it is all melted, add 
0.2ml of 20% Tween-20 and bring the final volume to 40ml with nuclease free 
water.  
 It can be stored at room temperature until needed.  
 
2. Oligomix preparation which contains the forward and reverse primers as well as the 
probe in one tube  
 Prepare the forward and reverse primers at a concentration of 300 µM and the 
probe at a concentration of 100 µM. Make small aliquots of the primers at these 
concentrations to prevent repeated freeze/thaw events. 
 Dilute the primers/probe to a working stock of 6µM (primers) and 2µM (probe). 
This is achieved by combining the stock solutions of the forward primer, reverse 
primer and probe in one tube (4 µl of the 300 µM forward primer, 4 µl of the 300 
µM reverse primer and 4 µl of the 100 µM probe in 600 µl total volume): 
Forward primer: 300 µM stock; use 4µl; 6 µM final conc. 
Reverse primer: 300 µM stock; use 4µl; 6 µM final conc. 
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Probe: 100 µM stock; use 4µl; 2 µM final conc. 
Nuclease free water: add 588 µl 
TOTAL VOLUME: 600 µl 
 Use 4.5 µl of this OligoMix per 30 µl MethyLight reaction. As shown in 
the PCR MasterMix Reaction Set-Up, this 4.5 µl volume represents the 
combined volumes from each of the two individual 6 µM primers and the 2 µM 
probe. After addition to the PCR reaction mixture, the forward/reverse primers 
are at a concentration of 0.3µM, and the probe at 0.1 µM. 
 
3. PreMix Preparation: 
 The PreMix contains all TaqMan reaction components except the primers/probe. 
FOR ONE REACTION: 
Taq Polymerase: 0.1 µl 
25mM MgCl2: 4.2µl 
10X Buffer: 3.0µl 
10X stabilizer: 3.0µl 
10mM dNTPs: 0.6µl 
Nuclease free water: 4.6µl 
TOTAL: 15.5µl 
 
4. Combine all agents expect bisulfite modified DNA. 
 PreMix: 15.5 µl 
OligoMix: 4.5 µl  
TOTAL: 20.0 µl 
 
5. PCR Reaction: 
Load 10 µl of bisulfite modified DNA into the wells of a 96-well plate and then add 
20µL of the MasterMix. 
Seal caps on the plate, mix and centrifuge at 2500 rpm for 1 minute. (use Jouan 
centrifuge) 
 
6. PCR program:  
95°C for 10 min 
Then 50 cycles of: 
95°C for 15 sec 
60°C for 1 min 
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7. MethyLight Plate Set-up: 
To analyze the methylation, bisulfite-DNA is required not only for the methylation 
reaction, but also for the control gene reaction. Also include bisulfite converted M.SssI-
treated DNA (diluted 1:10 (in duplicate)) for each methylation and control reaction.  
 4-point Standard Curve Set-up: For standard curve, we use bisulfite converted 
M.SssI-modified DNA (diluted 1:10).  
10 µl (in duplicate)  
5 µl (in duplicate) 
2.5 µl (in duplicate) 
1 µl (in duplicate) 
 
8. MethyLight (Percentage of methylated reference (PMR) calculations): 
The formula to calculate PMR values is essentially the quotient of two ratios (multiplied 
by 100): 
([geneX mean value for the sample]/[control gene mean value for the sample]) / ([geneX 
mean value for the M.SssI reference]/[ control gene mean value for the M.SssI 
reference]) * 100 
 
The log (fluorescence) is plotted as a function of the C(t) values of each standard, and 
the equation of the best fit line through the points that comprise the standard curve is 
generated.  
 
Then, the C(t) value of each unknown sample is converted to a “mean value” via the 
standard curve best fit equation.  
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B-9. Cell culture of HCT116 cells 
 
1. Preparation of complete McCoy’s 5A modified media for HCT 116 
(Modified from Manasvi Shah) 
References: 1) Fan et al. Am J Physiol. 1999 Aug; 277(2 Pt 1):C310-9,  
2) Kolar et al. Am J Phyisol. 293:G935-G943, 2007 
 
Reagents 
Product Company Product # size 
McCoy's 5A Invitrogen 16600-108 10 × 500 ml 
Glutamax Invitrogen 35050-061 100 ml 
PBS Invitrogen 14190-250 10 × 500 ml 
Trypsin-EDTA Invitrogen 25300-054 100 ml 
FBS Hyclone SH30070 500 ml 
Bottle top filter (1L) Corning 431174 1 L 
 
Procedure 
(1) Aliquot 28 ml FBS in 50 ml falcon tube. (freeze at -20°C) 
(2) Aliquot 5.5 ml glutamax in 15 ml falcon tube. (freeze at -20°C) 
(3) Thaw 1 tube of glutamax aliquot and 2 tubes of FBS aliquot at 4°C overnight. 
(4) Add glutamax and FBS into 500ml of McCoy’s 5A modified medium 
(without HEPES). 
a. 10% FBS: Add 56 ml FBS. 
b. 1% Glutamax: Add 5.5 ml Glutamax. 
(5) Gently tilt the bottle to mix. 
(6) Filter mixed media with bottle top filter (0.22 µm pore size) into autoclaved 
(121 °C for 20 min) orange cap bottle. 
(7) Label as “sterile, complete” (after adding FBS and glutamax, the media is 
now called complete.), your initials, and the date.  
(8) Store at 4°C. 
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2. Preparation of HCT116 cell culture 
Reagents 
Product Company Product # size 
Cell Culture Flask, 175 cm² BD Falcon 353112 40 ea 
Cell Culture Flask, 75 cm² BD Falcon 353136 60 ea 
Procedure 
(1) Warm complete McCoy’s 5A media to room temperature. 
(2) Aliquot 9 ml of complete McCoy’s 5A media in a 15ml falcon tube. 
(3) Take a vial of frozen cells from the liquid nitrogen tank (rack 15- box1). 
(4) Thaw rapidly with gentle agitation in the waterbath at 37°C 
(5) Slowly introduce cells to new environment by adding cells into (2). 
(6) Pipetting up and down several times. 
(7) Centrifuge at 150 x g for 5 min at room temperature. Must use centrifuge cover 
for HCT116 (because of BL2 lab rule: Cultured human cells are potentially 
biohazardous and infectious.) 
(8) Add 12 ml of the McCoy’s medium in T-75 flask. 
(9) Aspirate and discard supernatant using glass pipette with vacuum suction. 
(10) Resuspend the cell pellet in 3 ml of medium. 
(11) Add resuspended cells (3 ml) into a T-75 flask with 12 ml medium. 
(12) Gently rotate the flask to distribute the cells evenly. 
(13) Label the flask (Cell type, passage #, date and initials)  
(14) Incubate at 37°C, 5% CO2. 
(15) Check cell confluence under the microscope daily (commonly 10X) until 70-90% 
of cells are confluent, usually 2 days. 
 
3. Passage of HCT116 cells 
Procedure for cells in T-75 flask: 
(1) When cells are 70% confluent, remove all medium. 
(2) Wash cells with PBS, and aspirate PBS gently. 
(3) Add 6ml trypsin/EDTA, incubate 3 min at 37°C in CO2 incubator. 
(4) Tap the flask from the side and bottom. 
(5) Check if cells are detached. More than 90% of cells should be floating. 
(6) Add 12ml of media to deactivate trypsin. 
(7) Pipet cells in trypsin and media into 50 ml conical tube. 
(8) Spin down at 150 xg, 5 min at room temperature. 
(9) Aspirate and discard supernatant using glass pipette with vacuum suction. 
(10) Resuspend the cell pellet in 3 ml of medium. 
(11) Add resuspended cells (3 ml) into a T-75 flask with 12 ml medium. 
(12) Gently rotate the flask to distribute the cells evenly. 
(13) Label the flask (Cell type, passage #, date and initials) 
(14) Check cells under the microscope. (commonly 10X) 
(15) Incubate at 37°C, 5% CO2. 
(16) Check cell confluence under the microscope daily (commonly 10X) until 70-90% 
of cells are confluent, usually 2 days. 
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4. Seed HCT116 cells in 100 mm2 plate for actual experiment 
Reagents 
100 mm
2
 plate, Complete media, PBS, Trypsin, 1.5 ml microcentrifuge tube, 1000p 
tips, 200p tips, Glass pipet 
From T-75 flask 
(1) When cells are 70% confluent, remove all media. 
(2) Wash cells with PBS, and aspirate PBS gently. 
(3) Add 6ml trypsin/EDTA, incubate 3 min at 37°C in CO2 incubator. 
(4) Tap the flask from the side and bottom. 
(5) Check if cells are detached. More than 90% of cells should be floating. 
(6) Add 12ml of media to deactivate trypsin. 
(7) Pipet cells in trypsin and media into 50 ml conical tube. 
(8) Spin down at 150 xg, 5 min at room temperature. 
(9) Aspirate and discard supernatant using glass pipette with vacuum suction. 
(10) Resuspend the cell pellet in 30 ml of media. 
(11) Take 1 ml of media containing cells in 1.5 ml microcentrifuge tube for 
counting. 
(12) Put 50 ml conical tube with remaining media+cells in the incubator. 
(13) Apply 10 µl to each side of hemocytometer 
(14) Count the # of cells in at least 4 squares on one side and 2 squares on the 
opposite side. 
Cell counting – calculations (28 X 100 mm2 plate) 
 
30,000 cells/ml are needed, therefore add 10 ml per plate for 28 plates. 
30,000 cells/ml X 10 ml = 300,000 cells for one plate 
Total # of cells in all the counted squares = ____________ cells (a) 
# of squares = ______ (b) 
Cell density (Cell count per ml) =    a/b X 10,000 = _______________cells/ml (c) 
For 28 plates, prepare enough for 29 to account for any pipetting problems;  
Total ml needed = 10 ml X (28+1) = 290 ml 
Total cells needed = 30,000 cells/ml X 290 ml = 8,700,000 cells 
 
 
ViCi = VfCf 
 
 
Vi= Vf X Cf / Ci = 290 ml X 30,000 cells/ml   = ____________ ml (d) 
         cell density (c) cell/ml 
 
290 ml – (d) ml = __________ ml (e) 
Add (e) ml of media to the 50 ml conical tube in order to suspend cells. 
Dispense 10 ml into each well. 
Vi= initial volume  
Ci=initial concentration 
Vf= final volume 
Cf= final concentration 
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B-10. Fatty acid-BSA complex (10 mg) 
 
Purpose: To prepare 2.5 mM fatty acid and bovine serum albumin (BSA) complex. 
 
Materials 
 Spatula* 
 100 ml beaker* 
 2 ml V-bottom vials (X2)* 
 0.2 m Tuffryn filters and 10 ml syringes (1 for each fatty acid) (Acrodisc #PN 
4192) or Millipore steriflip SCGP00525 
 FA-free BSA (BM, #100069), MW: 68,000 
 Sodium carbonate-Na2CO3 (J T Baker, #3604-01), MW: 105.99 
 Sterile distilled water (Baxter,  2F7115) 
 DHA [22.64 g/L in EtOH], MW: 328.57 (5-16-07)  
 LA [18.6 g/L in EtOH], MW: 280.48 (8-3-10) 
 
Preparation 
*Glassware should be baked at 180°C for 4 hr 
Day before preparation: Bake 2 sets (1 stand-by) 
On prep day – ice bucket, vial screw caps (in the red lid container), and baked glassware  
 1000p micropipette, tips, 1.5 ml microcentrifuge tubes, 15 ml and 50 ml conical 
tubes 
 
Procedure 
1. vortex stock tubes of fatty acid vigorously 
2. Add 10 mg (volumes recorded below) of FA-ethanol 
 
(SUBJECT TO CHANGE) Calculations to make up 10 mg for fatty acid stocks  
DHA in EtOH – 22.64 µg/µl (dated) 5-16-07 
LA in EtOH    – 18.6 µg/µl (dated) 8-3-10 
DHA  = 10,000 µg   = 441.70 µL  LA = 10,000 µg  =  537.63 µL  
 22.64 µg/µL              18.6 µg/µL 
 
3. Clean Nitrogen tank needles with ethanol.  
4. Dry the fatty acid with N2 (30 psi). Set timer for 1 hour and check every 5- 10 
min. 
5. Aliquot 10 ml of sterile water (in 15 ml tube) and  two tubes containing 20 ml 
of McCoy’s 5A media under the hood 
6. Weigh 53 mg (0.053 g) of sodium carbonate and 3 g of fatty acid free BSA. 
7. Make 0.05M Na2CO3  
53 mg of Na2CO3 in 10 ml sterile H2O (need 2mL per FA-BSA) 
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8. Make 15% BSA solution 
Add 20 ml of McCoy’s 5A media into 100mL beaker  
Gently add 3 g of BSA into the media   
Do not stir but let the BSA powder slowly dissolve into media 
 
9. After drying down the fatty acid completely. Close the N2 tank valve.  
10. Add 2 ml of 0.05 M Na2CO3 to each FA vial.   
11. Flush the vial and lid with N2 and close the vial.  
12. Vortex the vials extensively for 1 hr at RT.  (every 10 min for the first 30 min 
and then every 15 min for the last 30 min to reduce the air bubbles).  
13. Make 2.5 mM FA-BSA complex at the FA/BSA 3:1 mole ratio. 
 
Sample Calculations: 
  DHA (MW: 328.5): 10 mg in 2 ml 0.05M Na2CO3;  
   BSA (MW: 68,000): 15% Solution 
(i)  Calculate the volume of 15% BSA solution needed for 10 mg DHA to obtain 
FA/BSA 3/1 mole ratio. 
   
      0.01 g DHA     x  _1  x 68000 (BSA MW) x  100  = 4.6 (ml) 
           328.5 (DHA mol wt)    3           15 
  
(ii) Calculate the total volume of solution needed for 10 mg DHA to make 2.5 mM 
DHA-BSA complex. 
   
10 (mg of DHA)/ 328.5 (DHA mol. wt)/ 2.5 (mM) = 0.012177 (L) = 12.177 ml 
 
(iii) Calculate the volume of plain McCoy’s 5A media needed for making the 2.5 mM 
DHA-BSA complex.   
12.177 (total volume) - 2 (FA in 0.05M Na2CO3) - 4.6 (15% BSA) = 5.577  
 
 ====>> DHA  15% BSA Media  2.5mM DHA-BSA  
   2 ml  4.6 ml              5.577 ml---> 12.177 ml 
 
It is difficult to completely retrieve the 2 ml FA-Na2CO3 from the glass vial. Therefore, 
take only 95% of everything to make the DHA-BSA complex. 
 1.9 ml DHA +  4.37 ml 15% BSA + 5.298 ml McCoy’s 5A media. 
Apply similar calculation to LA. 
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14. Add the following volumes of FA-Na2CO3 and 15% BSA to a 50 ml conical 
tube and let it mix for 5 min.  Then add the volume of media to a 50 ml 
conical tube for individual FA. 
 
     DHA TUBE    LA TUBE 
    10 mg                   10 mg                 
15 % BSA (ml)  4.37 ml    5.12ml  
McCoy’s 5A (ml)  5.3 ml     6.53 ml  
Fatty acid – Na2 Co3  1.9 ml     1.9 ml   
Total    11.57 ml    13.55 ml 
 
15. Flush the tubes and lids with N2.  
16. Shake the tubes on belly dancer for 1/2 hr at RT. 
17. Turn the UV light on before starting to do the filter sterilization, filter-
sterilize the FA-BSA complex using Millipore steriflip under sterile hood.  
18. Aliquot 500 µl of each into 1.7 ml microcentrifuge tubes and label the box. Store at 
-20°C 
19. Aliquots have to be used within 60 days. 
 
The final concentration of FA is 2.5 mM.  The solution is 5.67% BSA. 
Working concentration of FA is 50 M.  This solution is 0.11% BSA. 
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B-11. 5-Aza-2-deoxycytidine (AZA) dilution (MW=228.2)  
Methyltransferase inhibitor 
Cat #. sc-202424 from Santa Cruz Biotechnology 
 
100 mM (100,000 µM) Stock  
-Dissolve 25mg of AZA in 1.095 ml of PBS under the hood. It gives us 100mM solution.  
-Aliquot in sterile microcentrifuge tubes, 50 µl per tube under the hood. We have 21 
aliquots.  
-Store at -80°C.  
 
 
Dilution  
• Step 1 (1 ml of 1000 µM) 
1:100 dilution (1000 µM) by taking 10 µl 100mM stock + 990 µl media  
 
• Step 2 (50 ml of 1µM media) 
1:1000 dilution (1µM) by taking 50 µl Step #1 solution + 49,950 µl media  
 
• Step 3 (50 ml of 2µM media) 
1:500 dilution (2 µM) by taking 100 µl of Step #1 solution + 49,900 µl media  
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B-12. DNA extraction and quantification from cultured cells 
QIAamp DNA mini kit Cat #. 51304 from Qiagen 
RNase A  Cat #. 19101 from Qiagen 
Cell scraper Cat # 179707 from Thermo Scientific. 
 
Use the appropriate number of cells (do not use more than 5 x 10
6 
cells) 
1. Remove media  
2. Wash 3 times with PBS (make sure you add PBS to the plate wall) 
3. Add 600 µl of PBS and scrape the cells from plate using cell scraper. 
4. Put the solution into an microcentrifuge tube (1.5ml) 
5. Place tubes on ice (Store at -80°C until DNA extraction)  
6. Thaw cells in ice and centrifuge for 5 min at 300 x g at room temperature. 
Remove the supernatant completely and discard, taking care not to disturb the 
cell pellet.  
7. Resuspend cell pellet in PBS to a final volume of 200 μl. 
8. Add 20 μl proteinase K (in kit). 
9. Add 4 μl RNase A (100 mg/ml), vortex, spin down using countertop centrifuge, 
and incubate at room temperature for 2 min. 
10. Add 200 μl Buffer AL and vortex for 15 s. 
11. Incubate at 56°C for 10 min using Eppendorf thermomixer and spin down using 
countertop centrifuge. 
12. Add 200 μl of 100% ethanol to the sample, and vortex for 15 s and spin down 
using countertop centrifuge. 
13. Carefully apply 700 µl of solution from step 13 to the QIAamp Mini spin 
column/collection tube setup and close the cap. 
14. Centrifuge at 6000 x g for 1 min. Place the QIAamp Mini spin column in a clean 
2 ml collection tube or discard the solution which passed through the filter into 
the collection tube in order to reuse it. 
15. Repeat 13 and 14 until filter all of the solution generated in step 13. 
16. Carefully open the QIAamp Mini spin column and add 500 μl Buffer AW1. 
17. Close the cap and centrifuge at 6000 x g for 1 min. 
18. Place the QIAamp Mini spin column in an empty or new 2 ml collection tube. 
19. Carefully open the QIAamp Mini spin column and add 500 μl Buffer AW2. 
20. Close the cap and centrifuge at full speed (20,000 x g) for 3 min. 
21. Place the QIAamp Mini spin column in a new (not emptied) 2 ml collection tube 
and centrifuge at full speed for 1 min.  
22. Place the QIAamp Mini spin column in a clean 1.5 ml microcentrifuge tube and 
add 100 μl Buffer AE.  
23. Incubate at room temperature for 5 min, and then centrifuge at 6000 x g for 1 min. 
24. Repeat #22 for a second elution step with an additional 100 μl Buffer AE in same 
tube. 
25. Measure DNA concentration using Nanodrop. (Make sure to select DNA option). 
- Recommendation A260:A230 >1.7,  A260:A280 >1.8 
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B-13. ELISA Global DNA methylation quantification 
 
Purpose:  To determine the levels of global DNA methylation 
 
Materials: 
 MethylFlash Methylated DNA Quantification kit (Colorimetric) Cat #. P-1034 
from Epigentek 
 Input DNA: 100 ng per reaction (dilute each sample to 20 ng/µl DNA and take 5 
µl of each diluted sample to have 100 ng per reaction) 
 Distilled water, Cat #. 15230 from Gibco 
 Add 13 ml of ME1 (10X washing butter) from kit to 117 ml of distilled water 
(pH 7.2-7.5). 
 Multichannel pipet and tips 
 Foil 
 Turn on the microplate reader (Synergy HT, Bio-Tek), prepare protocol “450nm” 
 Turn on the incubator 37°C 
Procedure 
1. Single point control preparation; dilute ME4 (positive control from kit) to 5 ng/l (1 
l of ME4 + 3 l of TE buffer). 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A ME3 ME4 D2 LA3 DB4 LB5       
B ME3 ME4 LA2 DB3 LB4 Con6       
C ME3 ME4 DB2 LB3 Con5 Aza6       
D Con1 DB1 LB2 Con4 Aza5 But6       
E Aza1 LB1 Con3 Aza4 But5 D6       
F But1 Con2 Aza3 But4 D5 LA6       
G D1 Aza2 But3 D4 LA5 DB6       
H LA1 But2 D3 LA4 DB5 LB6       
 
2. Add 80 l of ME2 (binding solution) to each well. 
3. Add 1 l of ME3 (negative control), 1 l of Diluted ME4 (positive control, prepared 
in Step #1), and 100 ng of DNA into designated wells.  
4. Mix gently. Ensure the solution coats the bottom of the well evenly. 
5. Cover strip plate with plate seal or parafilm. 
6. Incubate at 37 °C for 90 min. 
7. Wash each well with 150 l of the Diluted ME1 for 3 times. Discard in the sink and 
slightly tap on a paper towel. 
8. Dilute ME5 (capture antibody) with the Diluted ME1 (at 1:1000 ratio) 
 3 l ME5 
 3000 l diluted ME1 
133 
 
9. Add 50 l of the diluted ME5 to each well. 
10. Cover and incubate at room temperature for 60 min. 
11. Remove the diluted ME5 solution from each well. Discard in the sink and slightly 
tap on a paper towel. 
12. Wash each well with 150 l of the diluted ME1 for 3 times. 
13. Dilute ME6 (detection antibody) (at 1:2000 ratio) with the Diluted ME1. 
 3 l ME6 
 6,000 l diluted ME1 
14. Add 50 l of the diluted ME6 to each well. 
15. Cover and incubate at room temperature for 30 min. 
16. Remove the diluted ME6 solution from each well. Discard in the sink and 
slightly tap on a paper towel. 
17. Wash each well with 150 l of the diluted ME1 for 4 times. 
18. Dilute ME7 (enhancer antibody) (at 1:5000 ratio) with the Diluted ME1. 
 1 l ME7 
 4,999 l diluted ME1 
19. Add 50 l of the diluted ME7 to each well. 
20. Cover and incubate at room temperature for 30 min. 
21. Remove the diluted ME7 solution from each well. Discard in the sink and 
slightly tap on a paper towel. 
22. Wash each well with 150 l of the diluted ME1 for 5 times. 
23. Add 100 l of ME8 (developer solution) to each well. 
24. Incubate at room temperature for 1-10 min away from light UNTIL the positive 
control turns medium blue (around 2 minutes) 
25. Add 50 l of ME9 (stop solution). 
26. Measure absorbance every 2 minutes for 10 measurements using the kinetic 
analysis protocol at 450 nm on the microplate reader. 
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B-14. ELISA Apoptosis Assay 
Purpose:  To determine apoptotic cells in cell culture experiment 
 
Materials: 
 ELISA kit: Cell death detection ELISA Plus from Roche- (BM# 11774425) 
 Reconstitute working solutions (refer to manual, pg 5) 
 Bottle 1: anti-histone-biotin: each bottle, reconstitute in 450 L double 
distilled H2O for 10 min and mix well (store at 2-8°C up to 2 months) 
 Bottle 2: anti-DNA-POD- reconstitute with 450 L double distilled H2O for 
10 min and mix well (store at 2-8°C upto 2 months) 
 Bottle 3: Positive control - reconstitute with 450 L double distilled H2O for 
10 min and mix well (store at 2-8°C upto 2 months) 
 Bottle 7: ABTS Tablets- dissolve 1 tablet in 5 ml of substrate buffer (vial 6). 
(100 L / sample). This is light sensitive and hence store container in a foil 
wrap (store for 1 month protected from light) 
 Complete media (without - INF): Make several aliquots to avoid 
contamination of stock solution 
 PBS: Make several aliquots to avoid contamination of stock solution 
 Trypsin; Make several aliquots to avoid contamination of stock solution 
 Label 2 sets of 2 ml and 1 set of 0.67 ml microcentrifuge tubes: floaters 
collection (2 ml tubes for step 1), counting cells (2 ml tubes for counting) 
supernatant collection (0.67 ml tubes for step 13). 
 Fill coulter counter cups the day before the assay with 10 ml. 
 
Procedure 
1. Under sterile conditions in the hood: swirl the 6-well plates and collect the media 
and floating cells into the 1
st
 set of 2 ml microcentrifuge tubes. If more than 1.5 
ml of media was in each well, prepare more microcentrifuge tubes to collect 
media and floating cells. 
2. Add 1ml of sterile PBS into the wells and put them in the 37oC incubator for 
counting later. If you have a plan to count cells later, add 1 ml of complete media. 
3. Centrifuge the first set of microcentrifuge tubes at 500 x g for 5 min at RT.  
4. Remove supernatant using 1ml pipette manually without disturbing the pellet 
(pellet cannot be seen most of the time so leave a little media on this step).  
5. Resuspend pellet in 1 ml PBS.  
6. Finger flick the tubes to mix. 
7. Centrifuge again at 500 x g for 5 min at RT to wash and remove the excess  
media. 
8. Remove as much of the supernatant as possible (without disturbing the pellet) 
and discard it. Use a p-200 pipette. 
9. Resuspend cell pellet with 100 L lysis buffer (bottle 5 of Cell death detection 
ELISA kit) 
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10. Mix thoroughly and incubate sample for 30 min at RT  
11. During incubation, prepare the immunoreagent (manual: pg 6) 
For 10 tests- 40 L of reconstituted reagent (bottle 1) + 40 L of 
reconstituted reagent (bottle 2) + 720 L of incubation buffer from bottle 4. 
Mix well.  
12. After incubation, centrifuge lysate at 500 x g for 10 min, at RT. (Pellets out the 
intact cells and nuclei etc leaving the cytosolic fraction in the supernatant for the 
assay)  
13. Transfer the supernatant carefully into another 0.67 ml microcentrifuge tube 
without shaking the pellet. 
14. Make plate layout. 
Use 20L of 
Well (A-1) – Background (Bottle 4 of kit) 
Well (B-1) – Lysis Buffer (Bottle 5 of kit) 
Well (C-1) – Positive control (Bottle 3 of kit) 
15. Transfer 20 l of all samples into microtiter plate (MP). Pipette into the middle 
of the MP well. 
16. Add to each well 80 l of the immunoreagent using multiple channel pipet. 
17. Remove all bubbles from the wells in the MP with a pipette tip (use different tip 
for each well). 
18. Cover the MP with an adhesive cover and foil. Incubate on a MP shaker under 
gently shaking (300 rpm) for 2hr at 15-25°C. 
19. Empty the solution from the MP thoroughly by tapping (tape both sides of the 
module strips in plateholder to secure them).  
20. Rinse each well 3x with 250 l of incubation buffer (bottle 4).  
21. Empty the solution carefully by tapping. 
22. In the dark (lights off), pipette to each well 100 l ABTS solution (light 
sensitive). 
23. Measure every 2 minutes for 10 measurements using the kinetic analysis protocol 
at 405nm against ABTS solution as a blank (reference wavelength approx 490nm, 
also test at 450nm).  
 COUNTING 
1. Remove the plates from the incubator 
2. Swirl the plates with the PBS and aspirate the PBS from the plates 
3. Add 0.5 ml Trypsin and put them in the incubator for 3 minutes @ 370C.  
4. Add 1ml media into each of the plates with the trypsin.  Mix by pipetting up 
and down. 
5. Add 20 µl of cell suspension to 10 ml of coulter counter solution. 
6. Count the cells using coulter counter.  
Repeat 3 times or until consistent cell numbers are obtained. 
7. Calculate the cell density and total number of apoptotic cells.  
8. Use this count to calculate the apoptotic index. 
9. Apoptotic Index = Optical Density/ # adherent cells 
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B-15. Gene specific methylation using PCR protocol 
Reference: Ciavatta DJ et al. Epigenetic basis for aberrant upregulation of autoantigen 
genes in humans with ANCA vasculitis. J Clin Invest. 2010;120:3209-19.  
 
Purpose: To determine gene-specific promoter methylation 
 
Material: 
Methyl-Profiler DNA methylation PCR array Cat #. MeAH-121 from SABiosciences 
Methyl-Profiler
 
Enzyme Kit Cat #. MeA-03 from SABiosciences 
RT
2
 SYBR Green qPCR mastermix Cat #. 330520 from SABiosciences 
 
This protocol is for a 24-gene, 96-well PCR Array and one DNA sample.  
 
Restriction digestion using enzyme kit 
 
1. Calculate sample volume to have 1 μg of DNA.  
2. Prepare a reaction cocktail as indicated below. Use 1 μg DNA. 
 
 
3. Vortex and spin down using countertop centrifuge. 
4. Label 4 1.5 ml microcentrifuge tubes for one sample. (Mo, Ms, Md and Msd)  
5. Add 28 μl of a reaction cocktail from Step #2 to each labeled microcentrifuge 
tube. All four tubes must contain equal amounts of DNA.  
6. Add RNase/DNase free water and enzymes as indicated below. (DO NOT votex 
enzymes) Pipette up and down to thoroughly, yet gently, mix the components. 
Spin down using countertop centrifuge. 
 
* Mock Digest (Mo) No enzymes are added in this reaction. The product of the 
mock digestion represents the total amount of input DNA for real-time PCR 
detection.  
* Methylation Sensitive Digest (Ms) Cleavage with a methylation-sensitive enzyme 
will digest unmethylated and partially methylated DNA. The remaining (hyper)-
methylated DNA will be detected by real-time PCR.  
* Methylation Dependent Digest (Md) Cleavage with a methylation-dependent 
enzyme will preferentially digest methylated DNA. The remaining unmethylated 
DNA will be detected by real-time PCR.  
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* Double Digest (Msd) Both enzymes are added in the double digest, and all DNA 
molecules (both methylated and unmethylated) will be digested. This reaction 
measures the background and the fraction of input DNA refractory to enzyme 
digestion. 
 
 
 
 
7. Incubate all four tubes at 37°C overnight.  
8. Stop the reactions by heat-inactivating the enzymes at 65°C for 20 minutes.  
9. Store at -20°C before using samples. 
 
Setting up the PCR Reactions  
1. Thaw 4 enzyme reaction tubes (for one sample) from the previous step. 
2. In each tube, add 300 μl RNase/DNase free water and 330 μl PCR master mix 
following the table below. 
3. Vortex and spin down using countertop centrifuge.  
 
 
4. Carefully add 25 μl of the Mo cocktail (described in table above) to each well in 
rows A & B of the 96-well PCR Array, 25 μl of the Ms cocktail to each well in 
rows C & D, 25 μl of the Md cocktail to each well in rows E & F, and 25 μl of 
the Msd cocktail to each well in rows G & H as indicated below. (This is for one 
sample.) 
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5. After loading the plate, carefully seal the plate or cap the wells. Centrifuge the 
plates briefly to remove air bubbles at 2000 rpm for 1 minute. 
 
Running the PCR Reactions using ABI 7900HT 
 
To run the reactions, use the four segment cycling program shown below.  
 
 
Data analysis  
1.  Obtaining the raw Threshold Cycle (Ct) Values  
Note that you must compare multiple plates so be sure that the settings for all 
plates are identical (Same baseline and threshold value) 
Baseline: Using the Linear View of the amplification plots, set the instrument to 
use the readings from cycle number 2 through the cycle just before the earliest 
visible amplification, usually between cycle 10 and 15.  
Threshold Value: Using the Log View of the amplification plots, place the 
threshold above the background signal but within the lower third of the linear 
portion of the amplification curves.  
2. Exporting Ct
 
Values  
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3. Excel-Based Data Analysis Template: Download the Methyl-Profiler PCR Array 
Excel-based data analysis template that matches the gene panel and plate format 
that you used from the SABiosciences website at: 
http://www.sabiosciences.com/methylationdataanalysis.php  
4. Paste in the Ct
 
value data and analyze the automatically generated results by 
following the directions in the “Instructions” worksheet of the Excel file. 
 
The ΔCt Data Analysis Method 
The fraction of DNA in each digest is calculated by normalizing the DNA amount to the 
amount of digestible DNA. The amount of digestible DNA is equal to the total amount 
of DNA (determined from the mock digest) minus the amount of DNA resistant to DNA 
digestion (determined from the double digest). 
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B-16. Histone H3 acetylation detection from HCT 116 cells 
 
Purpose:  To determine the levels of histone H3 acetylation 
 
Materials: 
 EpiQuik Total Histone H3 acetylation detection Kit (Colorimetric) (P-4030, 
Epigentek) 
 Distilled water, Cat. # 15230 from Gibco 
 Multichannel pipet and tips 
 Turn on the microplate reader. 
 Histone proteins were extracted as per Kit (OP-0006, Epigentek) instructions and 
the sample concentrations were measured using a BCA Protein Assay Kit (23225, 
Pierce) 
 
Procedure 
1. Prepare standard control dilutions. 
 dH2O Stock (100 ng/µl) Final amount Final conc. 
stock 0 µl 2 µl of stock  100 ng/µl 
A_50 5 µl 5 µl of stock 5 50 ng/µl 
B_25 5 µl 5 µl of vial A 5 25 ng/µl 
C_12 5. 42 µl 5 µl of vial B 5.42 12 ng/µl 
D_6 5 µl 5 µl of vial C 5 6 ng/µl 
E_3 5 µl 5 µl of vial D 5 3 ng/µl 
F_1.5 5 µl 5 µl of vial E 10 1.5 ng/µl 
Distilled water 2 µl 0  0 ng/µl 
2. Dilute C1 (wash buffer) with distilled water at a 1:9 ratio. (e.g. 1 ml of C1 
+ 9 ml of distilled water) 
3. Add 50 µl of C2 (antibody buffer) into each well. 
4. Add 100 ng of sample histones.  Add 1 µl of standard controls. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A SC100 But1 DHA2 LA3 DB1 LB2       
B SC50 DHA1 LA2 DB3 LB1 Con3       
C SC25 LA1 DB2 LB3 Con2 Aza3       
D SC12 DB1 LB2 Con1 Aza2 But3       
E SC0 LB1 Con3 Aza1 But2 DHA3       
F SC0 Con2 Aza3 But1 DHA2 LA3       
G Con1 Aza2 But3 DHA1 LA2 DB3       
H Aza1 But2 DHA3 LA1 DB2 LB3       
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5. Mix and cover the plate with parafilm. 
6. Incubate at room temperature for 2 hr. 
7. Wash wells with 150 µl of diluted C1 from kit three times. 
8. Dilute C3 (detection antibody) with C2 (antibody buffer). (1 µl of C3 + 
1000 µl of C2). 
9. Add 50 µl of diluted C3. 
10. Incubate at room temperature for 1 hr on an orbital shaker (100 rpm). 
11. Wash wells with 150 µl of diluted C1 six times. 
12. Add 100 µl of C4 (color developer) and incubate at room temperature 2-
10 minutes while protected from light. 
13. When the color of standard control turns medium blue (around 2 minutes, 
keep watching), add 50 µl of C5 (stop solution). 
14. Measure absorbance every 2 minutes for 10 measurements using the 
kinetic analysis protocol at 450nm on the microplate reader. 
 
Amount (ng/mg protein)  =        X 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OD (sample – blank) 
Protein (µg) * slope 
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B-17. Histone H4 acetylation detection from HCT 116 cells 
Purpose:  To determine the levels of histone H4 acetylation 
 
Materials: 
 EpiQuik Total Histone H4 acetylation detection Kit (Colorimetric) (P-4032, 
Epigentek) 
 Distilled water, Cat. # 15230 from Gibco 
 Multichannel pipet and tips 
 Turn on the microplate reader. 
 Histone proteins were extracted as per Kit (OP-0006, Epigentek) instructions and 
the sample concentrations were measured using a BCA Protein Assay Kit (23225, 
Pierce) 
Procedure 
 
1. Prepare standard control dilutions. 
 dH2O Stock (100 
ng/µl) 
Final amount Final conc. 
stock 0 µl 2 µl of stock  100 ng/µl 
A_50 5 µl 5 µl of stock 5 50 ng/µl 
B_25 5 µl 5 µl of vial A 5 25 ng/µl 
C_12 5. 42 µl 5 µl of vial B 5.42 12 ng/µl 
D_6 5 µl 5 µl of vial C 5 6 ng/µl 
E_3 5 µl 5 µl of vial D 5 3 ng/µl 
F_1.5 5 µl 5 µl of vial E 10 1.5 ng/µl 
water 2 µl 0  0 ng/µl 
 
2. Dilute C1 (wash buffer) with distilled water at a 1:9 ratio. (e.g. 1 ml of C1 
+ 9 ml of water) 
3. Add 50 µl of C2 (antibody buffer) into each well. 
4. Add 2 µg of sample histones. Add 1 µl of standard control. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A SC100 SC100 SC100 Con1 Con2 Con3       
B SC50 SC50 SC50 Con1 Con2 Con3       
C SC25 SC25 SC25 Aza1 Aza2 Aza3       
D SC12 SC12 SC12 But1 But2 But3       
E SC6 SC6 SC6 DHA1 DHA2 DHA3       
F SC3 SC3 SC3 LA1 LA2 LA3       
G SC1.5 SC1.5 SC1.5 DB1 DB2 DB3       
H SC0 SC0 SC0 LB1 LB2 LB3       
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5. Mix and cover the plate with parafilm. 
6. Incubate at room temperature for 1-2 hr. 
7. Prepare the Detection solution. 
 3 µl of C3 (detection antibody) + 1.5 µl of signal report solution  
+ 30 µl of diluted C1 
 Mix and incubate at room temperature for 10 min. 
 Add 60 µl of signal enhancer. 
 Mix and incubate at room temperature for 15 min. 
 Add 2910 µl of diluted C1. 
 
8. Wash wells with 150 µl of diluted C1 three times. 
9. Add 50 µl of detection solution. 
10. Incubate at room temperature for 1 hr on an orbital shaker (100 rpm). 
11. Wash wells with 150 µl of diluted C1 six times. 
12. Add 100 µl of C4 (color developer) and incubate at room temperature 2-
10 minutes away protected from light. 
13. When the color of standard control turns medium blue (around 2 minutes, 
keep watching), add 50 µl of C5 (stop solution). 
14. Measure absorbance every 2 minutes for 10 measurements using the 
kinetic analysis protocol at 450nm on the microplate reader. 
 
Amount (ng/mg protein)  =        X 100 
 
 
 
OD (sample – blank) 
Protein (µg) * slope 
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